Rank,NCT Number,Title,Recruitment,Study Results,Conditions,Interventions,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Types,Study Designs,Other IDs,First Received,Start Date,Completion Date,Last Updated,Last Verified,Results First Received,Acronym,Primary Completion Date,Outcome Measures,URL
70,NCT00021151,Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia,Completed,No Results Available,Leukemia,Biological: alemtuzumab,"Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",,2,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ILEX1999|CWRU-ILEX-1999|ILEX-CAM511-A1|NCI-G01-1977,11-Jul-01,1/1/00,5/1/02,7-Jan-14,Jan-14,No Study Results Posted,null,Apr-01,,https://ClinicalTrials.gov/show/NCT00021151
282,NCT00031005,Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency,Completed,No Results Available,Leukocyte-Adhesion Deficiency Syndrome,Procedure: modified stem cell transplant,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Senior",Phase 2,10,NIH,Interventional,Primary Purpose: Treatment,020126|02-I-0126,20-Feb-02,2/1/02,2/1/03,3-Mar-08,Feb-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00031005
146,NCT00056979,Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases,Terminated,No Results Available,Inherited Metabolic Storage Diseases,Drug: CAMPATH-1H|Drug: Anti-CD45|Drug: FK506|Drug: Fludarabine,Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System,All,"Child, Adult, Senior",Phase 1|Phase 2,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H11909|MAID,26-Mar-03,6/1/02,6/1/03,21-Sep-15,Sep-15,No Study Results Posted,null,Jun-03,,https://ClinicalTrials.gov/show/NCT00056979
217,NCT00073879,"Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation",Completed,No Results Available,Kidney Cancer,Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,Baylor College of Medicine,All,"Child, Adult, Senior",,null,Other,Interventional,Primary Purpose: Treatment,CDR0000328247|BCM-H-8447,10-Dec-03,4/1/03,4/1/04,27-Jan-15,Jan-15,No Study Results Posted,null,Apr-04,Number of patients with treatment related mortality,https://ClinicalTrials.gov/show/NCT00073879
276,NCT00023192,Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care,Completed,No Results Available,Chronic Granulomatous Disease,Drug: T-Cell Depleted & CD34+Select/w/StemCell Enriched Product,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Senior",Phase 3,60,NIH,Interventional,Primary Purpose: Treatment,010242|01-I-0242,29-Aug-01,8/1/01,6/1/04,3-Mar-08,Jun-04,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00023192
142,NCT00276809,"Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia",Completed,No Results Available,Chronic Lymphocytic Leukemia,Biological: alemtuzumab|Biological: filgrastim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,German CLL Study Group,All,18 Years to 60 Years Â  (Adult),Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,CLL3C|EU-20556|MEDAC-GCLLSG-CLL3C,12-Jan-06,6/1/01,9/1/04,23-Sep-16,Sep-16,No Study Results Posted,null,Sep-04,Safety and feasibility of CAMPATH-1H included into the myeloablative regimen (cyclophosphamide and TBI) of the CLL3 protocol monitoring of treatment related mortality and morbidity (CTC scale) continuous|Rate and duration of molecular responses MRD levels continuous|Rate and duration of clinical remissions NCIE sponsored remission criteria for CLL continuous|Overall survival time from treatment to death continuous,https://ClinicalTrials.gov/show/NCT00276809
76,NCT00051701,Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma,Terminated,No Results Available,Non-Hodgkins Lymphoma,Drug: alemtuzumab,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,61,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM.NHL232|BLA 99-0786,15-Jan-03,12/1/02,8/1/05,4-Mar-15,Mar-15,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00051701
67,NCT00685061,"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation",Completed,No Results Available,Renal Transplantation,Drug: Thymoglobulin|Drug: Campath-1H|Drug: Daclizumab,University of Miami,All,"16 Years and older Â  (Child, Adult, Senior)",Phase 4,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB#20020213,23-May-08,11/1/02,9/1/05,27-May-08,May-08,No Study Results Posted,null,Sep-04,Incidence and severity of biopsy-proven acute rejection at 1 year.|One-year and 3 year patient and graft survival.,https://ClinicalTrials.gov/show/NCT00685061
73,NCT00113048,Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies,Terminated,No Results Available,Hematologic Malignancies,Drug: CAMPATH (alemtuzumab),"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 1,24,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM111,3-Jun-05,12/1/03,9/1/05,4-Feb-14,Feb-14,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00113048
4,NCT00038883,Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies,Completed,No Results Available,"Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic, Acute|Lymphoma, Low-Grade|Lymphoma, T-Cell|Lymphoma, B-Cell",Drug: Campath-1H,M.D. Anderson Cancer Center|Leudosite,All,"15 Years to 60 Years Â  (Child, Adult)",,19,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID99-410,5-Jun-02,4/1/01,5/1/06,27-Jul-12,Jul-12,No Study Results Posted,null,May-06,CAMPATH 2-year event-free survival rate,https://ClinicalTrials.gov/show/NCT00038883
44,NCT00046683,"Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia",Completed,No Results Available,B Cell Chronic Lymphocytic Leukemia,Drug: alemtuzumab,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 3,284,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM307,1-Oct-02,7/1/01,6/1/06,27-Jul-16,Jul-16,No Study Results Posted,null,null,Campath vs. chlorambucil|survival comparison,https://ClinicalTrials.gov/show/NCT00046683
30,NCT00365846,"""A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation""",Completed,Has Results,Renal Transplant,Drug: Campath-1H,"University of Wisconsin, Madison",All,18 Years to 60 Years Â  (Adult),Phase 2,29,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,2000-032,16-Aug-06,8/1/00,7/1/06,21-Sep-12,Sep-12,22-Jun-12,null,Jul-05,Incidence of Allograft Rejection|Incidence of Severe Allograft Rejection ( Defined as >Banff 2A or Requiring Antibody Treatment)|Patient Survival|Incidence of Post-transplant Infection|Incidence of Malignancies|Kidney Allograft Survival,https://ClinicalTrials.gov/show/NCT00365846
133,NCT00162851,Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia,Completed,No Results Available,B-CLL,Drug: alemtuzumab,Karolinska University Hospital|Schering Nordiska AB,All,"18 Years to 80 Years Â  (Adult, Senior)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM219,8-Sep-05,4/1/03,7/1/06,23-Jul-07,Aug-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00162851
192,NCT00562770,Oral Valganciclovir Versus Valacyclovir,Completed,No Results Available,Chronic Lymphocytic Leukemia|Leukemia,Drug: Valganciclovir|Drug: Valacyclovir,M.D. Anderson Cancer Center|Roche Pharma AG,All,"16 Years and older Â  (Child, Adult, Senior)",Phase 2,46,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-666,20-Nov-07,9/1/03,7/1/06,27-Jul-12,Jul-12,No Study Results Posted,null,null,"CBC, platelet and differential. BUN, creatinine, total bilirubin, alkaline phosphatase, LDH, SGPT|CMV antigenemia",https://ClinicalTrials.gov/show/NCT00562770
1,NCT00102661,Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia,Completed,No Results Available,Chronic Lymphocytic Leukemia,Drug: Campath-1H,"M.D. Anderson Cancer Center|Berlex Laboratories, Inc.",All,"18 Years and older Â  (Adult, Senior)",Phase 2,10,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-424,31-Jan-05,10/1/02,9/1/06,27-Jul-12,Jul-12,No Study Results Posted,null,Sep-06,Response Rate (CR+PR) to CAMPATH-1H,https://ClinicalTrials.gov/show/NCT00102661
16,NCT00129753,Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease,Withdrawn,No Results Available,Hodgkin's Disease|Lymphoma,Drug: Alemtuzumab (Campath-1H),M.D. Anderson Cancer Center,All,"18 Years and older Â  (Adult, Senior)",Phase 2,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0742,11-Aug-05,6/1/05,9/1/06,6-Apr-16,Oct-10,No Study Results Posted,null,Sep-06,Response Rate,https://ClinicalTrials.gov/show/NCT00129753
251,NCT00344825,Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL),Completed,No Results Available,"Leukemia, B-Cell, Chronic","Drug: Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)","Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",,300,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,306003,26-Jun-06,1/1/04,11/1/06,2-Dec-13,Dec-13,No Study Results Posted,null,Nov-06,,https://ClinicalTrials.gov/show/NCT00344825
60,NCT00177138,Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation,Terminated,No Results Available,Diabetes Mellitus,Drug: Tacrolimus|Drug: Alemtuzumab,"University of Minnesota - Clinical and Translational Science Institute|Bayer|Gruessner, Rainer, MD",All,18 Years to 60 Years Â  (Adult),Phase 4,9,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,0308M51264|Berlex Study No. 107.G0001,13-Sep-05,7/1/04,11/1/06,5-Feb-13,Feb-13,No Study Results Posted,null,null,"Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance.|The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance.",https://ClinicalTrials.gov/show/NCT00177138
185,NCT00056966,Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases,Completed,No Results Available,Hematologic Malignancy,Drug: ANTI-CD45|Drug: CAMPATH-1H|Drug: FK506|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Stem cell infusion,"Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Senior",Phase 1|Phase 2,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,12472|ACHE,26-Mar-03,11/1/02,12/1/06,27-Jun-12,Jun-12,No Study Results Posted,null,May-05,"Assess safety and feasibility of monoclonal abs directed to CD45 and CD52 antigens, Fludarabine and low dose TBI, as a non-myeloablative preparatory regimen for allo HSCT. This will be determined by 100d Non-relapse mortality and 100d Graft rejection|To obtain a preliminary estimate of the efficacy of this therapy as defined by: Complete remission at day 100 and One-year disease free survival.",https://ClinicalTrials.gov/show/NCT00056966
32,NCT00166556,A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation,Completed,No Results Available,"Transplantation, Liver",Drug: Campath-1H and Tacrolimus,Mayo Clinic|University of Chicago|Immune Tolerance Network (ITN),All,"18 Years to 70 Years Â  (Adult, Senior)",Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2355-04,12-Sep-05,1/1/05,12/1/06,20-May-11,May-11,No Study Results Posted,null,Dec-06,To evaluate the safety and efficacy of an immunosuppression regimen comprising Campath-1H induction followed by maintenance therapy with tacrolimus in allowing liver allograft survival|Assess the safety of withdrawing tacrolimus after Campath-1H induced immuno-depletion and subsequent immune reconstitution|Gather additional safety information about the combination of Campath-1H and tacrolimus in liver allograft recipients|Define profiles of immunologic and genetic features present prior to or during tapering of immunosuppression that distinguish tolerant and non tolerant allograft recipients,https://ClinicalTrials.gov/show/NCT00166556
207,NCT00533923,Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders,Completed,No Results Available,AML|ALL|CLL|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma|Aplastic Anemia|Myeloproliferative Disorder,Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF,Beth Israel Deaconess Medical Center|Bayer,All,"up to 65 Years Â  (Child, Adult)",Phase 2,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2002P000219,20-Sep-07,12/1/02,1/1/07,14-Jul-16,Jul-16,No Study Results Posted,null,Jan-07,"Primary objective of study is to determine the safety of non-myeloablative allogenic stem cell transplantation from matched unrelated donors in patients with hematologic malignancies with a focus on the incidence of treatment-related mortality.|Secondary clinical endpoints includes; incidence of graft failure or rejection; incidence and severity of acute and chronic GVHD; tumor response, and long-term overall and disease-free survival.",https://ClinicalTrials.gov/show/NCT00533923
212,NCT00085449,"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,18 Years to 60 Years Â  (Adult),Phase 1|Phase 2,56,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-100102|CDR0000370797,10-Jun-04,5/1/06,1/1/07,1-Jul-16,Jul-16,No Study Results Posted,null,Jan-07,Engraftment rate|Risk of graft-vs-host disease|Progression-free survival (PFS),https://ClinicalTrials.gov/show/NCT00085449
117,NCT00079768,Alemtuzumab to Treat Sporadic Inclusion Body Myositis,Completed,No Results Available,"Myositis, Inclusion Body",Drug: Alemtuzumab (Campath),National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"25 Years to 80 Years Â  (Adult, Senior)",Phase 2,20,NIH,Interventional,Primary Purpose: Treatment,040133|04-N-0133,12-Mar-04,3/1/04,3/1/07,16-Jun-10,Jan-09,No Study Results Posted,null,Mar-07,Change in the muscle strength at 6 months by 15%.,https://ClinicalTrials.gov/show/NCT00079768
138,NCT00069992,"Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML",Terminated,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes,Radiation: Total Body Irradiation|Drug: Fludarabine|Drug: Campath 1H,"Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Senior",Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-10857-MPDMDSBMT,3-Oct-03,12/1/01,4/1/07,5-Oct-12,Oct-12,No Study Results Posted,MPDMDSBMT,Sep-06,"Day 100 Non-relapse mortality,|Day 100 graft rejection|1 year disease free survival|Complete Remission at 100 days",https://ClinicalTrials.gov/show/NCT00069992
43,NCT00579592,"Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation",Terminated,No Results Available,Acute Rejection|Renal Transplantation,"Drug: Campath-1H, rituximab, myfortic","University of Wisconsin, Madison",All,"18 Years and older Â  (Adult, Senior)",,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-2005-0454,17-Dec-07,4/1/06,4/1/07,22-Jun-12,Jun-12,No Study Results Posted,null,Mar-07,renal function|hypertension|drug side effects,https://ClinicalTrials.gov/show/NCT00579592
120,NCT00109993,Campath-1H + FK506 and Methylprednisolone for GVHD,Completed,No Results Available,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,Biological: alemtuzumab|Drug: methylprednisolone|Drug: tacrolimus,Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,34,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care,CASE1Z04|P30CA043703|CASE-CWRU-1Z04|CWRU-060419|CASE-1Z04,3-May-05,1/1/05,5/1/07,10-Jun-10,Jun-10,No Study Results Posted,null,Jun-06,"Graft-vs-host disease response|Incidence of serious infections by clinical, radiologic, and microbiologic assessments",https://ClinicalTrials.gov/show/NCT00109993
12,NCT00071396,Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Campath-1H|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,All,"15 Years and older Â  (Child, Adult, Senior)",Phase 2,48,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID02-368,21-Oct-03,10/1/02,8/1/07,1-Aug-12,Aug-12,25-Sep-09,null,Sep-06,Overall Response,https://ClinicalTrials.gov/show/NCT00071396
269,NCT00152100,Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome,Completed,No Results Available,Severe Combined Immunodeficiency,"Procedure: Stem cell transplant|Drug: Filgrastim, Alemtuzumab|Device: Miltenyi CliniMACS",St. Jude Children's Research Hospital,All,up to 2 Years Â  (Child),Phase 1,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ALSCID,7-Sep-05,2/1/04,8/1/07,19-May-09,May-09,No Study Results Posted,null,Aug-07,To investigate safety issues related to use of haploidentical highly purified CD133+ hematopoietic cells in patients with SCID|To study the effects (good and bad) of this procedure|To learn if this procedure will result in normal immune function in children with SCID,https://ClinicalTrials.gov/show/NCT00152100
26,NCT00214266,A Pilot Study of Campath-1H Induction Therapy Combined With CellCeptÂ® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation,Completed,No Results Available,Renal Transplantation,"Drug: Campath 1HÂ®, Rituximab, mycophenolate mofetil","University of Wisconsin, Madison",All,"18 Years and older Â  (Adult, Senior)",Phase 2,31,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0209,13-Sep-05,1/1/05,9/1/07,22-Jun-12,Jun-12,No Study Results Posted,null,Aug-07,renal allograft function|incidence of hypertension|incidence of diabetes|drug related side effects,https://ClinicalTrials.gov/show/NCT00214266
68,NCT00681343,"Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation",Completed,No Results Available,Living-Donor Kidney Transplant,Drug: Thymoglobulin|Drug: Campath-1H|Drug: Daclizumab,University of Miami|Hoffmann-La Roche,All,"16 Years and older Â  (Child, Adult, Senior)",Phase 4,38,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB#20010704,19-May-08,9/1/02,10/1/07,23-May-08,May-08,No Study Results Posted,null,Oct-06,"Incidence and severity of biopsy-proven acute rejection at 1 year.|Patient and graft survival|Incidence of biopsy-proven chronic allograft nephropathy.|Levels of lymphoid cell subsets.|Incidence of adverse reactions, for example: Infections, Malignancies, Thromboembolic events.",https://ClinicalTrials.gov/show/NCT00681343
159,NCT00199030,Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath,Completed,No Results Available,"Adult Acute Lymphocytic Leukemia T-Cell|Lymphoma, Lymphoblastic",Drug: Alemtuzumab (MabCampath)|Drug: Cladribine,Johann Wolfgang Goethe University Hospital,All,"18 Years and older Â  (Adult, Senior)",Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GMALL07,12-Sep-05,2/1/04,12/1/07,29-May-08,May-08,No Study Results Posted,null,null,"Arm A: rate of molecular remissions (MRD < 10(-4), toxicity according to CTC, remission duration/survival, feasibility of s.c. dose escalation and long term therapy, mortality|Arm B: response (CR/PR/MR), toxicity according to CTC, SCT rate, remission duration/survival, feasibility of i.v. dose escalation/long term therapy, mortality",https://ClinicalTrials.gov/show/NCT00199030
249,NCT00692562,Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease,Completed,No Results Available,Type 1 Diabetes Mellitus|End-stage Renal Disease,Procedure: simultaneous islet-kidney transplantation,Fuzhou General Hospital,All,18 Years to 60 Years Â  (Adult),Phase 1|Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SIK2005,3-Jun-08,6/1/05,12/1/07,15-Sep-11,Jun-08,No Study Results Posted,null,Dec-06,Exogenous insulin requirement|kidney function|Hemoglobin A1c|Glucose and C-peptide levels|Portal vein Ultrasound|liver function|Complete Blood Count|autoantibodies,https://ClinicalTrials.gov/show/NCT00692562
147,NCT00458250,Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H,Completed,No Results Available,"Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute",Procedure: Haploidentical hematopoietic stem cell transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: CAMPATH-1H|Drug: Cyclosporin A|Drug: Methotrexate,Tehran University of Medical Sciences,All,"2 Years to 50 Years Â  (Child, Adult)",Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,418-A-1954,7-Apr-07,9/1/06,2/1/08,15-Nov-08,Nov-08,No Study Results Posted,null,null,Engraftment one month after transplantation|six months survival,https://ClinicalTrials.gov/show/NCT00458250
150,NCT00458523,Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission,Completed,No Results Available,Leukemia,Biological: alemtuzumab|Genetic: fluorescence in situ hybridization|Genetic: mutation analysis|Other: flow cytometry,Leeds Cancer Centre at St. James's University Hospital|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,54,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,LCC-CTRU-CLL207|CDR0000538115|SPRI-LCC-CTRU-CLL207|ISRCTN23153249|EU-20715|EUDRACT-2006-000053-22,9-Apr-07,12/1/06,2/1/08,9-Aug-13,Apr-07,No Study Results Posted,null,null,Rate of undetectable minimal residual disease (MRD) after completion of alemtuzumab therapy|Rate of unacceptable toxicities|Rate of overall response (complete or partial response)|Time to MRD relapse|Overall survival|Expression of CD52 on chronic lymphocytic leukemia cells|Rate of re-achievement of MRD negativity after completion of alemtuzumab therapy|Incidence of successful retreatment|Toxicity from repeated therapy|Length of interval between required treatments,https://ClinicalTrials.gov/show/NCT00458523
88,NCT00416884,"Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML",Terminated,Has Results,Leukemia,Drug: Campath|Drug: Fludarabine|Radiation: Total Body Irradiation (TBI)|Other: T-Cell Deplete,OHSU Knight Cancer Institute|National Cancer Institute (NCI),All,"4 Years to 75 Years Â  (Child, Adult, Senior)",Phase 2,1,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000449649|OHSU-TPI-02032-L|OHSU-414,27-Dec-06,5/1/03,3/1/08,6-Jul-11,Jul-11,31-May-11,null,Mar-08,Number of Participants With Treatment-related Mortality,https://ClinicalTrials.gov/show/NCT00416884
216,NCT00582894,Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases,Completed,Has Results,Hematological Neoplasms|Hematopoietic Stem Cell Transplantation,"Drug: Busulfex, Fludarabine, ALemtuzumab",University of Oklahoma,All,"18 Years to 75 Years Â  (Adult, Senior)",,17,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Reduced-Intensity|IRB #11835,19-Dec-07,2/1/05,3/1/08,23-Mar-11,Mar-11,10-Jan-11,null,Mar-08,Number of Participants Experiencing Transplant Related Mortality (TRM)|Number of Participants Experiencing Engraftment Donor Chimerism (EDC)|Number of Participants Relapse-Free|Number of Participants Overall Survival as a Function of Time.,https://ClinicalTrials.gov/show/NCT00582894
160,NCT00193466,Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Completed,No Results Available,Non-Hodgkins Lymphoma,Drug: Rituximab|Drug: Fludarabine|Drug: CAMPTH-1H,"SCRI Development Innovations, LLC|Bayer",All,"18 Years and older Â  (Adult, Senior)",Phase 2,40,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI LYM 21|CAM-217,12-Sep-05,1/1/02,4/1/08,29-Dec-10,Dec-10,No Study Results Posted,null,Jan-07,Complete response rate|Molecular complete response rate|Progression free survival|Overall toxicity,https://ClinicalTrials.gov/show/NCT00193466
72,NCT00206726,Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL),Completed,Has Results,"Leukemia, Lymphocytic, Chronic, B-Cell",Drug: Alemtuzumab plus Fludarabine,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 2,60,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13603|305825,19-Sep-05,5/1/05,4/1/08,27-Jul-16,Jul-16,19-Nov-09,ECO-1,Apr-08,Complete Response (CR)|Overall Response (OR)|Overall Survival (OS)|Progression-free Survival (PFS)|Percentage of Participants With Overall Response at Different Observation Times|Number of Participants With Minimal Residual Disease (MRD),https://ClinicalTrials.gov/show/NCT00206726
225,NCT00104975,Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer,Completed,No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: alemtuzumab|Biological: therapeutic allogeneic lymphocytes|Drug: fludarabine phosphate|Drug: melphalan|Drug: tacrolimus|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation,Yale University|National Cancer Institute (NCI),All,18 Years to 55 Years Â  (Adult),Phase 1,20,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000413698|YALE-25971|NCI-6765,3-Mar-05,2/1/05,5/1/08,13-Dec-16,Dec-16,No Study Results Posted,null,May-08,,https://ClinicalTrials.gov/show/NCT00104975
224,NCT00638820,Reduced Intensity AlloTransplant For Osteopetrosis,Terminated,Has Results,Osteopetrosis,"Procedure: Stem Cell or Umbilical Cord Blood Transplantation|Drug: Campath, Busulfan, Clofarabine|Procedure: Total Lymphoid Irradiation","Masonic Cancer Center, University of Minnesota",All,"up to 45 Years Â  (Child, Adult)",Phase 2,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,0704M06581|MT2007-06,11-Mar-08,9/1/07,5/1/08,22-Feb-11,Feb-11,26-Aug-09,null,May-08,Number of Patients Achieving Donor Cell Engraftment|Number of Patients With Transplant Related Death|Number of Patients With Transplant Related Toxicity|Differential Imaging and Biologic Evaluations,https://ClinicalTrials.gov/show/NCT00638820
31,NCT00001984,Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys,Completed,Has Results,Graft Rejection|Kidney Disease,Drug: Alemtuzumab and DSG,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Senior",Phase 2,5,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,000013|00-DK-0013,26-Jan-00,11/1/99,6/1/08,22-Sep-16,Sep-16,13-Sep-10,null,Jun-08,Number of Patients With Renal Allograft Rejection|Rejection Day of Onset|Rise in Serum Creatineine Above Posttransplant Nadir|Creatinine Level at 6 Month Post Operation|Creatinine Level at Year 1 Post Operation|Creatinine at 2 Years|Monocyte Count,https://ClinicalTrials.gov/show/NCT00001984
3,NCT00142181,Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia,Completed,No Results Available,Lymphoplasmacytic Lymphoma|Waldenstrom's Macroglobulinemia,Drug: Campath-1H,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Bayer|University of California, Los Angeles|Northwestern University|Arizona Oncology Associates",All,"18 Years to 80 Years Â  (Adult, Senior)",Phase 2,27,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,02-079,1-Sep-05,3/1/03,6/1/08,19-Dec-12,Dec-12,No Study Results Posted,null,Oct-05,To determine the effectiveness of Campath-1H in treating patients with Waldenstrom's macroglobulinemia.|To determine the safety of Campath-1H.,https://ClinicalTrials.gov/show/NCT00142181
93,NCT00930605,The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL),Completed,No Results Available,Peripheral T-cell Lymphoma,Drug: CHOP regimen alternate with ESHAP regimen|Drug: Alemtuzumab,King Chulalongkorn Memorial Hospital|Bayer,All,"15 Years to 65 Years Â  (Child, Adult)",Phase 2,16,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TH011001,29-Jun-09,1/1/05,7/1/08,4-Oct-11,Oct-11,No Study Results Posted,C+CHOP/ESHAP,Nov-06,The response to treatment and the treatment-related toxicity.,https://ClinicalTrials.gov/show/NCT00930605
113,NCT00157274,Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome,Unknown status,No Results Available,Mycosis Fungoides|Sezary Syndrome,Drug: alemtuzumab,Latin American Cooperative Onco-Haematology Group - Peru,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MF/SS,7-Sep-05,7/1/05,7/1/08,2-Apr-07,Sep-05,No Study Results Posted,null,null,Overall response|Time to relapse|Event free survival|Toxicity,https://ClinicalTrials.gov/show/NCT00157274
205,NCT00684255,Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc),Terminated,Has Results,Systemic Lupus Erythematosus|Systemic Sclerosis,Procedure: Reduced Intensity Allogeneic Transplant|Drug: Fludarabine|Drug: Busulfan|Drug: Campath,New York Medical College,All,"7 Years to 50 Years Â  (Child, Adult)",Phase 1,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAB1324|CHNY-01-511,22-May-08,8/1/07,7/1/08,6-Feb-14,Feb-14,22-Dec-08,null,Jul-08,Toxicity|Chimerism|Immune Reconstitution.|Progression Free and Overall Survival.,https://ClinicalTrials.gov/show/NCT00684255
294,NCT00586547,Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation,Completed,No Results Available,Leukemia|Cancer,Drug: Ara-C|Drug: Cyclophosphamide|Drug: Mesna|Biological: Campath 1H|Radiation: TBI|Procedure: Stem Cells Infusion|Procedure: T-cell Infusion,"Baylor College of Medicine|University of Texas, Southwestern Medical Center at Dallas",All,"Child, Adult, Senior",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-9033,21-Dec-07,7/1/00,9/1/08,2-Dec-09,Oct-09,No Study Results Posted,null,Sep-08,Determining the number of donor lymphocytes given to recipients of haploidentical stem cell transplants after depletion of recipient-reactive T lymphocytes by ex-vivo treatment with a fixed dose of RFT5-dgA immunotoxin.|To measure their overall and disease free survival.,https://ClinicalTrials.gov/show/NCT00586547
314,NCT00586755,Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma,Completed,No Results Available,Mantle Cell Lymphoma,Procedure: Intensive Induction-BMT,Duke University,All,"18 Years and older Â  (Adult, Senior)",Phase 2,48,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2165,21-Dec-07,2/1/98,11/1/08,16-Jul-14,Jul-14,No Study Results Posted,null,Oct-07,Disease Free Survival (DFS)|Progression Free Survival (PFS)|Response to the induction regimen|Response to the transplant phase of therapy|Toxicity of the trial|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT00586755
119,NCT00565981,"A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response",Unknown status,No Results Available,B-Cell Chronic Lymphocytic Leukemia,Drug: Fludarabine phosphate|Drug: Alemtuzumab,Arbeitsgemeinschaft medikamentoese Tumortherapie|Schering-Plough,All,"19 Years to 75 Years Â  (Adult, Senior)",Phase 2,28,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FLUSALEM,29-Nov-07,3/1/04,12/1/08,4-Jun-08,Jun-08,No Study Results Posted,null,Oct-07,"Safety and tolerability|Complete and overall response rate|Infections grade III, IV|Rate of CMV reactivation|Time to retreatment|Overall survival|Response in lymphatic compartments|Molecular response/ immunologic MRD response|Quality of Life",https://ClinicalTrials.gov/show/NCT00565981
51,NCT01046955,Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation,Completed,No Results Available,End-Stage Renal Disease|Living Donors,Drug: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab,University of Miami|Hoffmann-La Roche,All,"14 Years and older Â  (Child, Adult, Senior)",Phase 4,38,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,20010704,11-Jan-10,11/1/05,12/1/08,11-Jan-10,May-08,No Study Results Posted,null,Apr-07,To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor kidneys.|Patient/graft survival.|Incidence of adverse reactions.,https://ClinicalTrials.gov/show/NCT01046955
194,NCT00113269,"Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients",Completed,Has Results,Kidney Transplantation,Drug: basiliximab|Drug: rabbit anti-thymocyte globulin|Drug: tacrolimus|Drug: alemtuzumab|Drug: mycophenolate mofetil|Drug: steroids,Astellas Pharma Inc,All,"18 Years and older Â  (Adult, Senior)",Phase 4,501,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20-04-003,7-Jun-05,5/1/05,3/1/09,9-Aug-11,Aug-11,7-Jun-11,INTAC,Mar-09,Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 Months|Overall Patient Incidence of BCAR|Efficacy Failure|Clinically Treated Acute Rejection|Time to First BCAR|Graft Survival at 12 Months|Overall Graft Survival|Patient Survival at 12 Months|Overall Patient Survival|Renal Function Abnormalities Based on Creatinine Clearance|Renal Function Abnormalities Based on Serum Creatinine,https://ClinicalTrials.gov/show/NCT00113269
202,NCT02711202,Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation,Completed,No Results Available,Kidney Transplantation,"Drug: MabCampath,|Drug: Remicade|Drug: Sirolimus|Drug: Tacrolimus","Institute for Clinical and Experimental Medicine|Charite University, Berlin, Germany|Miltenyi Biotec GmbH",All,"18 Years and older Â  (Adult, Senior)",,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening,EudraCT Number: 2006-003110-18,9-Mar-16,1/1/07,3/1/09,12-Mar-16,Mar-16,No Study Results Posted,null,Mar-09,"number of patients with functional graft|number of patients alive|kidney graft function (measured by serum creatinine and glomerular filtration)|the number of bioptically verified rejection episodes and their severity|fibrosis grade and presence of subclinical rejection in protocol biopsy at 12 months|intragraft gene expression (inflammatory cytokines, chemokines and protective factors)|peripheral blood gene expression (inflammatory cytokines, chemokines and protective factors)",https://ClinicalTrials.gov/show/NCT02711202
98,NCT00027560,"Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",Completed,Has Results,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 2,51,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-092|MSKCC-01092|NCI-G01-2028,7-Dec-01,7/1/01,4/1/09,3-Dec-12,Dec-12,27-Nov-12,null,Apr-09,Overall Survival|Acute Graft-versus-Host Disease Matched Related Patients|Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients|Extensive Chronic Graft-versus-Host Disease Matched Related Patients|Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients,https://ClinicalTrials.gov/show/NCT00027560
204,NCT00337519,Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia,Unknown status,No Results Available,Chronic Lymphocytic Leukemia,Procedure: allogeneic stem cell transplantation|Drug: Alemtuzumab,"Charite University, Berlin, Germany|University Hospital Carl Gustav Carus|Deutsche Klinik fuer Diagnostik",All,"up to 65 Years Â  (Child, Adult)",Phase 2,82,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL #02|DJCLS-R03/01,15-Jun-06,1/1/03,4/1/09,28-Jan-09,Jan-09,No Study Results Posted,null,Apr-09,Progression-free survival|safety according to common toxicity criteria (CTC)|rate of primary and secondary graft failure|rate of acute and chronic GVHD|response rate|chimerism,https://ClinicalTrials.gov/show/NCT00337519
42,NCT01213329,Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab,Terminated,Has Results,Kidney Transplant,Drug: Alemtuzumab,Northwestern University|American Society of Transplant Surgeons,All,18 Years to 65 Years Â  (Adult),Phase 4,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,STU00011048,30-Sep-10,2/1/06,4/1/09,18-Apr-13,Apr-13,3-May-11,null,Apr-09,The Effect of T Cell Depletion on Phenotypic & Functional Profiles of Peripheral Blood Mononuclear Cells in Steroid-free Kidney Transplant Recipients.|Identify Development of Donor-specific Hyperactivity,https://ClinicalTrials.gov/show/NCT01213329
121,NCT00836043,"Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia",Terminated,No Results Available,Chronic Lymphocytic Leukemia,Drug: Alemtuzumab (MabCampath),"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",,6,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,13418|13858|14241|MC0701|STAR,2-Feb-09,10/1/08,4/1/09,2-Dec-13,Dec-13,No Study Results Posted,null,Apr-09,"Efficacy related variables are patient's condition, physician's assessment of efficacy and tolerability, information whether application could be completed, clinical and laboratory findings. Safety Variables.",https://ClinicalTrials.gov/show/NCT00836043
110,NCT00214201,Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation,Completed,Has Results,Primary Renal Transplant,Drug: Calcineurin inhibitor withdrawal,"University of Wisconsin, Madison",All,"18 Years to 75 Years Â  (Adult, Senior)",,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-125,13-Sep-05,5/1/03,5/1/09,21-Sep-12,Sep-12,13-Aug-12,null,May-09,Number of Participants With Biopsy Proven Rejection|Serum Creatinine at 36 Months (End of Study),https://ClinicalTrials.gov/show/NCT00214201
49,NCT00472433,The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias,Terminated,No Results Available,Autoimmune Cytopenias,Drug: Alemtuzumab,Phramongkutklao College of Medicine and Hospital|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TH011003,25-Apr-07,3/1/07,5/1/09,18-Jun-09,Jun-09,No Study Results Posted,null,May-09,"To investigate the efficacy of alemtuzumab in terms of objective response rate (ORR: complete remission [CR], partial remission [PR]), progression free survival (PFS), and relapse rate in patients with autoimmune cytopenias|To determine the safety profiles of alemtuzumab in patients with autoimmune cytopenias.",https://ClinicalTrials.gov/show/NCT00472433
295,NCT00801931,Double Cord Blood Transplantation,Terminated,No Results Available,Leukemia|Lymphoma|Neuroblastoma|Immunodeficiencies|Anemia,"Drug: TBI, Thiotepa, Cyclophosphamide, ATG|Drug: Busulfan, Melphalan, Rabbit ATG|Drug: Busulfan, Fludarabine, Alemtuzumab|Drug: Busulfan, Fludarabine, Rabbit ATG|Drug: Fludarabine, Cyclophosphamide, ATG|Drug: Busulfan, Cyclosphosphamide, Rabbit ATG,",Columbia University,All,"up to 30 Years Â  (Child, Adult)",Phase 1|Phase 2,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAC3457|CHNY-06-533,5-May-08,9/1/07,5/1/09,17-Jul-13,Jul-13,No Study Results Posted,null,May-09,To determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant.|To quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.,https://ClinicalTrials.gov/show/NCT00801931
36,NCT00004143,Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes,Completed,Has Results,Sickle Cell Anemia|Severe Aplastic Anemia|Paroxysmal Nocturnal Hemoglobinuria (PNH)|Pure Red Cell Aplasia,"Drug: Campath, Chemo and/or TBI Allo SCT","David Rizzieri, MD|Duke University",All,"18 Years and older Â  (Adult, Senior)",Phase 2,2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00008771|DUMC-1340-99-7|NCI-G99-1617|CDR0000067374,10-Dec-99,9/1/99,6/1/09,19-Nov-14,Nov-14,6-Sep-13,null,May-08,Number of Patients With Neutrophil Engraftment|Number of Patients With Platelet Engraftment|Number of Patients With Grade 3-4 Acute Graft Versus Host Disease (GVHD)|Number of Participants With Grade 3-4 Unexpected Adverse Events|Number of Participants With Transplant-related Mortality|Overall Survival,https://ClinicalTrials.gov/show/NCT00004143
292,NCT00586274,Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT,Terminated,No Results Available,FANCONI ANEMIA,Procedure: CD34 selected haploidentical PBSCT|Drug: Fludarabine|Biological: T cell infusion|Biological: Campath 1h|Biological: anti-CD45,"Baylor College of Medicine|University of Texas, Southwestern Medical Center at Dallas|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"up to 64 Years Â  (Child, Adult)",Phase 1,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-11428,21-Dec-07,3/1/02,7/1/09,3-Mar-14,Mar-14,No Study Results Posted,RAFHAS,Jul-09,"Determine # of donor lymphocytes that can be given to recipients of haplo-SCT with FA after depletion of recipient-reactive T lymphocytes by ex-vivo tx with a fixed dose of RFT5-dgA immunotoxin, and will result in Grade III/IV GVHD of < / = 25%.|To analyze immune reconstitution in these patients.|To measure their overall and disease free survival, at 100 days and at 1 year after transplant.",https://ClinicalTrials.gov/show/NCT00586274
180,NCT00153985,Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies,Completed,Has Results,Hemoglobinopathies|Sickle Cell Disease|Thalassemia,Drug: Busulfex|Drug: Fludarabine|Drug: Alemtuzumab|Procedure: Stem Cell Transfusion,Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Emory University|Feist-Weiller Cancer Center at Louisiana State University Health Sciences|Ohio State University,All,"18 Years and older Â  (Adult, Senior)",Phase 2,2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,03-338,8-Sep-05,3/1/04,7/1/09,24-Jul-13,Jul-13,5-Dec-12,null,Mar-08,Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy.|Solid Organ Toxicity Related to the Conditioning Regimen.|The Incidence of Grade II-IV Acute Graft vs. Host Disease.,https://ClinicalTrials.gov/show/NCT00153985
103,NCT00143065,"Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",Completed,No Results Available,"Lymphoma, Small Lymphocytic|Lymphocytic Leukemia, Chronic",Drug: Fludarabine|Drug: Rituximab|Drug: Alemtuzumab,Ohio State University Comprehensive Cancer Center,All,"18 Years and older Â  (Adult, Senior)",Phase 2,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,OSU-0404,31-Aug-05,8/1/05,7/1/09,6-Feb-17,Feb-17,No Study Results Posted,null,Feb-07,"Assess the rate of complete (CR) and overall response (ORR) using fludarabine, rituximab, and alemtuzumab|Assess toxicity of this regimen.",https://ClinicalTrials.gov/show/NCT00143065
124,NCT00274976,Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine,Completed,No Results Available,Leukemia,Biological: alemtuzumab,German CLL Study Group|National Cancer Institute (NCI),All,18 Years to 65 Years Â  (Adult),Phase 2,null,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000455059|GCLLSG-CLL2H|EU-20550|MEDAC-GCLLSG-CLL2H|AMGEN-GCLLSG-CLL2H,10-Jan-06,9/1/02,8/1/09,5-Nov-13,May-06,No Study Results Posted,null,null,Safety and efficacy|Response,https://ClinicalTrials.gov/show/NCT00274976
48,NCT00441025,The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL,Terminated,No Results Available,Peripheral T-Cell Lymphoma,Drug: Alemtuzumab,Mahidol University|Bayer,All,"15 Years to 65 Years Â  (Child, Adult)",Phase 2,4,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TH 011002,26-Feb-07,9/1/06,8/1/09,24-Jun-09,Feb-07,No Study Results Posted,null,null,"To determine the effectiveness of alemtuzumab given in combination with CHOP in terms of the rates of objective response rate (ORR:complete remission[CR] and|partial remission[PR]),progressive disease-free(PFS) and overall survivals(OS)|in patients newly diagnosed with PTCL.|To determine the safety profiles of alemtuzumab given in combination with CHOP",https://ClinicalTrials.gov/show/NCT00441025
149,NCT00590460,Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia,Terminated,Has Results,Fanconi Anemia|Severe Aplastic Anemia,Biological: CAMPATH-1H|Biological: Anti-CD45|Drug: Fludarabine|Procedure: Stem cell infusion,"Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"Child, Adult, Senior",Phase 1|Phase 2,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-9938,26-Dec-07,7/1/01,9/1/09,21-Nov-13,Nov-13,2-Jul-12,Mafia,Sep-09,"Number of Patients With Donor Engraftment|Number of Patients With Graft Failure|Number of Patients With Treated Related Death|Days to Absolute Neutrophil Count (ANC) of 500/mm3|Days to Platelet Count of 20,000/mm3 Without Transfusions|Number of Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)|Number of Patients Alive at 1 Year Post Transplant|Number of Patients With Limited Chronic GVHD From Day 100 to 365|Number of Patients With Extensive Chronic GVHD From Day 100 to 365|Number of Patients With Grade III - IV Acute GVHD",https://ClinicalTrials.gov/show/NCT00590460
306,NCT00057005,Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation,Completed,No Results Available,Leukemia,Drug: CAMPATH-1H|Drug: Anti-CD45|Drug: Ara-C|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total Body Irradiation,"Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"up to 45 Years Â  (Child, Adult)",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H12870|ADVL,26-Mar-03,2/1/03,10/1/09,19-Jan-10,Nov-09,No Study Results Posted,ADVL,Oct-09,To evaluate the toxicity and the anti-tumor activity of anti-human CD45 antibodies (anti-CD45) administered to patients with relapsed/resistant leukemia prior to bone marrow transplantation.|To describe the effects of anti-CD45 on normal hematopoiesis and on complement levels and to describe the effects of anti-CD45 on leukemic blast cells.,https://ClinicalTrials.gov/show/NCT00057005
171,NCT00086775,Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia,Completed,No Results Available,Leukemia,Biological: alemtuzumab|Biological: rituximab|Drug: fludarabine phosphate,Bayer|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,null,Industry,Interventional,Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment,BRLX-FLUCAM106|CDR0000365631|BRLX-STA1-03-058|OHSU-HEM-03050-P|DMS-F0334,8-Jul-04,7/1/03,10/1/09,1-Aug-13,Oct-09,No Study Results Posted,null,Jun-05,,https://ClinicalTrials.gov/show/NCT00086775
132,NCT00336206,Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia,Unknown status,No Results Available,B-Cell Chronic Lymphocytic Leukemia,Drug: Alemtuzumab,Tawam Hospital,All,"18 Years to 75 Years Â  (Adult, Senior)",,60,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,39338,12-Jun-06,7/1/06,10/1/09,21-Jul-06,Jun-06,No Study Results Posted,null,null,To determine the Time to Treatment Failure (TTF)|To evaluate Complete Remission (CR) rate.|To evaluate Partial Response (PR) rate.|Minimal Residual Disease (MRD) evaluated with flow-cytometry (â€œMRD flow panelâ€ù) in patients with CR|To determine Overall Response Rate (ORR).|To evaluate duration of response.|To evaluate safety,https://ClinicalTrials.gov/show/NCT00336206
148,NCT00579137,Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders,Terminated,Has Results,Severe Combined Immunodeficiency Disease|Severe Primary Immunodeficiency Disorder|Undefined T Cell Deficiency Disorder|Wiskott-Aldrick Syndrome,Biological: Campath -1H|Drug: Fludarabine|Biological: Anti-CD45|Procedure: Stem cell infusion,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital",All,"Child, Adult, Senior",Phase 1|Phase 2,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,21123-MASCI,19-Dec-07,10/1/07,10/1/09,28-Jun-13,Jun-13,30-Mar-13,MASCI,Oct-09,Number of Patients With Donor Engraftment|Patients Alive at 1 Year|Number of Patients With Grade III or IV Toxicity|Number of Patients With Grade III to IV Acute GVHD,https://ClinicalTrials.gov/show/NCT00579137
46,NCT00505921,Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma,Terminated,Has Results,Lymphoma,Drug: Campath-1H|Drug: G-CSF|Drug: GM-CSF|Drug: BCNU|Drug: Stem Cell Transplant|Drug: Preparative Regimen for Allogenic Stem Cell Transplantation|Drug: Cytarabine|Drug: Etoposide|Drug: Melphalan|Drug: Campath|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Low dose total body irradiation,M.D. Anderson Cancer Center|Bayer,All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 2,27,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,ID02-645,20-Jul-07,3/1/03,11/1/09,8-Nov-11,Nov-11,30-Sep-11,null,Nov-09,Participant Progression Free Survival at 2 Years,https://ClinicalTrials.gov/show/NCT00505921
155,NCT00183248,Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients,Completed,Has Results,Kidney Transplantation|Kidney Disease|Kidney Failure,Drug: Alemtuzumab|Drug: Mycophenolate mofetil|Drug: Sirolimus|Drug: Tacrolimus|Procedure: Donor bone marrow stem cell infusion|Procedure: Kidney transplant,University of Miami|Immune Tolerance Network (ITN),All,18 Years to 65 Years Â  (Adult),Phase 1|Phase 2,9,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment,DAIT ITN022ST,11-Sep-05,9/1/04,11/1/09,17-Sep-12,Sep-12,5-Apr-12,null,Nov-09,Overall Participant Survival at One Year Post Kidney Transplant|Overall Kidney Graft Survival at One Year Post-Transplant|Participant Survival at Three Years Post Kidney Transplant|Graft Survival at Three Years Post-Transplant|Number of Kidney Biopsy-proven Acute Rejection|Number of Chronic Allograft Nephropathies|Number of Graft-versus-host Disease (GVHD) Events,https://ClinicalTrials.gov/show/NCT00183248
57,NCT00240994,Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients,Completed,Has Results,"Kidney Failure, Chronic|Kidney Transplantation|Immunosuppression",Drug: Alemtuzumab|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Sirolimus,National Institute of Allergy and Infectious Diseases (NIAID)|Cooperative Clinical Trials in Pediatric Transplantation,All,"1 Year to 20 Years Â  (Child, Adult)",Phase 2,35,NIH|Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,DAIT PC01,14-Oct-05,1/1/05,11/1/09,15-Nov-16,Nov-16,13-Sep-12,null,Nov-09,The Proportion of Participants With Graft Loss or Death Within 12 Months Post Kidney Transplantation,https://ClinicalTrials.gov/show/NCT00240994
6,NCT00587847,Campath Maintenance in Chronic Lymphocytic Leukemia,Terminated,Has Results,Chronic Lymphocytic Leukemia,Drug: Campath,Northwell Health|Bayer,All,"18 Years and older Â  (Adult, Senior)",,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,05.10.030|Berlex Study# 106.0621,21-Dec-07,8/1/05,11/1/09,16-Sep-15,Sep-15,29-May-13,null,Nov-09,Time to Progression (Months)|Rate of Infections,https://ClinicalTrials.gov/show/NCT00587847
168,NCT00278213,Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia,Completed,No Results Available,Prolymphocytic Leukemia,Biological: alemtuzumab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mitoxantrone hydrochloride,German CLL Study Group,All,"18 Years to 70 Years Â  (Adult, Senior)",Phase 2,17,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,T-PLL1|EU-20562,16-Jan-06,9/1/02,12/1/09,30-Sep-16,Sep-16,No Study Results Posted,null,Feb-07,Adverse effects at 2 months after treatment|Remission rate at 2 months after treatment|Overall survival at 2 months after treatment|Progression-free survival at 2 months after treatment|Remission quality at 2 months after treatment,https://ClinicalTrials.gov/show/NCT00278213
106,NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose RebifÂ® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Interferon beta-1a|Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg,"Genzyme, a Sanofi Company|Bayer|Sanofi",All,18 Years to 50 Years Â  (Adult),Phase 2,334,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,CAMMS223,19-Dec-02,12/1/02,1/1/10,6-Jan-15,Jan-15,3-Nov-08,null,Sep-07,Probability of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment|Percent Change From Baseline in T1 Cerebral Volume at Year 3|Percent Change From Baseline in MRI T2 Lesion Volume at Year 3,https://ClinicalTrials.gov/show/NCT00050778
78,NCT00634881,Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia,Completed,No Results Available,Chronic Lymphocytic Leukemia,Biological: Alemtuzumab i.v.|Biological: Alemtuzumab s.c.,German CLL Study Group,All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,13,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL2i|CDR0000587746,12-Mar-08,11/1/03,1/1/10,22-Nov-16,Sep-16,No Study Results Posted,null,Jan-10,Dose-limiting toxicity|Maximum tolerated dose|Rate of complete minimal residual disease response|Rate of immunophenotypic remission using 4-color flow cytometry|Rate of infections (especially CMV infections and reactivations)|Rate of severe hematologic and non-hematologic side effects|Pharmacokinetics of alemtuzumab (after IV and subcutaneous administration)|Progression-free survival|Overall survival|Complete remission rate,https://ClinicalTrials.gov/show/NCT00634881
247,NCT00626626,Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation,Terminated,No Results Available,Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia|Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma,Drug: Dose Level I|Drug: Dose Level 2,Milton S. Hershey Medical Center,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,25223|PSU25223,20-Feb-08,5/1/07,1/1/10,8-Jan-13,Jan-13,No Study Results Posted,null,Jan-10,Establish the safety of Clofarabine and cyclophosphamide preceding allogeneic hematopoietic engraftment. Assess the efficacy of Clofarabine and cyclophosphamide as conditioning for promoting allogeneic hematopoietic engraftment.|Observe disease free and overall survivals in acute leukemia and lymphoma patients receiving allogeneic hematopoietic transplant after Clofarabine and cyclophosphamide conditioning.,https://ClinicalTrials.gov/show/NCT00626626
47,NCT00004857,Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia,Completed,No Results Available,Leukemia,Biological: alemtuzumab|Drug: fludarabine phosphate,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,86,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-19901|U10CA031946|CDR0000067506,7-Mar-00,1/1/00,2/1/10,1-Jul-16,Jul-16,No Study Results Posted,null,Mar-03,Response|Toxicity,https://ClinicalTrials.gov/show/NCT00004857
172,NCT00078559,Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults,Completed,Has Results,Kidney Transplantation|Kidney Disease,"Drug: Alemtuzumab|Drug: Sirolimus|Drug: Tacrolimus|Procedure: Kidney transplant|Drug: Methylprednisolone (or equivalent)|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|Drug: Valgancyclovir|Drug: Acyclovir|Drug: Pentamidine|Drug: Clotrimazole|Drug: Nystatin","University of Wisconsin, Madison|Immune Tolerance Network (ITN)",All,18 Years to 65 Years Â  (Adult),Phase 1|Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DAIT ITN013ST,1-Mar-04,11/1/03,2/1/10,25-Jul-12,Jul-12,13-Apr-12,null,Feb-10,"Number of Acute Rejections in All Enrolled Participants|Number of Acute Rejections in All Enrolled Participants Following Sirolimus Withdrawal|Number of Acute Rejections Between Initiation of Sirolimus Withdrawal and End of Study|Time From Transplantation to Acute Rejection in Participants for Whom Sirolimus Withdrawal Was Not Initiated|Time From Transplantation to Acute Rejection in Participants for Whom Acute Rejection Occurred During the 1 Year Post-transplant Period|Number of Deaths Stratified by Sirolimus Withdrawal Status|Number of Participants Who Experienced Graft Loss Stratified by Sirolimus Withdrawal Status|Number of Severe Acute Rejections Stratified by Sirolimus Withdrawal Status|Number of Participants Requiring Anti-lymphocyte Therapy for an Acute Rejection, Stratified by Sirolimus Withdrawal Status|Number of Alemtuzumab Associated Adverse Events, Stratified by Sirolimus Withdrawal Status|Number of Tacrolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status|Number of Sirolimus Associated Adverse Events, Stratified by Sirolimus Withdrawal Status|Number of Side Effects of Conventional Immunosuppression, Stratified by Withdrawal Status|Change in Renal Function as Measured by Serum Creatinine, Stratified by Withdrawal Status",https://ClinicalTrials.gov/show/NCT00078559
259,NCT00668564,Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism,Terminated,Has Results,"Hurler's Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Sphingolipidoses|Krabbe Disease|Wolman's Disease|Niemann-Pick Disease Type B|Niemann-Pick Disease, Type C",Procedure: Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Campath-1H|Drug: Busulfan,"Masonic Cancer Center, University of Minnesota",All,"up to 21 Years Â  (Child, Adult)",Phase 2,18,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2008-02|0801M25202,25-Apr-08,3/1/08,2/1/10,6-Nov-12,Nov-12,14-Jun-11,null,Feb-10,Number of Patients Achieving Engraftment|Overall Survival,https://ClinicalTrials.gov/show/NCT00668564
50,NCT00453193,Alemtuzumab and Pentostatin In T-cell Neoplasms,Terminated,Has Results,Lymphoma|Leukemia,Drug: Pentostatin|Drug: Alemtuzumab,M.D. Anderson Cancer Center|Astex Pharmaceuticals|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 2,26,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0408,26-Mar-07,9/1/04,3/1/10,1-Aug-12,Aug-12,1-Mar-11,null,Mar-10,Number of Participants With Objective Response,https://ClinicalTrials.gov/show/NCT00453193
8,NCT00309270,Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation,Completed,No Results Available,Kidney Transplant,Drug: Campath-1H,Mario Negri Institute for Pharmacological Research,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 2,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CAMPATH,30-Mar-06,2/1/03,4/1/10,18-May-06,Mar-06,No Study Results Posted,null,null,Time course of immunophenotyping and lymphocyte function assays in the two groups of kidney transplant recipients randomized to low-dose sirolimus or CsA- based maintenance immunosuppression after Campath-1H induction therapy|Graft function and survival|Safety of induction therapy with Campath-1H and low-dose maintenance immunosuppressive regimen,https://ClinicalTrials.gov/show/NCT00309270
143,NCT00166712,A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression,Terminated,Has Results,Kidney Transplant Failure and Rejection,Drug: Tacrolimus (TAC)|Drug: Sirolimus|Drug: Alemtuzumab|Drug: Mycophenolate mofetil (MMF),Northwestern University|Roche Pharma AG,All,18 Years to 65 Years Â  (Adult),Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,STU8789 0811-007|CNV0042139,9-Sep-05,4/1/05,4/1/10,20-Oct-15,Oct-15,29-Nov-12,Cell220,Apr-10,The Incidence of Biopsy-proven Acute Allograft Rejection During the First 12 Months of Transplant.|Severity of Acute Rejection During the First 6 and 12 Months Post-transplant|Renal Function at 12 Months Post-transplant|Incidence of Donor Specific Hyporesponsiveness Allowing for the Conversion to Monotherapy|Patient and Graft Survival Rates at 6 and 12 Months Post-transplant,https://ClinicalTrials.gov/show/NCT00166712
176,NCT01172418,Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols,Completed,Has Results,"Transplant; Failure, Kidney",Drug: Alemtuzumab/Thymoglobulin|Drug: Daclizumab/Thymoglobulin,University of Miami,null,"18 Years and older Â  (Adult, Senior)",Phase 4,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,IRB #20057672,10-Jun-10,2/1/06,5/1/10,24-May-16,May-16,1-Aug-14,null,May-10,Incidence of Acute Rejection at One Year Post-transplant|Graft Survival|Patient Survival,https://ClinicalTrials.gov/show/NCT01172418
94,NCT00086580,"Fludarabine (FludaraÂ®) Plus Alemtuzumab (CAMPATHÂ®, MabCampathÂ®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia,Biological: FluCAM [Fludara + Campath]|Biological: fludarabine phosphate,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 3,335,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM314|2004-000149-39,6-Jul-04,7/1/04,6/1/10,10-Feb-14,Feb-14,13-Jun-11,null,Jun-10,Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment|Participant Best Response to Treatment Assessed by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Overall Survival Time|Kaplan Meier Estimates for Time to Disease Progression Assessed by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates for Duration of Response Assessed by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates for Time to Alternative Therapy|Mean EQ-5Dâ„¢ Index Scores to Measure Quality of Life at Baseline|Mean EQ-5Dâ„¢ Index Scores to Measure Quality of Life at End of Treatment|Mean EuroQol Visual Analogue Scale (EQ-VAS) Scores to Measure Quality of Life at Baseline|Mean EuroQol Visual Analogue Scale (EQ-VAS) Scores to Measure Quality of Life at End of Treatment|Summary of Participants With Adverse Experiences (AEs)|Mean Systemic Clearance (CL) of Fludarabine|Total Volume of Distribution (Vss) of Fludarabine|Area Under the Curve (AUC) of Fludarabine From (AUC 0-tau)|Maximum Plasma Concentration (Cmax) of Fludarabine|Participants With Minimal Residual Disease (MRD),https://ClinicalTrials.gov/show/NCT00086580
289,NCT00829647,A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia,Unknown status,No Results Available,Chronic Lymphocytic Leukemia|Leukemia,Drug: dasatinib and lenalidomide,Scripps Health|Bristol-Myers Squibb|Celgene Corporation,All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCLL084993,23-Jan-09,1/1/09,6/1/10,13-Oct-09,Oct-09,No Study Results Posted,null,Jan-10,"Safety and maximum tolerated dose (phase I) and overall response rate (phase II)|Assess responses in subgroups of high-risk patients, including 17p- and 11q- deletion, and CD38 and ZAP-70 positive expression",https://ClinicalTrials.gov/show/NCT00829647
252,NCT00281983,Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia,Completed,No Results Available,Chronic Lymphocytic Leukemia,Biological: alemtuzumab|Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: rituximab|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,German CLL Study Group,All,18 Years to 65 Years Â  (Adult),Phase 1|Phase 2,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,CLL3X|EU-20554|MEDAC-FLUD.10/CLL,24-Jan-06,6/1/00,7/1/10,23-Feb-17,Apr-07,No Study Results Posted,null,null,Feasibility as measured by the proportion of eligible patients completing the transplant procedure successfully|Safety as measured by a treatment-related mortality of < 25% at 2 years following transplant|Clinical remission rate by NIH criteria at 12 months following transplant|Minimal residual disease negativity rate as measured by high-resolution flow or CDR PCR at 12 months following transplant|Chimerism as measured by STR-PCR at 12 months following transplant|Event-free and overall survival at 5 years following transplant,https://ClinicalTrials.gov/show/NCT00281983
7,NCT00800943,Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy,Unknown status,No Results Available,B-Cell Chronic Lymphocytic Leukemia,Biological: Alemtuzumab (Campath-1H),Chronic Lymphocytic Leukemia Research Consortium|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 2,31,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CRC005,1-Dec-08,12/1/03,8/1/10,2-Dec-08,Dec-08,No Study Results Posted,CRC005,Aug-10,To evaluate whether CAMPATH-1H given to patients with CLL after maximum response to chemotherapy will: a) eliminate residual disease (documented by flow cytometry) or b) convert partial remission to complete remission|To evaluate the time-to-progression of patients according to pretreatment characteristics and response status at study entry.|To evaluate whether CAMPATH-1H given to patients with CLL after maximum response to chemotherapy will eliminate minimal residual disease as determined by real-time quantitative PCR.,https://ClinicalTrials.gov/show/NCT00800943
74,NCT00749112,Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias,Completed,No Results Available,"Idiopathic Thrombocytopenic Purpura|Anemia, Hemolytic, Autoimmune","Drug: Alemtuzumab, Rituximab",Hospital Universitario Dr. Jose E. Gonzalez,All,"16 Years and older Â  (Child, Adult, Senior)",Phase 2|Phase 3,19,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HE08-004,8-Sep-08,8/1/08,8/1/10,27-Aug-10,Aug-10,No Study Results Posted,null,Aug-10,"Objective response rate (CR: complete remission, PR: partial remission, relapse rate.",https://ClinicalTrials.gov/show/NCT00749112
69,NCT00038844,Safety and Efficacy of Campath in Nonmyeloablative Transplantation,Completed,No Results Available,Lymphoma|Leukemia,Drug: Campath-1 H (Alemtuzumab)|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab,M.D. Anderson Cancer Center,All,"up to 70 Years Â  (Child, Adult, Senior)",,65,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID01-200,5-Jun-02,6/1/01,9/1/10,31-Oct-11,Oct-11,No Study Results Posted,null,Dec-07,Number of Participants Surviving 100 days post-transplant,https://ClinicalTrials.gov/show/NCT00038844
244,NCT00525876,Non-Myeloablative Allogeneic Stem Cell Transplantation,Completed,Has Results,Lymphoma,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rituximab|Drug: Alemtuzumab|Procedure: Allogeneic Stem Cell Infusion,M.D. Anderson Cancer Center,All,"up to 70 Years Â  (Child, Adult, Senior)",,49,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0309,4-Sep-07,1/1/05,9/1/10,2-Nov-11,Nov-11,2-Nov-11,null,Sep-10,Overall Survival at 100 Days Post Transplant (Number of Surviving Participants),https://ClinicalTrials.gov/show/NCT00525876
104,NCT00775632,Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants,Completed,No Results Available,Graft Versus Host Disease|Bone Marrow Transplantation,Drug: Alemtuzumab|Drug: mycophenolate or cyclosporine and methotrexate,"University Health Network, Toronto|Bayer",All,"16 Years to 70 Years Â  (Child, Adult, Senior)",Phase 2,78,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UHN REB 07-0436C,16-Oct-08,10/1/08,9/1/10,21-Jun-16,Jun-16,No Study Results Posted,null,Sep-10,Chronic extensive GVHD at 1-year (yes vs. no),https://ClinicalTrials.gov/show/NCT00775632
161,NCT00579111,Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB),Terminated,Has Results,Myelodysplastic and Myeloproliferative Disorders|Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Multiple Myeloma|Plasma Cell Dyscrasia|Lymphoproliferative Disorders|Hematologic Diseases,Drug: Campath|Drug: Busulfan|Drug: Fludarabine|Procedure: Hematopoietic stem cell infusion|Drug: FK-506,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System",All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 1|Phase 2,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,19386|FAB,19-Dec-07,6/1/07,10/1/10,29-Mar-16,Mar-16,3-Jul-12,null,Feb-09,Number of Patients With Successful Donor Engraftment|Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity,https://ClinicalTrials.gov/show/NCT00579111
97,NCT00637390,A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.,Terminated,No Results Available,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Alemtuzumab,University of Michigan Cancer Center,Female,"18 Years and older Â  (Adult, Senior)",Phase 1,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 2007.120,10-Mar-08,3/1/08,10/1/10,1-Dec-16,Dec-16,No Study Results Posted,null,Oct-10,"safety & maximally tolerated dose|Effectiveness of Alemtuzumab to eliminate VLCs.|Assess molecular markers associated with reduction in VLCs.|Anti-tumor activity measured by decline or stabilization of CA125(a protein that is a tumor marker)or radiological(ie. CT, MRI, X-Ray)improvement or improvement in progression free survival.|Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.",https://ClinicalTrials.gov/show/NCT00637390
112,NCT00536978,Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies,Completed,Has Results,Lymphoma|Leukemia,Drug: ARA-C|Drug: BCNU|Drug: Campath-1H|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Fludarabine|Drug: Melphalan|Drug: Rituximab|Other: Allogeneic Stem Cell Transplantation|Radiation: Total body radiation (TBI)|Drug: Methotrexate|Drug: Tacrolimus|Procedure: Adback NK or T Cell,M.D. Anderson Cancer Center,All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 2,22,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-0230,27-Sep-07,9/1/07,11/1/10,23-Apr-12,Apr-12,23-Apr-12,null,Nov-10,6-month Treatment Related Mortality (TRM)|One-year Disease-free Survival (DFS),https://ClinicalTrials.gov/show/NCT00536978
287,NCT00315614,Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus,Terminated,Has Results,Type 1 Diabetes Mellitus,Biological: Islet Transplantation and Bone Marrow,University of Miami|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Diabetes Research Institute Foundation,All,18 Years to 65 Years Â  (Adult),Phase 2,3,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2000/0024|R01DK056953,14-Apr-06,12/1/00,12/1/10,29-Mar-17,Mar-17,20-Dec-13,null,Dec-10,The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.|A Reduction or Absence of Rejection Episodes|Number of Subjects With Basal C-peptide Greater Than 0.5 ng/ml|Number of Subjects With Reduction of Severe Hypoglycemia and Improvement in Hypoglycemia Awareness,https://ClinicalTrials.gov/show/NCT00315614
56,NCT00771602,Alemtuzumab + Rituximab Consolidation in CLL,Terminated,Has Results,Chronic Lymphocytic Leukemia|Leukemia,Drug: Rituximab|Drug: Alemtuzumab,"M.D. Anderson Cancer Center|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",Phase 2,1,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-0767,10-Oct-08,8/1/08,12/1/10,27-May-15,May-15,4-Apr-11,null,Dec-10,Number of Patients With Molecular Remissions at 52 Weeks|Progression-free Survival|52 Week Toxicity Rate,https://ClinicalTrials.gov/show/NCT00771602
183,NCT00871546,SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715),Terminated,No Results Available,"Lymphoma, Mantle-Cell|Leukemia, Lymphocytic, Chronic, B-Cell",Drug: SCH 727965|Drug: Bortezomib|Biological: Alemtuzumab,Merck Sharp & Dohme Corp.,All,"18 Years and older Â  (Adult, Senior)",Phase 2,8,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,P04715,26-Mar-09,3/1/09,12/1/10,6-Aug-15,Aug-15,No Study Results Posted,null,Dec-10,Response rate of initial treatment with SCH 727965 in subjects with MCL or B-CLL.|Response rate in subjects treated with SCH 727965 after disease progression on comparator drug.|Time to disease progression for initial treatment with SCH 727965.|Time to disease progression and response rate for treatment with the comparator drug.|Response rate for treatment with the comparator drug.|Time to disease progression in participants treated with SCH 727965 after disease progression on comparator drug.,https://ClinicalTrials.gov/show/NCT00871546
141,NCT01082939,"Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,All,"Child, Adult, Senior",Phase 2,80,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DM02-593,5-Mar-10,12/1/02,1/1/11,17-Feb-12,Feb-12,26-Jul-11,null,Jan-11,Number of Participants With an Overall Response,https://ClinicalTrials.gov/show/NCT01082939
200,NCT00407160,A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients,Completed,No Results Available,Kidney Diseases,,"The University of Texas Medical Branch, Galveston",All,"18 Years to 75 Years Â  (Adult, Senior)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,04-245,21-Nov-06,8/1/04,1/1/11,6-Sep-11,Sep-11,No Study Results Posted,null,Jan-11,,https://ClinicalTrials.gov/show/NCT00407160
19,NCT01806337,CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma,Completed,No Results Available,Peripheral T-Cell Lymphoma,Drug: Alemtuzumab,University of GÃ¶ttingen,All,"18 Years to 70 Years Â  (Adult, Senior)",Phase 2,41,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DSHNHL-2003-1|German High Grade Lymphoma SG,25-Feb-13,7/1/03,2/1/11,6-Mar-13,Mar-13,No Study Results Posted,null,Jul-06,Feasibility of alemtuzumab consolidation after CHO(E)P 14 induction chemotherapy|rate of complete remissions|Overall survival,https://ClinicalTrials.gov/show/NCT01806337
64,NCT00098670,"Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia",Completed,Has Results,B-cell Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia,Biological: alemtuzumab|Biological: rituximab|Drug: fludarabine phosphate,National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,102,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-02812|CDR0000398139|CALGB-10101|P30CA014236|U10CA031946,7-Dec-04,10/1/04,2/1/11,6-May-14,Dec-12,5-Nov-12,null,Feb-11,Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab|Number of Participants With a Complete or Partial Response After Induction Therapy With Fludarabine & Rituximab|2 Year Progression Free Survival|2 Year Survival|Number of Participants With Severe Non-Hematologic Adverse Events During Treatment With Alemtuzumab,https://ClinicalTrials.gov/show/NCT00098670
87,NCT00105235,Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients,Completed,Has Results,Liver Disease|Liver Transplantation,Drug: Alemtuzumab|Drug: Cyclosporine|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Procedure: Liver transplant|Procedure: Immunosuppression withdrawal,National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN),All,"18 Years and older Â  (Adult, Senior)",Phase 2,27,NIH|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DAIT ITN024ST,10-Mar-05,6/1/05,3/1/11,23-Nov-12,Nov-12,2-Mar-12,TILT,Mar-07,Proportion of Participants Who Have Graft Loss or Death|Proportion of Participants Who Had Graft Loss or Death|Number of Events: Immunosuppression-related Complications|Proportion of Participants Successfully Withdrawn From Immunosuppressants|Proportion of Participants Successfully Withdrawn and Remain Off Immunosuppressants,https://ClinicalTrials.gov/show/NCT00105235
55,NCT00246129,Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation,Unknown status,No Results Available,Kidney Transplantation|Kidney Diseases|Kidney Failure,Drug: Alemtuzumab|Drug: Daclizumab,Hammersmith Hospitals NHS Trust,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 4,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,SMHREN0501|EUdraCT 2005âˆ’002856âˆ’17,28-Oct-05,10/1/05,4/1/11,9-May-08,May-08,No Study Results Posted,null,Apr-09,"One year survival with a functioning graft|Occurrence, severity, and type of rejection episodes|Occurrence, severity, and type of infection episodes|Initial length of stay in hospital and subsequent admissions|Cost over the first year of the two therapies|Presence in the blood of cells which might trigger rejection in, or promote tolerance to the graft|Early development of scarring in the grafts|Graft function|Patient survival and graft survival censored for death with function",https://ClinicalTrials.gov/show/NCT00246129
90,NCT00530348,"Comparison of Alemtuzumab and RebifÂ® Efficacy in Multiple Sclerosis, Study One",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab|Biological: Interferon beta-1a,"Genzyme, a Sanofi Company|Bayer|Sanofi",All,18 Years to 50 Years Â  (Adult),Phase 3,581,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,CAMMS323|ISRCTN21534255|ACTRN12608000435381|CARE-MS I|2007-001161-14,13-Sep-07,8/1/07,4/1/11,17-Nov-14,Nov-14,17-Nov-14,CARE-MS I,Apr-11,Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2,https://ClinicalTrials.gov/show/NCT00530348
83,NCT00698685,Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation,Terminated,Has Results,"Leukemia|Lymphoma|Hodgkin's Disease|Hematologic Neoplasms|Multiple Myeloma|Carcinoma, Renal Cell",Drug: Pentostatin|Biological: Alemtuzumab|Procedure: Allogeneic hematopoietic stem cell transplantation,University of Arizona|National Cancer Institute (NCI),All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 2,14,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,05-0624-04|R21CA106177|05110|UARIZ-05-0624-01|UARIZ-SRC17920,14-Jun-08,1/23/06,4/26/11,23-Mar-17,Mar-17,28-Dec-10,null,13-Apr-09,Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).|Non-relapse Mortality at or Before Day 100,https://ClinicalTrials.gov/show/NCT00698685
290,NCT00342134,Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis,Completed,No Results Available,Multiple Sclerosis,Procedure: Stem Cell Transplanataion,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"18 Years to 70 Years Â  (Adult, Senior)",Phase 2,34,NIH,Interventional,Primary Purpose: Treatment,999902196|02-N-N196,19-Jun-06,5/1/02,5/4/11,24-Jan-17,4-May-11,No Study Results Posted,null,4-May-11,,https://ClinicalTrials.gov/show/NCT00342134
18,NCT00316810,Simultaneous Pancreas-kidney Transplantation With Campath Protocol,Completed,No Results Available,Pancreas-Kidney Transplantation,Drug: Alemtuzumab|Drug: Rabbit Anti-Human Thymocyte Globulin,Dr. Claudia BÃ¶smÃ_ller|Astellas Pharma GmbH|Medical University Innsbruck,All,18 Years to 55 Years Â  (Adult),Phase 3,30,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SIMPATICO|EudraCT Number: 2006-000845-21,19-Apr-06,4/1/06,6/1/11,18-Jun-12,Jun-12,No Study Results Posted,null,Feb-11,"Biopsy-proven (Kidney) rejection episodes|Kidney/Pancreas function|Patient and graft survival|Lipid profile ( Total Cholesterol, HDL, LDL, Triglycerides, Treatment with statins)|Infections|Side effects|Blood Pressure|Treatment failure for any reason, such as permanent discontinuation of a drug, change from immunosuppressive protocol, graft loss or death|Percentage of steroid free patients",https://ClinicalTrials.gov/show/NCT00316810
213,NCT00462332,Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia,Completed,Has Results,Leukemia,Drug: Fludarabine|Drug: Campath|Procedure: Transplant|Drug: Campath|Drug: Fludarabine|Drug: Campath|Drug: Campath,Gruppo Italiano Malattie EMatologiche dell'Adulto,All,"up to 60 Years Â  (Child, Adult)",Phase 2,86,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LLC0405|2005-002476-15,18-Apr-07,5/1/07,6/1/11,20-Aug-13,Aug-13,20-Aug-12,LLC0405,Jun-11,Number of Patients With Complete Response|Toxicity|Length of Survival|Event-free Survival|Disease-free Survival,https://ClinicalTrials.gov/show/NCT00462332
307,NCT00767650,Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia,Completed,No Results Available,Aplastic Anemia,,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"15 Years and older Â  (Child, Adult, Senior)",,7,NIH,Observational,Time Perspective: Prospective,080222|08-H-0222,6-Oct-08,9/23/08,6/28/11,24-Jan-17,28-Jun-11,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00767650
21,NCT00147381,Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection,Completed,No Results Available,Kidney Transplantation,Drug: Alemtuzumab|Drug: Tacrolimus|Drug: Alemtuzumab,Dr. Claudia BÃ¶smÃ_ller|Astellas Pharma GmbH|Medical University Innsbruck,All,18 Years to 65 Years Â  (Adult),Phase 3,197,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,TaCam 07_MC|DE-02-RG-121/Margreiter,6-Sep-05,1/1/04,7/1/11,18-Jun-12,Jun-12,No Study Results Posted,null,Aug-08,"Biopsy proven acute rejection episodes 6 months after transplantation (Banff Classification)|Biopsy proven acute rejection episodes 12 months after transplantation (Banff Classification)|Time to 1st biopsy proven acute rejection episode (Banff Cl.)|Patient and graft survival|Number of patients who will get antilymphocyte preparation for treatment of steroid resistant acute rejection episodes|Treatment failure defined as change from immunosuppressive protocol because of biopsy proven intractable rejection|Adverse events (e.g. infections, PTLD)|Creatinine clearance",https://ClinicalTrials.gov/show/NCT00147381
181,NCT00525603,CFAR Study in Patients With Chronic Lymphocytic Leukemia,Completed,Has Results,Leukemia|Chronic Lymphocytic Leukemia,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Alemtuzumab|Drug: Rituximab,M.D. Anderson Cancer Center|Bayer,All,"up to 69 Years Â  (Child, Adult, Senior)",Phase 2,60,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0269,4-Sep-07,6/1/05,7/1/11,25-Jan-13,Jan-13,4-Oct-12,null,Jul-11,Overall Participant Response,https://ClinicalTrials.gov/show/NCT00525603
5,NCT00773149,Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia,Completed,No Results Available,Acute Lymphocytic Leukemia,Drug: Alemtuzumab (CAMPATH 1H) associated to G-CSF,Assistance Publique - HÃ´pitaux de Paris,All,"15 Years and older Â  (Child, Adult, Senior)",Phase 1|Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P051003,15-Oct-08,10/1/06,7/1/11,25-Jul-12,Feb-11,No Study Results Posted,Campath,Jan-11,"Partial and complete remission, overall response rates|Valuation of tolerance, more particularly targeted at the immunodeficiency shortage, contagious complications and neurotoxicity assessed according to the NCI (National Cancer Institute) classification.|Valuation of the response waiting time, from the first day of the induction treatment to the REEVOLUTING.",https://ClinicalTrials.gov/show/NCT00773149
184,NCT00354120,Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant,Completed,No Results Available,Acute Myeloblastic Leukemia|Lymphoblastic Leukemia|Myelodysplasia|Chronic Myeloid Leukemia|Myelofibrosis|Lympho-proliferative Diseases,Drug: Alentuzumab|Drug: Globulina antilinfocitaria,Gruppo Italiano Trapianto di Midollo Osseo,All,18 Years to 65 Years Â  (Adult),Phase 2|Phase 3,121,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EudraCT:2005-000805-68,19-Jul-06,3/1/05,8/1/11,20-Mar-14,Mar-14,No Study Results Posted,GLOBAL,Aug-11,Overall Survival|Event Free Survival and Disease Free Survival|Safety:|Major infective complications (CMV and EBV related PTLD)|Acute and chronic GvHD|Haematological and immunologic reconstitution|Incidence of CMV and EBV reactivation|Other infective complications|Other toxicities|Need for DLI,https://ClinicalTrials.gov/show/NCT00354120
10,NCT00328198,"Subcutaneous Alemtuzumab (CAMPATHÂ®, MabCampathÂ®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia",Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia (B-CLL),Biological: Alemtuzumab|Biological: Alemtuzumab,"Genzyme, a Sanofi Company|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 2,86,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM203|2005-005074-69,18-May-06,5/1/06,8/1/11,10-Feb-14,Feb-14,25-Jun-12,null,Aug-11,Number of Participants With Best Disease Response as Determined by the Independent Response Review Panel (IRRP)|Percentage of Participants Who Had an Overall Response (OR) as Determined by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Progression Free Survival as Determined by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Duration of Response as Determined by the Independent Response Review Panel (IRRP)|Kaplan-Meier Estimates of Overall Survival|Participants With a Minimal Residual Disease (MRD) Status of Negative|Participants With Treatment-Emergent Adverse Events (TEAE),https://ClinicalTrials.gov/show/NCT00328198
45,NCT00923182,A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Completed,No Results Available,"Leukemia, Lymphocytic, Chronic, B-Cell",Drug: alemtuzumab,"Genzyme, a Sanofi Company|Sanofi",All,"20 Years to 75 Years Â  (Adult, Senior)",Phase 1,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAMCLL07709|14020,9-Jun-09,2/1/10,8/1/11,29-Apr-15,Apr-15,No Study Results Posted,null,Aug-11,"Safety profile: As measured by physical examinations, vital signs, adverse events, concomitant medications and laboratory tests|Overall response rate: Defined as the proportion of patients who achieved complete remission (CR) or partial remission (PR) as the best response according to the investigator's determination using the NCIWG response criteria|Pharmacokinetic profiles: Area under the serum concentration vs time curve over the dosing interval, Maximum drug concentration in serum, terminal elimination half-life following the last dose, total body clearance and volume of distribution|Time to response: Defined as the time from date of initial treatment until first objective documentation of response (CR or PR) as determined by the investigator.|Duration of response: Defined as the time from first objective documentation of response (CR or PR) by the investigator to first objective documentation of progressive disease by the investigator|Time to progression: Defined as the time from date of initial treatment to first objective documentation of progressive disease by the investigator",https://ClinicalTrials.gov/show/NCT00923182
173,NCT00301834,"Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders",Completed,Has Results,Congenital Amegakaryocytic Thrombocytopenia|Diamond-blackfan Anemia|Leukemia|Myelodysplastic Syndromes|Severe Congenital Neutropenia,Biological: alemtuzumab|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation,"University of California, San Francisco|National Cancer Institute (NCI)",All,"up to 21 Years Â  (Child, Adult)",Phase 2,35,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000462406|UCSF-04152|UCSF-00452|UCSF-H411-25738-02,9-Mar-06,1/1/05,9/1/11,15-May-13,May-13,31-Jan-13,null,Sep-11,Number of Participants Achieving Durable Engraftment (Presence of Donor Cells) at 6 Weeks Post Transplantation|Treatment-related Mortality at 100 Days and 1 Year Post Transplantation|Toxicity Grade â‰¥ 3 From Start of Conditioning Through the First Year Post Transplantation|Cytomegalovirus (CMV) Viral Infection and Disease Symptoms|Disease-free Survival With Correction of Disease at One Year Post Transplantation,https://ClinicalTrials.gov/show/NCT00301834
100,NCT00548405,"Comparison of Alemtuzumab and RebifÂ® Efficacy in Multiple Sclerosis, Study Two",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg|Biological: Interferon beta-1a,"Genzyme, a Sanofi Company|Bayer|Sanofi",All,18 Years to 55 Years Â  (Adult),Phase 3,840,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,"CAMMS32400507|2007-001162-32|CAMMS324,|ISRCTN70702834|ACTRN12608000426381|NTR1469|CARE-MS II",22-Oct-07,10/1/07,9/1/11,6-Jan-15,Jan-15,17-Nov-14,CARE-MS II,Sep-11,Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2,https://ClinicalTrials.gov/show/NCT00548405
71,NCT00983528,Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia,Unknown status,No Results Available,Acute Lymphoblastic Leukemia,Biological: Alemtuzumab|Drug: Clofarabine,"University of California, San Diego|Genzyme, a Sanofi Company",All,"16 Years and older Â  (Child, Adult, Senior)",Phase 1|Phase 2,28,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,90331,23-Sep-09,9/1/09,9/1/11,3-May-11,May-11,No Study Results Posted,null,Sep-11,To determine the maximum tolerated dose of clofarabine when administered in combination with alemtuzumab as measured by CTC version 3.0. (Phase 1)|To determine the complete response rate based on bone marrow morphologic assessment. (Phase 2)|To evaluate the safety and tolerability of clofarabine when administered in combination with alemtuzumab to patients with relapsed and refractory ALL as measured by CTC version 3.0 (Phase 2)|Evaluate how many patients who are potential allogeneic stem cell transplant candidates receive stem cell transplant.|Determine progression-free survival and overall survival.,https://ClinicalTrials.gov/show/NCT00983528
139,NCT00230282,"Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia",Completed,Has Results,Leukemia|B-cell Leukemia|Chronic Leukemia|Chronic Lymphocytic Leukemia (CLL),Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cytoxan,Steven E. Coutre|Bayer|Stanford University,All,"18 Years and older Â  (Adult, Senior)",Phase 2,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB-13053|31185|80071|HEMCLL0001,28-Sep-05,7/1/04,10/1/11,25-Sep-14,Sep-14,27-Aug-14,null,Dec-10,Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)|Duration of Response,https://ClinicalTrials.gov/show/NCT00230282
215,NCT00278616,Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome,Withdrawn,No Results Available,ANTIPHOSPHOLIPID SYNDROME,Biological: Stem Cell Transplantation,"Richard Burt, MD|Northwestern University",All,18 Years to 55 Years Â  (Adult),Phase 1,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NU APS AUTO 2004,16-Jan-06,8/1/05,10/1/11,9-Apr-12,Apr-12,No Study Results Posted,null,Oct-11,Toxicity; Survival;Disease improvement;Time to disease progression;,https://ClinicalTrials.gov/show/NCT00278616
101,NCT00436904,"Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia",Completed,Has Results,Leukemia,Drug: Alemtuzumab|Drug: Rituximab,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,30,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000529809|P30CA015083|MC038G|801-04|106.G0309|U3023s,15-Feb-07,12/1/04,11/1/11,21-Nov-11,Nov-11,16-Sep-11,null,Jul-08,"Confirmed Response, Defined as Objective Complete Remission or Partial Remission for a Duration of at Least 2 Months|Number of Participants With Treatment Related Adverse Events|Time to Response|Duration of Response|Survival|Time to Disease Progression",https://ClinicalTrials.gov/show/NCT00436904
162,NCT00147901,"Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)",Completed,No Results Available,B-cell Chronic Lymphocytic Leukemia,Drug: FCCam,German CLL Study Group|University of Cologne|MedacSchering Onkologie,All,"18 Years and older Â  (Adult, Senior)",Phase 2,61,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL-2L|2005-003017-32,2-Sep-05,1/1/05,11/1/11,30-Sep-16,Sep-16,No Study Results Posted,null,Nov-08,Overall response rate (complete and partial response rate)|Toxicity|MRD response rate|Response rate in biological defined risk groups|Duration of response|Treatment administration (dose intensity)|Overall survival,https://ClinicalTrials.gov/show/NCT00147901
261,NCT00587158,Oral Paricalcitol in Kidney Transplant Recipients,Completed,Has Results,"Transplant; Failure, Kidney|Renal Disease, End Stage|Hyperparathyroidism, Secondary",Drug: Paricalcitol|Other: Corticosteroid Avoidance Immune Suppression Protocol,Mayo Clinic|Abbott,All,"18 Years and older Â  (Adult, Senior)",,100,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,256-06,21-Dec-07,1/1/07,11/1/11,9-May-13,May-13,24-Jan-13,null,Nov-11,Number of Subjects With Hyperparathyroidism at One Year|Number of Subjects With Osteopenia/Osteoporosis of the Hip at One Year|Number of Subjects With Osteopenia/Osteoporosis of the Lumbar Spine at One Year|Serum Parathyroid Hormone (PTH) Level Over Time|Serum Bone Alkaline Phosphatase (BAP) Level Over Time|Change in Lumbar Spine Bone Mineral Density (BMD)|Change in Hip Bone Mineral Density (BMD)|Number of Subjects Who Died or Lost Their Renal Graft During First Year|Episodes of Acute Cellular Rejection (ACR) of the Renal Transplant|Mean Estimated Glomerular Filtration Rate (eGFR) at One Year|Mean Change in Estimated Glomerular Filtration Rate (eGFR) Between 3 Weeks and 1 Year Post Transplant|24-hour Total Protein in the Urine at 1 Year Post Transplant|Degree of Interstitial Fibrosis on Graft Biopsy at One Year,https://ClinicalTrials.gov/show/NCT00587158
95,NCT00781781,Alemtuzumab Use (MabCampathÂ®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning,Terminated,No Results Available,Graft Versus Host Disease,Drug: Alemtuzumab,CABYC|Grupo EspaÃ±ol de Linfomas y Transplante AutÃ_logo de MÃ©dula Ã“sea,All,40 Years to 65 Years Â  (Adult),Phase 2,34,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ALOTIRNE-EC06007|2007-006440-22,28-Oct-08,7/1/08,12/1/11,3-Feb-15,Oct-08,No Study Results Posted,null,Aug-08,Analyze the results of incidence and severity of acute and chronic GVHD,https://ClinicalTrials.gov/show/NCT00781781
96,NCT00914758,Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS),Unknown status,No Results Available,Relapsing Remitting Multiple Sclerosis,,"Washington Neuropsychology Research Group|Genzyme, a Sanofi Company",All,25 Years to 50 Years Â  (Adult),,1,Other|Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,WNRG02,3-Jun-09,3/1/09,12/1/11,4-Jun-09,Jun-09,No Study Results Posted,null,Oct-11,Paced Auditory Serial Addition Test|Stroop Test|Symbol Digit Modalities Test|Lexical and Categorical Associative Fluency Tests|Automated Neuropsychological Assessment Metrics|MS Quality of Life Instrument-54|Fatigue Severity Scale|Epworth Sleepiness Scale|MS Fatigue Impact Scale|MRI data,https://ClinicalTrials.gov/show/NCT00914758
242,NCT00943293,Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies,Terminated,No Results Available,Preleukemia|Myeloproliferative Disorders|Lymphoma|Myeloma|Graft Versus Host Disease,Drug: Fludarabine|Drug: Melphalan|Drug: Campath,University of Chicago,All,"18 Years and older Â  (Adult, Senior)",Phase 1,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12175A,20-Jul-09,5/1/03,1/1/12,14-Mar-14,Mar-14,No Study Results Posted,null,Sep-11,"To determine in HLA A2 positive patients with hematological malignancies undergoing transplantation from HLA-identical donors, if HA1/2-peptide vaccinations can induce or enhance short- and long-term allogeneic HA1/2-specific T cell immunity.|To evaluate if HA1/2 peptide vaccination induces toxicity, especially acute GVHD after HLA-identical transplantation.",https://ClinicalTrials.gov/show/NCT00943293
272,NCT00393185,Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis,Withdrawn,No Results Available,Primary Biliary Cirrhosis,Biological: Non-myeloablative Hematopoietic Stem Cell Transplantation,"Richard Burt, MD|Northwestern Memorial Hospital|Northwestern University",All,18 Years to 55 Years Â  (Adult),Phase 1,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PBC,24-Oct-06,1/1/06,1/1/12,4-Oct-12,Oct-12,No Study Results Posted,null,Jan-12,No liver-related death or LTx over the 2-year (extended to 5 years) follow-up; Normalization of serum alkaline phosphatase over 6 months;Amelioration of PBC histological stage with reduction of both inflammation and fibrosis scores 42,https://ClinicalTrials.gov/show/NCT00393185
35,NCT01042509,Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease,Completed,Has Results,Graft vs Host Disease,Drug: Alemtuzumab and rituximab,Hospital Universitario Dr. Jose E. Gonzalez,All,18 Years to 65 Years Â  (Adult),,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HE09-013,4-Jan-10,10/1/09,1/1/12,7-Dec-16,Dec-16,16-Feb-12,LowAR,Oct-11,Clinical Response of Patients With Refractory Chronic GVHD Based on the Working Group Report 2006.|Side Effects,https://ClinicalTrials.gov/show/NCT01042509
260,NCT00818961,Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer,Terminated,Has Results,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation,"Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia",All,"40 Years to 72 Years Â  (Adult, Senior)",Phase 2,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000630617|BMTGG-NSH-756,7-Jan-09,5/1/05,3/1/12,28-Oct-13,Oct-13,22-Mar-13,null,Mar-11,Survival at Day 100|Overall Survival at 1 Year|Non-relapse Mortality at Day 100|Non-relapse Mortality at 1 Year Post-transplant|Complete Donor Chimerism|Neutrophil Recovery|Platelet Engraftment|Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism|Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant|Number of Patients Experiencing Chronic Graft Versus Host Disease|Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant,https://ClinicalTrials.gov/show/NCT00818961
179,NCT00807144,Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation,Unknown status,No Results Available,End-stage Renal Failure|Graft Rejection,Drug: Tacrolimus (Kidney transplant maintenance immunosuppression)|Drug: Kidney transplant maintenance immunosuppression,Hammersmith Hospitals NHS Trust,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,ICKTI08TX02|2008-000889-22,10-Dec-08,12/1/08,3/1/12,27-Jun-11,Jun-11,No Study Results Posted,TAESR,Mar-12,"Patient survival with a functioning graft|Rejection-free patient survival with a functioning graft|Patient-reported Quality of life, and medication adherence",https://ClinicalTrials.gov/show/NCT00807144
65,NCT01315457,Infections Associated With the Use of Alemtuzumab,Completed,No Results Available,Patients Treated With Alemtuzumab,,"Samsung Medical Center|National Taiwan University Hospital|Dr Cipto Mangunkusumo General Hospital|Asan Medical Center|Soon Chun Hyang University|Chonnam National University|Chonbuk National University|Chulalongkorn University|Queen Mary Hospital, Hong Kong|Yonsei University|Kyungpook National University",All,"15 Years to 90 Years Â  (Child, Adult, Senior)",,182,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2009-03-006,13-Mar-11,4/1/09,3/1/12,22-May-12,May-12,No Study Results Posted,null,Mar-12,Infectious event,https://ClinicalTrials.gov/show/NCT01315457
152,NCT00175253,Alemtuzumab Induction in Islet Transplantation,Completed,No Results Available,Type 1 Diabetes,Drug: alemtuzumab|Procedure: islet transplant,University of Alberta|Juvenile Diabetes Research Foundation,All,18 Years to 65 Years Â  (Adult),Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,5369,13-Sep-05,11/1/05,4/1/12,11-Jul-12,Jul-12,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00175253
280,NCT00278655,Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis,Terminated,Has Results,Multiple Sclerosis,Biological: Hematopoietic stem cell transplantation,Northwestern University,All,18 Years to 50 Years Â  (Adult),Phase 1|Phase 2,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DIAD MS.Auto2002,16-Jan-06,6/1/03,5/1/12,31-Mar-14,Mar-14,9-Apr-13,null,Dec-11,Disease Progression|Survival,https://ClinicalTrials.gov/show/NCT00278655
13,NCT00167661,Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation,Terminated,No Results Available,Disorder Related to Renal Transplantation,Drug: Campath-1H,"University of Wisconsin, Madison",All,"18 Months to 19 Years Â  (Child, Adult)",Phase 1|Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2011-0661 (2003-0493),11-Sep-05,6/1/04,5/1/12,9-Oct-15,Oct-15,No Study Results Posted,null,Dec-11,The incidence of graft rejection and graft loss|Renal function|Incidence of infection and malignancy|Growth post-transplant|Incidence of hypertension and hyperlipidemia|Survival|Incidence of diabetes mellitus,https://ClinicalTrials.gov/show/NCT00167661
195,NCT00349349,HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab,Completed,Has Results,"Leukaemia, Lymphocytic, Chronic",Drug: ofatumumab,GlaxoSmithKline,All,"18 Years and older Â  (Adult, Senior)",Phase 2,223,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,111773|Hx-CD20-406,6-Jul-06,6/1/06,6/1/12,29-May-14,Jun-13,20-Oct-11,null,May-08,"Number of Participants (Par.) Classified as Responders and Non-responders for Objective Response as Assessed by an Independent Endpoint Review Committee (IRC) in Accordance With the National Cancer Institute Working Group (NCIWG) 1996 Guidelines|Duration of Response|Progression-Free Survival (PFS)|Time to Next Chronic Lymphocytic Leukemia (CLL) Treatment|Overall Survival|Percent Change From Baseline to Week 7 in Peripheral CD5+CD19+ Cell Counts|Percent Change From Baseline to Week 7 in Peripheral CD5+CD20+ Cell Counts|Median Percent Change of Tumor Size (Sum of Products Dimensions [SPD]) From Baseline (Visit 2) to Week 24 (Visit 14)|Number of Participants With Complete Resolution of Constitutional Symptoms at Week 24|Number of Participants With Complete Resolution of Lymphadenopathy|Number of Participants With Improvement on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale at Week 24|Number of Participants Who Were Positive, Negative, or Had Missing Data for the Indicated Fluorescence in Situ Hybridization (FISH) Prognostic Factors at Screening|Number of Participants With Improvement in Hemoglobin|Number of Participants With Improvement in Thrombocytopenia (Thromb.)|Number of Participants With Complete Resolution of Hepatomegaly|Number of Participants With Improvement in Neutropenia|Number of Participants With Complete Resolution of Splenomegaly|Number of Participants Who Experienced Any Adverse Event|Cmax and Ctrough at Dose 1 (Visit 2, Week 0), Dose 8 (Visit 9, Week 7), and Dose 12 (Visit 14, Week 24)|AUC (0-inf) and AUC(0-tau) at Dose 8 (Visit 9, Week 7) and Dose 12 (Visit 14, Week 24)|Half-life (t1/2) at Dose 8 (Visit 9, Week 7) and at Dose 12 (Visit 14, Week 24)|Clearance (CL) After Dose 8 (Visit 9, Week 7) and Dose 12 (Visit 14, Week 24)|Volume of Distribution at Steady State (Vss) at Dose 8 (Visit 9, Week 7) and at Dose 12 (Visit 14, Week 24)",https://ClinicalTrials.gov/show/NCT00349349
102,NCT00504491,R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia,Withdrawn,No Results Available,Chronic Lymphocytic Leukaemia|Patients Resistant to a Purine Analogous|Patients Relapsed With Purines Therapy,Drug: Rituximab-CHOP-Alemtuzumab,"CABYC|Francesc Bosch, MD|Grupo EspaÃ±ol de Linfomas y Transplante AutÃ_logo de MÃ©dula Ã“sea|Fundacion Clinic per a la Recerca BiomÃ©dica|Bayer|Genzyme, a Sanofi Company",All,"18 Years to 70 Years Â  (Adult, Senior)",Phase 2,0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GELLC-2|2007-003097-26,19-Jul-07,7/1/07,6/1/12,28-Dec-11,Dec-11,No Study Results Posted,R-CHOP,Jan-12,"Response rate obtained after R-CHOP regimen followed by consolidation therapy with Alemtuzumab, as second line therapy. Haematological and non haematological toxicity will be graded in accordance with the WHO system",https://ClinicalTrials.gov/show/NCT00504491
234,NCT00578903,Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia,Terminated,Has Results,Aplastic Anemia,Drug: Cytoxan|Drug: Campath|Radiation: Total Body Irradiation (TBI)|Drug: FK-506|Drug: Methotrexate|Procedure: Stem cell infusion,"Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"up to 60 Years Â  (Child, Adult)",Phase 2,22,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,10915-SAA MUD|SAA MUD,19-Dec-07,2/1/02,7/1/12,24-Mar-16,Mar-16,4-Aug-13,null,Jul-12,Number of Subjects Alive at 100 Days Post Transplant|Number of Patients With Engraftment Rate at 100 Days Post Transplant|Number of Patients With Acute GVHD at 100 Days Post Transplant|Number of Patients With Chronic GVHD at 2 Years Post Transplant|Number of Subjects Alive at 1 Year Post Transplant|Number of Subjects Alive at 2 Years Post Transplant,https://ClinicalTrials.gov/show/NCT00578903
14,NCT00061048,Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma,Completed,Has Results,Acute T-Cell Leukemia-Lymphoma,Biological: Alemtuzumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years and older Â  (Adult, Senior)",Phase 2,29,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,030194|03-C-0194,20-May-03,5/1/03,7/1/12,26-Oct-12,Oct-12,17-May-11,null,Jul-09,Overall Response Rate|Overall Survival|Time to Progression|Cell Surface Expression of CD52 on Tumor Cells|The Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00061048
221,NCT00578344,"Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP",Terminated,No Results Available,Sickle Cell Disease|Hemoglobin SC,Drug: Busulfan|Biological: Campath 1H|Drug: Cyclophosphamide and MESNA,Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System,All,"up to 40 Years Â  (Child, Adult)",,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-16447-SCALLOP|SCALLOP,19-Dec-07,7/1/05,7/1/12,22-Apr-14,Apr-14,No Study Results Posted,SCALLOP,Jul-12,"Evaluate recovery of organ function in patients with sickle cell disease (SCD) or sickle hemoglobin variants after undergoing allogeneic SCT/BMT from HLA genotype identical donors and if they can be improved or reversed.|Evaluate the use of PET scan examination in assessing metabolic function of organs in patients with SCD, hemoglobin SC, or hemoglobin Sb0/+ after undergoing allogeneic SCT/BMT from HLA genotype identical donors.|Evaluate response to immunization after BMT in patients with SCD, hemoglobin SC, or hemoglobin Sb0/+.",https://ClinicalTrials.gov/show/NCT00578344
126,NCT01679860,Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma,Completed,No Results Available,"Lymphoma, T-Cell, Peripheral",Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|Drug: Clin B (CHOP- CAMPATH) Chemo-immunotherapy,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",All,18 Years to 60 Years Â  (Adult),Phase 2,92,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PTCL-062006-004234-33,30-Aug-12,11/1/06,8/1/12,3-Sep-12,Sep-12,No Study Results Posted,PTCL-06,Dec-11,Efficacy|evaluation of OS (overall survival)|DFS (Disease Free Survival)|TRM (Treatment Related Mortality),https://ClinicalTrials.gov/show/NCT01679860
255,NCT01163799,A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients,Terminated,No Results Available,"Transplant; Failure, Kidney",Drug: Alefacept (ASP0485),Northwestern University|Astellas Pharma Inc,All,"18 Years and older Â  (Adult, Senior)",Phase 1,9,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STU 00029396|640 5442000 60026221 01,14-Jul-10,7/1/10,8/1/12,1-May-13,May-13,No Study Results Posted,null,Sep-11,Incidence of first biopsy- proven acute rejection (Banff Gradeâ‰¥ 1) (BCAR rate) and infections|Affect on Immune cells|Assess secondary outcome measures of efficacy and safety,https://ClinicalTrials.gov/show/NCT01163799
105,NCT00061945,Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia,Drug: allopurinol|Drug: cyclophosphamide|Drug: daunorubicin hydrochloride|Drug: vincristine sulfate|Drug: dexamethasone|Drug: asparaginase|Biological: filgrastim|Drug: imatinib mesylate|Drug: methotrexate|Drug: cytarabine|Drug: trimethoprim-sulfamethoxazole|Drug: mercaptopurine|Drug: leucovorin calcium|Biological: alemtuzumab|Drug: acyclovir|Other: laboratory biomarker analysis|Other: pharmacological study,National Cancer Institute (NCI),All,"15 Years and older Â  (Child, Adult, Senior)",Phase 1|Phase 2,302,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-02807|CDR302482|CALGB 10102|CALGB-10102|U10CA031946,5-Jun-03,6/1/03,10/1/12,20-Mar-14,Dec-13,5-Dec-13,null,Dec-07,Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)|Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)|Modulation of Minimal Residual Disease During Treatment With Alemtuzumab (Phase II)|Disease-free Survival (Phase II)|Overall Survival (Phase II),https://ClinicalTrials.gov/show/NCT00061945
27,NCT00495755,Campath in Chronic GVHD,Completed,Has Results,Chronic Graft-vs.-Host Disease,Drug: Alemtuzumab (Campath),"Dana-Farber Cancer Institute|Genzyme, a Sanofi Company|Bayer",All,"18 Years and older Â  (Adult, Senior)",Phase 1,13,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DFCI 07-057,2-Jul-07,7/1/07,10/1/12,7-Aug-13,Aug-13,14-Apr-13,null,Oct-11,The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids|The Efficacy of a Four-week Course of Alemtuzumab in Patients With Steroid-refractory Chronic GVHD (cGVHD).|The Effect of Alemtuzumab Therapy on Parameters of Cellular and Humoral Immunity in the Late Post Transplant Period. This Information is Exploratory in Nature Only Due to the Heterogeneity of the Anticipated Patient Population.,https://ClinicalTrials.gov/show/NCT00495755
305,NCT01453062,Phase IV Observational Study in Chronic Lymphocytic Leukemia,Completed,No Results Available,"Leukaemia, Lymphocytic, Chronic",Drug: Arzerra,GlaxoSmithKline,All,"Child, Adult, Senior",,1,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,114429|WEUSRTP4799|EPI40635,13-Oct-11,9/1/11,11/1/12,3-Jul-14,Jul-14,No Study Results Posted,null,Nov-12,Physicians' assessment of response|Adverse events|Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01453062
273,NCT00282425,Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis,Terminated,No Results Available,Scleroderma,Biological: Hematopoietic stem cell transplantation,"Richard Burt, MD|Northwestern University",All,18 Years to 55 Years Â  (Adult),Phase 1,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DIAD Scl.Allo2005,24-Jan-06,5/1/05,12/1/12,14-Dec-12,Dec-12,No Study Results Posted,null,Dec-12,Survival; Disease improvement;Time to disease progression,https://ClinicalTrials.gov/show/NCT00282425
153,NCT00262925,Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,Terminated,Has Results,Recurrent Adult Acute Lymphoblastic Leukemia,Biological: alemtuzumab|Drug: asparaginase|Drug: methotrexate|Drug: dexamethasone|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: vincristine,National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,12,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2009-00518|E1904|U10CA021115,6-Dec-05,6/1/06,2/1/13,14-Apr-15,Oct-13,25-Apr-14,null,Oct-12,Complete Response Rate|Overall Survival,https://ClinicalTrials.gov/show/NCT00262925
59,NCT00947388,Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL),Terminated,No Results Available,Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma,Drug: Bendamustine Hydrochloride|Biological: Alemtuzumab,Case Comprehensive Cancer Center|Cephalon,All,"18 Years and older Â  (Adult, Senior)",Phase 1,9,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CASE1907|NCI-2010-00272,24-Jul-09,11/1/08,3/1/13,20-Aug-13,Aug-13,No Study Results Posted,null,Sep-12,Evaluate the safety of the combination of alemtuzumab and bendamustine in patients with advanced CLL|Establish the maximum tolerated dose of alemtuzumab up to the standard dose of 30mg thrice weekly when combined with bendamustine at a standard dose of 70 mg/m2 day 8 and 9 monthly.|Clinical activity and response of the combination of bendamustine hydrochloride and alemtuzumab,https://ClinicalTrials.gov/show/NCT00947388
40,NCT00580034,Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath,Completed,Has Results,Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors,Drug: Campath Purged Non-myeloablative ASCT|Procedure: Donor Apheresis,"David Rizzieri, MD|Miltenyi Biotec GmbH|Duke University",All,"17 Years and older Â  (Child, Adult, Senior)",Phase 2,176,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00009528,20-Dec-07,2/1/03,4/1/13,2-May-14,May-14,5-Feb-14,null,Apr-13,Toxicity|Overall Survival (OS)|Response,https://ClinicalTrials.gov/show/NCT00580034
11,NCT00578942,Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath,Completed,Has Results,Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors,Drug: Campath Purged Non-myeloablative ASCT,"David Rizzieri, MD|Miltenyi Biotec GmbH|Duke University",All,"17 Years and older Â  (Child, Adult, Senior)",Phase 2,48,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00008380,19-Dec-07,5/1/05,4/1/13,23-May-16,May-16,25-Apr-14,null,Apr-13,Toxicity|Overall Survival (OS)|Response,https://ClinicalTrials.gov/show/NCT00578942
326,NCT01019876,Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases,Unknown status,No Results Available,Bone Marrow Failure|Osteopetrosis|Fanconi Anemia|Severe Combined Immunodeficiency,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Cyclophosphamide 40|Drug: Cyclophosphamide 30,Columbia University,All,"up to 30 Years Â  (Child, Adult)",Phase 2|Phase 3,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAB0170|CHNY-01-509,23-Nov-09,6/1/02,5/1/13,18-Oct-11,Oct-11,No Study Results Posted,null,May-12,This study is to determine the toxicity of administering a fludarabine/cyclophosphamide (Flu/CY) or busulfan (Bu)/Flu based conditioning regimen followed by allogeneic stem cell transplant.|To determine the risk of disease progression (including neuropsychological deterioration in patients with metabolic non-malignant diseases) following a Flu/CY or Bu/Flu based conditioning regimen.|To measure immune reconstitution following a Flu/CY or Bu/Flu based conditioning regimen and AlloSCT in patients with selected non-malignant diseases.|To estimate the incidence and severity of GVHD following a Flu/Cy or Bu/Flu based conditioning regimen|To determine metabolic/immune (gene/protein) reconstitution by standard biochemical/PCR assays in patients,https://ClinicalTrials.gov/show/NCT01019876
190,NCT00618540,Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis,Terminated,Has Results,"Histiocytosis, Langerhans-cell",Biological: alemtuzumab|Drug: fludarabine phosphate|Drug: melphalan|Procedure: stem cell transplantation,"Masonic Cancer Center, University of Minnesota",All,"Child, Adult, Senior",Phase 2,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2007UC002|UMN-0612M98407|LCH-HCT-2006|UMN-MT2006-07,19-Feb-08,1/1/07,5/1/13,2-Oct-15,Jul-14,22-Apr-15,null,May-13,Overall Survival|Disease-free Survival at 12 Months Post Transplantation|Transplantation-related Death|Neutrophil Engraftment|Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD)|Incidence of Chronic GVHD|Platelet Engraftment|Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD),https://ClinicalTrials.gov/show/NCT00618540
214,NCT00578539,"T-Reg Cell Kinetics, Stem Cell Transplant, REGALE",Terminated,Has Results,Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Disorders,Drug: ARA C|Drug: Cyclophosphamide|Drug: MESNA|Radiation: Total Body Irradiation (TBI)|Biological: Campath-1h|Procedure: Stem Cell Infusion,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital",All,"Child, Adult, Senior",,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-21079-REGALE|REGALE,19-Dec-07,10/1/07,5/1/13,24-Mar-16,Mar-16,28-Aug-14,REGALE,May-13,Median Percentage of Treg Cells at 1 Year Post Transplant,https://ClinicalTrials.gov/show/NCT00578539
122,NCT00564512,"Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP",Completed,No Results Available,Leukemia,Biological: Campath|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine,French Innovative Leukemia Organisation,All,18 Years to 65 Years Â  (Adult),Phase 3,178,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000577580|CLL-2007-FMP,27-Nov-07,11/1/07,7/1/13,24-Jul-13,Apr-09,No Study Results Posted,null,Jan-09,"Progression-free survival at 36 months|Disease-free survival|Event-free survival|Overall survival|Time to next treatment|Overall response rate (complete response [CR] and partial response [PR])|Duration of phenotypic, molecular, NCI complete and partial responses|Response rates and survival times in biological subgroups|Treatment-related adverse effects",https://ClinicalTrials.gov/show/NCT00564512
325,NCT00777231,Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies,Completed,No Results Available,Sickle Cell Disease,Biological: Enriched Hematopoetic Stem Cell Infusion,University of Louisville|Duke University|St. Christopher's Hospital for Children|The Western Pennsylvania Hospital|University of Florida|Medical College of Pennsylvania Hospital|Hahnemann University Hospital,All,"Child, Adult, Senior",Phase 1|Phase 2,9,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,ICT-7621-042298|549.02|430.98|445.98|417.98|Pro00009281,20-Oct-08,1/1/05,8/1/13,17-Mar-17,Mar-17,No Study Results Posted,null,Aug-10,Level of Donor Chimerism from Enriched Hematopoietic Stem Cell Engraftment,https://ClinicalTrials.gov/show/NCT00777231
111,NCT01182675,"Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim",Terminated,Has Results,Severe Combined Immunodeficiency,Drug: Transplant Conditioning with Mobilization Only|Drug: Transplant Conditioning with Mobilization and Alemtuzumab,"University of California, San Francisco",All,up to 3 Years Â  (Child),Phase 2,7,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UCSF10-00701,9-Aug-10,8/1/10,9/1/13,26-Oct-16,Oct-16,28-Oct-14,null,Sep-13,Engraftment of Donor B-cells in Blood by STR Testing|Incidence of Acute GVHD|Incidence of Chronic GVHD|Percentage of Patients Who Become Independent From Regular IVIG Infusion|Percent Engraftment of Donor Stem Cells in Bone Marrow by STR Testing|Percent Engraftment of Donor T-cells in Blood by STR Testing,https://ClinicalTrials.gov/show/NCT01182675
329,NCT02520895,Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia,Completed,No Results Available,LYMPHOMA,Biological: blood samplings,Hospices Civils de Lyon,All,"18 Years and older Â  (Adult, Senior)",,98,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2009.548|2010-A00591-38,15-Sep-14,9/1/10,10/1/13,7-Aug-15,Jul-15,No Study Results Posted,RIPAL,Oct-13,change in variations of the T and B cell repertoire in patients with lymphoid blood disease under treatment|performance of the mapping of the immune repertoire to predict treatment response|performance of the mapping of the immune repertoire to predict progression free survival|performance of the mapping of the immune repertoire to predict the risk of infection|sensitivity of detection of the circulating clones,https://ClinicalTrials.gov/show/NCT02520895
158,NCT00943592,Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies,Completed,Has Results,Advanced Hematologic Malignancies|Leukemia|Preleukemia,Drug: Clofarabine|Drug: Melphalan|Drug: Campath|Procedure: Stem Cell Transplant,University of Chicago,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 1|Phase 2,82,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14341B,20-Jul-09,3/1/06,11/1/13,9-Jan-14,Jan-14,17-Sep-13,null,Apr-11,Number of Participants With Hepatic Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation|Number of Participants With Renal Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation|Number of Participants With Skin Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation|Number of Participants With Other Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation|Overall Survival (OS)|Progression-free Survival (PFS)|Treatment-related Mortality (TRM)|Relapse Rate,https://ClinicalTrials.gov/show/NCT00943592
256,NCT00597714,Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant,Completed,Has Results,Hodgkin's Disease|Non Hodgkin's Lymphoma|Myeloma|Leukemia|Myelodysplasia,Drug: Non-myeloablative Stem Cell Transplantation,"David Rizzieri, MD|Duke University",All,"18 Years and older Â  (Adult, Senior)",Phase 2,264,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00003567,14-Jan-08,2/1/08,11/1/13,2-May-14,Feb-14,5-Feb-14,null,Jul-13,Disease Free Survival|Immune Recovery|Progression Free Survival|Overall Survival|Graft Failure,https://ClinicalTrials.gov/show/NCT00597714
258,NCT01626092,Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders,Completed,Has Results,Lysosomal Storage Disease|Peroxisomal Disorder,Drug: Campath-1H|Drug: Clofarabine|Drug: Melphalan|Radiation: Total Body Irradiation with Marrow Boosting|Biological: Hematopoietic stem cell transplantation|Drug: Cyclosporine A|Drug: Mycophenolate mofetil,"Masonic Cancer Center, University of Minnesota",All,"up to 55 Years Â  (Child, Adult)",,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2011LS147|MT2011-24,20-Jun-12,7/11/12,11/1/13,17-Feb-17,Feb-17,17-Aug-16,null,Nov-13,Donor (Allogeneic) Hematopoietic Engraftment|Transplant-Related Mortality|Neurologic Outcomes,https://ClinicalTrials.gov/show/NCT01626092
236,NCT01679041,High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment,Terminated,No Results Available,Multiple Sclerosis,Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cyclophosphamide,Seah Lim M.D.|Texas Oncology Cancer Center,All,18 Years to 60 Years Â  (Adult),Phase 2,1,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,20112015,29-Aug-12,11/1/12,11/1/13,21-Nov-13,Nov-13,No Study Results Posted,null,Nov-13,To evaluate the toxicity of autologous HPC transplant in patients with multiple sclerosis that have failed at least two lines of disease modifier therapy|To evaluate the effectiveness of high dose chemotherapy with HPC transplant for multiple sclerosis sclerosis that has failed at least two lines of therapy,https://ClinicalTrials.gov/show/NCT01679041
270,NCT00315627,Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation,Completed,No Results Available,Type 1 Diabetes Mellitus,Drug: Islet transplantation,Rodolfo Alejandro|Juvenile Diabetes Research Foundation|University of Miami,All,18 Years to 65 Years Â  (Adult),Phase 2,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0205,14-Apr-06,7/1/05,1/1/14,9-Nov-16,Nov-16,No Study Results Posted,null,Jan-14,"Steroid-free/calcineurin-free immunosuppression (Campath/sirolimus/mycophenolate mofetil [MMF]) will be as effective or better with less side effects than the use of the sirolimus/tacrolimus/daclizumab regimen.|Secondary endpoints will include: partial graft function, as evidenced by basal C-peptide greater than 0.5 ng/ml; reduction in insulin requirements in those patients who do not achieve insulin independence|improvement in metabolic control as evidenced by improvement in: hemoglobin A1c [HbA1c] (should be < 6.5%)|mean glucose meter readings, elimination or reduction in the incidence of hypoglycemic coma or unawareness",https://ClinicalTrials.gov/show/NCT00315627
52,NCT00330252,Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL,Completed,No Results Available,Chronic Lymphocytic Leukemia,Drug: Rituximab|Drug: Alemtuzumab,"Dana-Farber Cancer Institute|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",Phase 1,29,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,05-404,25-May-06,5/1/06,1/1/14,11-May-16,May-16,No Study Results Posted,null,Jan-13,"Maximum tolerated dose of alemtuzumab given once weekly|Response rate of combined rituximab and subcutaneous alemtuzumab (complete or partial response)|Dose limiting toxicities defined as non-hematologic toxicity of grade 3 or greater or irreversible grade 2 renal, neurologic or cardiac toxicity or infectious toxicities if grade 4 or greater|Dose limiting toxicities defined as hematologic toxicities of grade 3 or greater neutropenia or thrombocytopenia for greater than 2 weeks OR ANC < 250 or platelets < 20,000|Response rate as measured by Chest/abdominal/pelvic (+/- neck) CT 4 to 8 weeks following conclusion of 8 Weeks of therapy or at time of study withdrawal|Response rate as measured by physical exam of lymph nodes at 4 to 8 weeks following conclusion of 8 Weeks of therapy or at time of study withdrawal, then every 3 months until disease progression",https://ClinicalTrials.gov/show/NCT00330252
22,NCT01408342,Alemtuzumab and Rituximab in Aplastic Anemia,Withdrawn,No Results Available,Aplastic Anemia,Drug: Alemtuzumab and Rituximab,Hospital Universitario Dr. Jose E. Gonzalez,All,"12 Months and older Â  (Child, Adult, Senior)",,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HE11015|AA,29-Jul-11,7/1/11,1/1/14,3-Jan-14,Jan-14,No Study Results Posted,null,Jan-13,Evaluate efficacy of alemtuzumab and rituximab in aplastic anemia.|Measuring the side effects of alemtuzumab and rituximab combination through clinical evaluation,https://ClinicalTrials.gov/show/NCT01408342
312,NCT02512679,Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells,Terminated,Has Results,Stem Cell Transplantation|Bone Marrow Transplantation|Peripheral Blood Stem Cell Transplantation|Allogeneic Transplantation|Genetic Diseases|Thalassemia|Pediatrics|Diamond-Blackfan Anemia|Combined Immune Deficiency|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|X-linked Lymphoproliferative Disease|Metabolic Diseases,Drug: Cyclophosphamide Dose Level 1|Drug: Cyclophosphamide Dose Level 2|Drug: Cyclophosphamide Dose Level 3|Drug: Cyclophosphamide Dose Level 4,Children's Hospital Los Angeles|Lucile Packard Children's Hospital,All,"3 Months and older Â  (Child, Adult, Senior)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CCI-06-00177,21-May-15,2/1/07,2/1/14,12-Jan-17,Jan-17,29-Jan-16,null,Sep-13,"Number of Participants With Neutrophil Engraftment (=/>500 Cells/uL) and Platelet Engraftment (>20K Cell/uL) at 30 Days|Number of Participants With Disease Recurrence at 1 Year Post-transplant|Number of Participants Who Developed Severe Mucositis, Veno-occlusive Disease (VOD), Toxicity of the Kidney, Liver, or Gastrointestinal (GI) Tract up to 1 Year Post-transplant|Number of Participants Who Developed Graft-Versus-Host-Disease (GVHD) as Determined by the Glucksberg Scale|Number of Participants Who Were Disease Progression-Free and Death-Free at 1 Year Post-transplant",https://ClinicalTrials.gov/show/NCT02512679
82,NCT00725231,Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP,Unknown status,No Results Available,"Peripheral T Cell Lymphoma, Unspecified|Angioimmunoblastic Lymphadenopathy|Extranodal NK/T-cell Lymphoma",Biological: alemtuzumab|Drug: chemotherapy,University of GÃ¶ttingen|German High-Grade Non-Hodgkin's Lymphoma Study Group|Nordic Lymphoma Group,All,"61 Years to 80 Years Â  (Adult, Senior)",Phase 3,274,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,DSHNHL 2006-1B / ACT-2|BMBF GFVT 01014715,25-Jul-08,2/1/08,3/1/14,4-May-12,May-12,No Study Results Posted,A-CHOP-14,Mar-14,Event free survival|Rate of complete and partial remissions|treatment related deaths|Overall survival|protocol adherence|immune reconstitution after alemtuzumab CHOP,https://ClinicalTrials.gov/show/NCT00725231
23,NCT01405807,Alemtuzumab for ANCA Associated Refractory Vasculitis,Unknown status,No Results Available,Vasculitis|Microscopic Polyangiitis|Granulomatosis With Polyangiitis|Wegener's,Drug: Alemtuzumab,Cambridge University Hospitals NHS Foundation Trust,All,18 Years to 60 Years Â  (Adult),Phase 4,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AL1.1|2009-017087-17,27-Jul-11,2/1/11,3/1/14,28-Jul-11,Jul-11,No Study Results Posted,ALEVIATE,Mar-14,Proportion of patients with a vasculitis response at 6 months|Proportion of patients with a severe adverse event|Proportion of patients with treatment failure|Combined damage assessment (CDA) scores|Non severe adverse events|Cumulative dose of corticosteroids|Time to remission|Relapse|Change in SF-36,https://ClinicalTrials.gov/show/NCT01405807
38,NCT01333358,Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients,Unknown status,No Results Available,Multiple Sclerosis,Drug: Alemtuzumab,"Central Texas Neurology Consultants|Genzyme, a Sanofi Company",All,"Child, Adult, Senior",Phase 3,30,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IND 111746,8-Apr-11,5/1/11,3/1/14,22-Apr-11,Apr-11,No Study Results Posted,CAMA-2,Dec-13,The primary study objective is to demonstrate whether treatment with alemtuzumab is effective in stabilizing overall neurocognitive functioning in relapsing-remitting multiple sclerosis over time.,https://ClinicalTrials.gov/show/NCT01333358
310,NCT00744692,Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders,Completed,Has Results,Non Malignant Disorders|Immunodeficiencies|Congenital Marrow Failures|Hemoglobinopathies|Inborn Errors of Metabolism|Sickle Cell|Thalassemia|Lysosomal Storage Disease,Biological: Unrelated Umbilical Cord Blood Transplant|Drug: Reduced Intensity Conditioning,Duke University,All,"up to 21 Years Â  (Child, Adult)",Phase 1,22,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00008753,28-Aug-08,10/1/08,4/1/14,23-Jul-14,Jul-14,23-Jul-14,null,Dec-12,"Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving UCBT for Non-malignant Disorders.|To Describe the Pace of Neutrophil Recovery|To Evaluate the Pace of Immune Reconstitution.|To Determine the Overall Survival at day180 Post-transplant|To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)|To Describe the Incidence of Grade 3-4 Organ Toxicity|To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure|To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant|To Describe the Pace of Platelet Recovery",https://ClinicalTrials.gov/show/NCT00744692
300,NCT01246557,Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment,Completed,No Results Available,Chronic Lymphatic Leukemia,Drug: Lenalidomide|Drug: Dexamethasone,Hospital Universitari Vall d'Hebron Research Institute,All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LENDEX-LLC-09|2009-012571-95,30-Sep-10,12/1/09,4/1/14,3-Apr-14,Feb-11,No Study Results Posted,LENDEX-LLC-09,Apr-14,To assess the safety of the association of lenalidomide and dexamethasone in patients with relapsed or refractory CLL|To assess the efficacy of lenalidomide and dexamethasone in patients with Chronic Lymphocytic Leukemia (CLL) relapsing of resistant to treatment.,https://ClinicalTrials.gov/show/NCT01246557
140,NCT00669318,"Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",Completed,Has Results,Leukemia|Lymphoma,Biological: alemtuzumab|Biological: rituximab|Drug: pentostatin|Drug: sargramostim,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,41,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LS0881|08-000673,29-Apr-08,7/1/08,5/1/14,20-Jun-14,Jun-14,20-May-14,null,May-13,Complete Response Rate|Overall Response Rate (Complete and Partial Response)|Overall Survival|Progression-free Survival|Time to Retreatment,https://ClinicalTrials.gov/show/NCT00669318
109,NCT01186640,Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL),Completed,No Results Available,T-cell-prolymphocytic Leukemia,"Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|Drug: Alemtuzumab","German CLL Study Group|Genzyme, a Sanofi Company|University of Cologne",All,"18 Years and older Â  (Adult, Senior)",Phase 2,16,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,T-PLL2|2008-001421-34,20-Aug-10,6/1/10,5/1/14,23-Sep-16,Sep-16,No Study Results Posted,null,May-14,Remission Rate|Overall Survival Time,https://ClinicalTrials.gov/show/NCT01186640
233,NCT00881556,Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB),Unknown status,No Results Available,Epidermolysis Bullosa,Drug: Reduced Intensity Transplant conditioning,Columbia University,All,"up to 21 Years Â  (Child, Adult)",Early Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAD5420|CHNY-08-536,14-Apr-09,3/1/09,7/1/14,14-Feb-12,Feb-12,No Study Results Posted,RDEB,Jun-14,"To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.|Quantitate the percent of whole blood (CD45), T-cell (CD3), and NK cell (CD56) chimerism following RIC and AlloSCT in selected patients with RDEB|Quantitate the percent of donor skin dermal chimerism following RIC and AlloSCT in selected patients with RDEB.|Compare the gene and protein expression of COL7A1 in the skin pre and post AlloSCT",https://ClinicalTrials.gov/show/NCT00881556
222,NCT01518153,Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT),Terminated,Has Results,Leukemia|Lymphoma|Myeloma|Myeloproliferative Diseases,Drug: Fludarabine|Drug: Melphalan|Drug: Alemtuzumab|Procedure: Stem Cell Infusion|Drug: Tacrolimus|Drug: Methotrexate|Drug: G-CSF|Procedure: Low Dose Donor T-Cells|Procedure: High Dose Donor T-Cells,M.D. Anderson Cancer Center,All,18 Years to 65 Years Â  (Adult),Phase 2,16,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2011-1104|NCI-2012-00131,23-Jan-12,2/1/12,8/1/14,18-Feb-16,Feb-16,22-Jan-16,null,Aug-14,Success Rate|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01518153
135,NCT00058825,Stem Cell Transplant for Hematologic Diseases,Terminated,Has Results,Hematologic Malignancies,Biological: Campath 1H|Drug: Fludarabine|Procedure: Stem Cell Transplant|Radiation: Total Body Irradiation (TBI)|Drug: FK506 (Tacrolimus) or Cyclosporine,Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System,All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 1|Phase 2,27,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,8713-HIMSUM,11-Apr-03,8/1/00,9/1/14,20-Sep-16,Sep-16,23-Sep-15,HIMSUM,Sep-14,Transplant Related Mortality (TRM)|Time in Days to ANC Engraftment|Donor Chimerism Engraftment of Greater Than 50%|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease|2-year Relapse-free Survival|2-year Overall Survival|Number of Patients Who Engrafted With the Isolex/CLINIMACs System|Median Time to Engraftment With the Isolex/CLINIMACs System,https://ClinicalTrials.gov/show/NCT00058825
262,NCT00383448,HSCT for High Risk Inherited Inborn Errors,Completed,No Results Available,Adrenoleukodystrophy|Metachromatic Leukodystrophy|Globoid Cell Leukodystrophy|Tay Sachs Disease|Sandhoffs Disease|Wolman Disease|I-Cell Disease|Sanfilippo Syndrome|GM1 Gangliosidosis,Drug: Clofarabine|Procedure: Total body Irradiation|Drug: Melphalan|Biological: Hematopoietic Stem Cell Transplantation|Drug: Alemtuzumab|Drug: mycophenylate mofetil|Device: Cyclosporine A|Drug: Hydroxyurea,"Masonic Cancer Center, University of Minnesota",All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 2,39,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2006-14|0606M87246,29-Sep-06,9/1/06,9/1/14,22-Apr-15,Apr-15,No Study Results Posted,null,Sep-14,Donor Cell Engraftment|Transplant Related Mortality|Concentrations of mycophenylate mofetil (MMF)|Changes in Magnetic Resonance Imaging (MRI)|Changes in Neuropsychometric Function|Incidence of Acute Graft Versus Host Disease|Incidence of Chronic Graft Versus Host Disease,https://ClinicalTrials.gov/show/NCT00383448
15,NCT01208337,Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation,Completed,Has Results,Evidence of Liver Transplantation|Rejection|ALEMTUZUMAB/NATALIZUMAB [VA Drug Interaction],Drug: Alemtuzumab,University of Pittsburgh,All,"4 Months to 25 Years Â  (Child, Adult)",Phase 2,23,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB0701088,22-Sep-10,4/1/07,11/1/14,11-May-16,May-16,13-Jan-16,null,Nov-14,Incidence of Post Transplant Lymphoproliferative Disorder (PTLD)|Incidence of Biopsy-proven Acute Cellular Rejection|Incidence of Patients in Whom Steroids Are Not Used|Incidence of Patients in Whom Tacrolimus Whole Blood Concentration Less Than 10 ng/ml Are Being Used at 1-year Follow-up.,https://ClinicalTrials.gov/show/NCT01208337
188,NCT01446484,Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection,Unknown status,No Results Available,End-Stage Renal Disease|Kidney Failure,Biological: CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Drug: Alemtuzumab|Drug: Mycophenolate mofetil|Drug: Sirolimus|Drug: Tacrolimus|Drug: Cyclosporine|Drug: Everolimus|Procedure: Kidney transplantation,Pirogov Russian National Research Medical University|Russian Academy of Medical Sciences,All,"1 Year to 18 Years Â  (Child, Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,RSMU-001,3-Oct-11,10/1/11,11/1/14,17-Nov-11,Nov-11,No Study Results Posted,null,Nov-14,"Patient and graft survival|Incidence rate of biopsy-proven acute rejection, defined as a renal biopsy demonstrating acute cellular or humoral rejection of Banff Grade IA or greater|Incidence of chronic allograft nephropathy, determined using renal biopsies and laboratory values, including 24-hour urine protein excretion|Incidence of adverse events associated with renal transplantation and immunosuppression",https://ClinicalTrials.gov/show/NCT01446484
219,NCT00683046,T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies,Completed,Has Results,"Acute Myelogenous Leukemia|Lymphoid Leukemia|Chronic Myelogenous Leukemia|Malignant Lymphoma|Hodgkin's Disease|Chronic Lymphocytic Leukemia|Myeloproliferative Disorder|Anemia, Aplastic|Myelodysplastic Syndromes",Drug: Fludarabine|Drug: Melphalan|Drug: Stem cells|Drug: Campath,University of Chicago,All,"up to 100 Years Â  (Child, Adult, Senior)",Phase 2,204,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,11300A,21-May-08,11/1/01,12/1/14,7-Oct-16,Oct-16,14-Feb-14,null,Dec-14,Median Disease-free Survival|Median Overall Survival,https://ClinicalTrials.gov/show/NCT00683046
296,NCT01680861,Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium,Completed,Has Results,"Transplant; Failure, Kidney",Drug: Tacrolimus|Drug: Everolimus|Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)|Drug: Corticosteroids,Gaetano Ciancio|University of Miami,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 3,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20110126,6-Mar-12,11/1/12,12/1/14,21-Oct-16,Oct-16,20-Jun-16,null,Dec-14,"BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant|Incidence of Chronic Allograft Nephropathy (CAI) at 12 Months Post-transplant|Graft Loss (Return to Permanent Dialysis or Death)|eGFR (Calculated Glomerular Filtration Rate), i.e., Renal Function, at 1 Month Post-transplant.|eGFR (Renal Function) at Month 3 Post-transplant|eGFR (Renal Function) at 6 Months Post-transplant|Discontinuance of Any Study Medication (Tacrolimus, Everolimus, or EC-MPS)",https://ClinicalTrials.gov/show/NCT01680861
81,NCT00065260,Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia,Completed,Has Results,Aplastic Anemia,Drug: Campath-1H|Drug: r-ATG|Drug: CsA,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years and older Â  (Child, Adult, Senior)",Phase 2,54,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,030249|03-H-0249,18-Jul-03,7/1/03,3/1/15,3-Feb-16,Feb-16,3-Feb-16,null,Dec-14,"No Longer Meeting Criteria for Severe Aplastic Anemia.|Secondary Endpoints Will Include: Relapse; Clonal Evolution to Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) or Acute Leukemia",https://ClinicalTrials.gov/show/NCT00065260
257,NCT01436305,Optimization of NULOJIXÂ® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation,Terminated,No Results Available,Kidney Transplantation|Renal Transplantation,Drug: Alemtuzumab|Drug: MMF|Biological: Basiliximab|Drug: Short-term Tac|Drug: tacrolimus|Biological: Belatacept|Drug: methylprednisolone,National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation,All,18 Years to 65 Years Â  (Adult),Phase 2,19,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,DAIT CTOT-10,13-Sep-11,9/1/11,4/1/15,20-Apr-16,Apr-16,No Study Results Posted,null,Apr-15,The incidence of all adverse events (AEs) and serious adverse events (SAEs),https://ClinicalTrials.gov/show/NCT01436305
91,NCT00453427,Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas,Completed,No Results Available,Peripheral T-cell Lymphomas,Drug: Alemtuzumab (Campath-1H),"Ontario Clinical Oncology Group (OCOG)|Sunnybrook Health Sciences Centre|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,20,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CTA-Control-103662,27-Mar-07,9/1/06,5/1/15,1-Jun-15,Jun-15,No Study Results Posted,ACCAPELA,Jun-13,toxicity|efficacy|tumour response|pharmacokinetic analysis|immunological monitoring,https://ClinicalTrials.gov/show/NCT00453427
136,NCT00951457,Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL),Unknown status,No Results Available,"Leukemia, Lymphocytic, Chronic, B-Cell",Drug: Bendamustine,Arbeitsgemeinschaft medikamentoese Tumortherapie|Mundipharma Pte Ltd.,All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGMT CLL-6 BendAlem,3-Aug-09,3/1/09,6/1/15,6-Mar-15,Mar-15,No Study Results Posted,null,Jun-15,"To determine the percentage of patients achieving a response, defined as the percentage of patients achieving complete response, partial response and stable disease/ no change upon treatment with the combination therapy|To evaluate the efficacy of a bendamustine/ alemtuzumab combination therapy in terms of complete response rates|To evaluate the achievable cumulative doses of bendamustine and alemtuzumab in terms of maximum tolerated doses while on treatment|To determine response rates in all phases by 4-colour flow cytometric MRD analysis|To identify and characterize potential risk factors via FISH cytogenetics, CD38/ Zap-70 expression and mutational status|To define clonal evolution by use of longitudinal FISH cytogenetics|To define T cell subsets including prognostic EM T cells and Treg cells|To document change upon quality of life by use of a standardized QoL questionnaire",https://ClinicalTrials.gov/show/NCT00951457
301,NCT01521689,Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment,Unknown status,No Results Available,Chronic Lymphocytic Leukemia,Drug: Rituximab,Institut Paoli-Calmettes,All,"18 Years and older Â  (Adult, Senior)",Phase 2,35,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LLCR lowdoz / IPC 2009-004,22-Dec-11,12/1/11,6/1/15,19-Mar-15,Mar-15,No Study Results Posted,LLCRlowdoz,Jun-15,Residual disease|overall survival|Adverse events|-Quality of life|Immune functions|- Progression free survival|treatment free survival,https://ClinicalTrials.gov/show/NCT01521689
177,NCT00849745,Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases,Terminated,No Results Available,Systemic Lupus Erythematosus|Systemic Sclerosis,Procedure: Nonmyeloablative allogeneic stem cell transplant,Duke University,All,"18 Years to 69 Years Â  (Adult, Senior)",Phase 1,4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00010324,22-Feb-09,1/1/03,7/1/15,21-Jun-16,Jun-16,No Study Results Posted,null,Jul-15,Engraftment|Graft versus Host Disease|Toxicity|Mortality|Response Rate|Immune Function Post-engraftment|Progression Free Survival|Overall Survival,https://ClinicalTrials.gov/show/NCT00849745
275,NCT00278590,Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus,Withdrawn,No Results Available,Systemic Lupus Erythematosus,Biological: Allogeneic Stem Cell Transplantation,Northwestern University,All,18 Years to 50 Years Â  (Adult),Phase 1,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DI SLE.Allo2004,16-Jan-06,7/1/04,7/1/15,12-Jan-17,Jan-17,No Study Results Posted,null,Jul-15,"Survival, disease free survival, number of relapses, organ function",https://ClinicalTrials.gov/show/NCT00278590
239,NCT00775931,Allogeneic Transplantation For Severe Osteopetrosis,Unknown status,No Results Available,Severe Osteopetrosis,Procedure: umbilical cord blood transplantation|Drug: Campath-1H|Radiation: Total Lymphoid Irradiation|Drug: Cyclophosphamide|Drug: Busulfan|Drug: Fludarabine monophosphate|Procedure: marrow graft transplantation,"Masonic Cancer Center, University of Minnesota",All,"up to 45 Years Â  (Child, Adult)",Phase 2|Phase 3,23,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2008-20|0808M42261,16-Oct-08,8/1/08,10/1/15,22-Apr-15,Apr-15,No Study Results Posted,null,Oct-15,Estimate the rate of donor engraftment for patients treated by hematopoietic stem cell transplantation|Estimate Peri-transplant mortality (deaths)|Transplant related toxicity|Graft-versus-host disease (incidence and severity)|Tolerance of Campath-1H administration|Clinical Disease Monitoring,https://ClinicalTrials.gov/show/NCT00775931
114,NCT00935792,Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Completed,Has Results,Lymphocytic Leukemia,Drug: alemtuzumab|Drug: everolimus,Mayo Clinic,All,"18 Years to 120 Years Â  (Adult, Senior)",Phase 1|Phase 2,28,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MC088C|NCI-2009-00935|08-008775,6-Jul-09,7/1/09,12/1/15,19-Oct-16,Jan-16,29-Apr-16,null,Dec-15,Clinical Response (Complete or Partial Remission)|Number of Participants With Dose-Limiting Toxicities|Test the Safety and Tolerability of the Combination of Everolimus and Alemtuzumab.|Survival Time|Progression-free Survival|Duration of Response|Time to Subsequent Therapy,https://ClinicalTrials.gov/show/NCT00935792
154,NCT00997386,Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States,Completed,No Results Available,"Hematologic Neoplasms|Multiple Myeloma|Anemia, Aplastic|Hemoglobinuria, Paroxysmal|Myelofibrosis","Drug: busulfan, and melphalan, and alemtuzumab",University of Arizona,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 2,16,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-0679-04,15-Oct-09,9/1/09,1/1/16,30-Mar-16,Dec-15,No Study Results Posted,ALBUM,Apr-14,"The primary efficacy endpoint is the presence of donor lymphohematopoietic chimerism (defined as at least 50% donor cells in the peripheral blood) in peripheral blood by day +100 (i.e., 100 days after allogeneic PBSCT).|Analyses of relapse-free survival, event-free survival and overall survival will be performed",https://ClinicalTrials.gov/show/NCT00997386
211,NCT00618969,Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors,Completed,No Results Available,"Hematologic Neoplasms|Anemia, Aplastic|Hemoglobinuria, Paroxysmal|Multiple Myeloma",Other: haploidentical allogeneic PBSC transp,University of Arizona,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 2,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BIO 07-122,8-Feb-08,2/1/08,2/1/16,1-Mar-16,Mar-16,No Study Results Posted,null,Dec-13,"The primary efficacy endpoint is the presence of donor lymphohematopoietic chimerism (defined as at least 50% donor cells in the peripheral blood)in peripheral blood by day +100.|To determine the safety of haploidentical related allogeneic PBSCT using a preparative regimen of busulfan, melphalan and alemtuzumab.",https://ClinicalTrials.gov/show/NCT00618969
86,NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Completed,No Results Available,"Multiple Sclerosis, Relapsing-Remitting",Biological: alemtuzumab|Biological: alemtuzumab,"Genzyme, a Sanofi Company|Bayer|Sanofi",All,"Child, Adult, Senior",Phase 3,1322,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,CAMMS03409|2009-010788-18|LTE12824,26-Jun-09,8/1/09,2/1/16,11-Mar-16,Mar-16,No Study Results Posted,null,Feb-16,"Time to Sustained Accumulation of Disability (SAD)|Relapse Rate|Time to sustained reduction in disability (SRD) as measured by the EDSS (Expanded Disability Status Scale)|Change over time in EDSS scores|Change over time in MRI findings|Change over time in self-reported quality of life as assessed by the Medical Outcome Study SF-36 Version 2, FAMS (Functional Assessment of Multiple Sclerosis), and EQ-5D findings",https://ClinicalTrials.gov/show/NCT00930553
281,NCT01459211,Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL),Completed,No Results Available,Chronic Lymphocytic Leukemia,Drug: Lenalidomide & Dexamethasone,"University College, London",All,"18 Years and older Â  (Adult, Senior)",Phase 2,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UCL/09/387,18-Oct-11,5/1/12,2/1/16,7-Nov-16,Nov-16,No Study Results Posted,LenD,Feb-16,Proportion of patients who achieve objective response (CR + PR) according to the updated 1996 NCIWG criteria measured at 4 weeks after the completion of chemotherapy|Duration of response|Time to next treatment,https://ClinicalTrials.gov/show/NCT01459211
299,NCT01652911,A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation,Terminated,No Results Available,Type I Diabetes,Device: Sernova Cell Pouch,University of Alberta|Sernova Corp,All,"18 Years to 68 Years Â  (Adult, Senior)",Phase 1|Phase 2,3,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00028097,12-Jul-12,6/1/12,3/1/16,6-Jul-16,Jul-16,No Study Results Posted,null,Mar-16,To assess the safety of the Sernova Cell Pouchâ„¢ in adult participants with Type-1 diabetes receiving islet transplantation for the first time.|To determine the proportion of subjects implanted with the Cell Pouchâ„¢ and transplanted with islets into the Cell Pouchâ„¢ who achieve insulin independence after islet transplantation.|To obtain preliminary data on the efficacy of the Cell Pouchâ„¢.,https://ClinicalTrials.gov/show/NCT01652911
115,NCT02205489,Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA,Completed,No Results Available,Relapsing-remitting Multiple Sclerosis,Drug: Alemtuzumab GZ402673|Drug: cetirizine|Drug: ranitidine|Drug: methylprednisolone|Drug: methylprednisolone|Drug: aciclovir|Drug: esomeprazole|Drug: ibuprofen|Drug: paracetamol,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 4,58,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LPS13650|2014-000092-62|U1111-1153-3922,29-Jul-14,10/1/14,4/1/16,8-Jun-16,Jun-16,No Study Results Posted,EMERALD,Apr-16,Proportion of IARs that are graded mild according to the Common Toxicity Criteria (CTC). An IAR is any adverse event occurring during or within 24 hours of LEMTRADA infusion.|Proportion of IARs|Proportion and type of serious IARs|Proportion by type (as defined by clinical symptoms),https://ClinicalTrials.gov/show/NCT02205489
243,NCT00578292,"Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO",Terminated,No Results Available,Thalassemia,Drug: Busulfan|Drug: Fludarabine|Drug: Campath 1H|Drug: Cyclophosphamide|Drug: MESNA,Baylor College of Medicine|Texas Children's Hospital,All,"up to 64 Years Â  (Child, Adult)",,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-14539-THALLO|THALLO,19-Dec-07,2/1/04,5/1/16,20-Jul-16,Jul-16,No Study Results Posted,THALLO,May-16,"Evaluate engraftment.|To evaluate the occurrence of transient and stable mixed hematopoietic chimerism (HC) after unrelated donor SCT, and its effect on the recurrence of clinically measurable thalassemia.|To measure hematopoietic and immune reconstitution, and assess the effects on infectious complications.|Toxicities.|Loss of chimerism.|GVHD|Morbidity and mortality post-transplant.",https://ClinicalTrials.gov/show/NCT00578292
9,NCT01346397,Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation,Completed,Has Results,Acute Graft Rejection|Chronic Allograft Nephropathy|Polyomavirus-related Transplant Nephropathy,Drug: cyclosporine or tacrolimus,Russian Academy of Medical Sciences|Russian Scientific Center of Surgery,All,"6 Months to 60 Years Â  (Child, Adult)",,170,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,RSCS-Campath-06,7-Jul-10,4/1/09,5/1/16,4-Oct-16,Oct-16,4-Oct-16,RSCS-Campath,May-13,Patient Survival|Graft Survival,https://ClinicalTrials.gov/show/NCT01346397
203,NCT00260689,Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia,Completed,No Results Available,Immunosuppresion|Thrombocytopenia|Pancytopenia|Neutropenia,Biological: Anti-thymocyte globulin (rabbit)|Biological: Anti-thymocyte globulin (horse)|Drug: Cyclosporine,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years and older Â  (Child, Adult, Senior)",Phase 2,136,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,060034|06-H-0034,1-Dec-05,11/28/05,5/4/16,24-Jan-17,15-Aug-16,No Study Results Posted,null,4-May-16,Hematologic response,https://ClinicalTrials.gov/show/NCT00260689
230,NCT00176852,Stem Cell Transplant for Hemoglobinopathy,"Active, not recruiting",No Results Available,Sickle Cell Disease|Thalassemia|Severe Congenital Neutropenia|Diamond-Blackfan Anemia|Shwachman-Diamond Syndrome,"Drug: Busulfan, Fludarabine, ATG, TLI|Drug: Busulfan, Cyclophosphamide, ATG, GCSF|Drug: Campath, Fludarabine, Cyclophosphamide|Radiation: Total Body Irradiation|Procedure: Stem cell infusion","Masonic Cancer Center, University of Minnesota|National Marrow Donor Program",All,"up to 50 Years Â  (Child, Adult)",Phase 2|Phase 3,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2002-07|0206M26241,12-Sep-05,6/1/02,6/1/16,23-Feb-16,Feb-16,No Study Results Posted,null,Mar-14,"Grade 3-5 Regimen Related Toxicity|Determine the incidence of chimerism at 100 days, 6 months and 1 year.|Determine the incidence of grade 2-4 and 3-4 acute GVHD at 100 days.|Determine the incidence of chronic GVHD at 6 months and 1 year.|Compare the quality of life (QOL) at 1, 2 and 5 years with the pre-transplant assessment.|Determine overall and disease free survival at 100 days and 1 year.|Determine physical characteristics and biologic effects of mixed populations of donor and host red blood cells|Determine the concentration of Campath in the serum",https://ClinicalTrials.gov/show/NCT00176852
277,NCT00282412,Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism,Terminated,No Results Available,Rheumatoid Arthritis,Biological: Hematopoietic Stem Cell Transplantation,Northwestern University,All,18 Years to 60 Years Â  (Adult),Phase 1,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DIAD RA ALLO,24-Jan-06,9/1/02,6/1/16,11-Jul-16,Jul-16,No Study Results Posted,null,Jun-16,Tender joint count;Swollen joint count; Patient's global assessment of disease;Patient's assessment of pain;Patient's assessment of physical activity; (Health Assessment Questionnaire [HAQ]); Acute phase reactant value (erythrocyte sedimentation rate).,https://ClinicalTrials.gov/show/NCT00282412
288,NCT01288053,Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease,Terminated,No Results Available,Crohn's Disease,Biological: Allogeneic Stem Cell Therapy,Northwestern University,All,18 Years to 45 Years Â  (Adult),Phase 1|Phase 2,9,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DIADCDAllo2005,27-Jan-11,1/1/10,6/1/16,11-Jul-16,Jul-16,No Study Results Posted,null,Jun-16,Survival|CDAI|CSS|IBDQ|CPAQ|SF-36,https://ClinicalTrials.gov/show/NCT01288053
302,NCT01911546,Role of Everolimus in Highly Sensitized Patients,"Active, not recruiting",No Results Available,Highly-sensitized Kidney Transplant Recipients,Drug: everolimus + low-dose tacrolimus,"Joseph Kahwaji, MD, MPH|Novartis|Cedars-Sinai Medical Center",All,"18 Years and older Â  (Adult, Senior)",,20,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,CRAD001AUS200T,4-Mar-13,6/1/13,7/1/16,8-Feb-16,Feb-16,No Study Results Posted,null,Jan-16,The number of CMV and Polyomavirus BK infections|Incidence of acute rejection and/or graft loss,https://ClinicalTrials.gov/show/NCT01911546
178,NCT00578266,Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia,Completed,No Results Available,"Anemia, Aplastic","Drug: Cyclophosphamide,Campath IH and TBI",Mayo Clinic,All,"up to 60 Years Â  (Child, Adult)",Phase 1,8,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,06-006216,17-Dec-07,2/1/07,8/16/16,23-Mar-17,Mar-17,No Study Results Posted,null,16-Aug-16,"1. Engraftment at 6 months, 1 year and 2 years 2.Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years|Patient survival probability at 100 days, 1 year and 2 years.",https://ClinicalTrials.gov/show/NCT00578266
33,NCT00323323,CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: CHOP|Drug: Alemtuzumab|Procedure: Plasma Samples,Ohio State University Comprehensive Cancer Center|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 1,24,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,OSU-0303,8-May-06,3/1/04,10/1/16,19-Jan-17,Jan-17,No Study Results Posted,null,Aug-12,Toxicity and safety of concurrent CHOP and Alemtuzumab|Determine pharmacokinetics of Alemtuzumab|Determine immunosuppressive properties of Alemtuzumab + CHOP|Determine if Fc Receptor-gamma (FcÎ_R) polymorphism is predictive of response or toxicity with Alemtuzumab treatment.,https://ClinicalTrials.gov/show/NCT00323323
263,NCT00455312,SCT for Dyskeratosis Congenita or SAA,"Active, not recruiting",No Results Available,Dyskeratosis Congenita|Aplastic Anemia,Drug: Campath 1H|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Total Body Irradiation|Procedure: Stem Cell Transplantation|Drug: antithymocyte globulin|Drug: Methylprednisolone,"Masonic Cancer Center, University of Minnesota",All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 2|Phase 3,33,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2006-06|0612M98727,30-Mar-07,8/1/07,11/1/16,21-Jan-16,Jan-16,No Study Results Posted,null,Mar-15,Neutrophil Engraftment|Incidence of Regimen Related Mortality at 100 days|Incidence of Chronic GVHD|Incidence of Late Secondary Malignancies|Incidence of grade 2-4 and 3-4 acute graft versus host disease (GVHD)|Overall Survival|Incidence of Pulmonary Complications,https://ClinicalTrials.gov/show/NCT00455312
99,NCT01392079,"Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine","Active, not recruiting",No Results Available,Chronic Lymphocytic Leukemia,Drug: Alemtuzumab,"University of Ulm|IMSE, TU Munich (Biometry)|WiSP Wissenschaftlicher Service Pharma GmbH|German CLL Study Group",All,"18 Years and older Â  (Adult, Senior)",Phase 2,135,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Cll2O|2007-003099-20,28-Jun-11,2/1/08,12/1/16,27-May-15,May-15,No Study Results Posted,null,Dec-14,Response rate|Progression-free-survival|Failure-free survival|Overall survival|Number of participants with Adverse Events as a measure of safety and tolerability,https://ClinicalTrials.gov/show/NCT01392079
134,NCT00646854,Alemtuzumab and CHOP in T-cell Lymphoma,Unknown status,No Results Available,"Lymphoma, T-Cell, Peripheral","Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF","Aarhus University Hospital|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|University of Aarhus",All,18 Years to 60 Years Â  (Adult),Phase 3,308,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-006130-17,14-Feb-08,6/1/08,12/1/16,8-Jan-15,Nov-12,No Study Results Posted,ACT-1,Apr-15,Event-free Survival|Overall survival|Overall response rate|Overall response rate related to the CD52 expression|Tumor control or time-to-progression|Safety measured as number of adverse events (AEs) and serious adverse events (SAEs)|Feasibility of successful stem cell harvest i.e. >/=2E6 CD34 positive cells,https://ClinicalTrials.gov/show/NCT00646854
304,NCT01013441,CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia,"Active, not recruiting",No Results Available,Chronic Lymphocytic Leukemia,Biological: Infusion of CD3/CD28 stimulated T cells,University of Pennsylvania|M.D. Anderson Cancer Center,All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCC 15408,5-Nov-09,3/1/09,12/1/16,6-Sep-16,Sep-16,No Study Results Posted,null,Dec-16,"The occurrence of treatment-related adverse events or treatment related trial discontinuations, defined as NCI CTC â‰¥ grade 3 and clinical events that are possible, likely, or definitely related to study treatment at any time|The ability to complete the outlined course of therapy|The ability to harvest, expand, and reinfuse autologous T cells in this target population of patients",https://ClinicalTrials.gov/show/NCT01013441
75,NCT01757574,Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD),Unknown status,No Results Available,Chronic Inflammatory Demyelinating Neuropathy,Drug: Alemtuzumab infusion,"Johns Hopkins University|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",Phase 4,16,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAMIMD01108IST,6-Dec-12,11/1/12,12/1/16,23-Dec-12,Dec-12,No Study Results Posted,null,Dec-15,Change from baseline in disability at 36 months measured by GBS/CIDP Rasch-built Overall Disability Scale (GBS/CIDP-RODS).|Change from baseline in disability measured with Overall Neuropathy Limitations Scale (ONLS) at 36 months.,https://ClinicalTrials.gov/show/NCT01757574
250,NCT00566696,Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies,"Active, not recruiting",Has Results,"Leukemia, Acute Lymphocytic (ALL)|Leukemia, Myeloid, Acute(AML)|Leukemia, Myeloid, Chronic(CML)|Juvenile Myelomonocytic Leukemia (JMML)|Hemoglobinuria, Paroxysmal Nocturnal (PNH)|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin (NHL)|Myelodysplastic Syndrome (MDS)",Device: CliniMACS|Procedure: Stem cell transplantation|Drug: Fludarabine|Drug: ThioplexÂ®|Drug: L-phenylalanine mustard|Drug: Mycophenolate mofetil|Drug: Rituxanâ„¢|Drug: Alemtuzumab|Drug: Cyclophosphamide|Drug: Anti-thymocyte globulin (Rabbit)|Drug: G-CSF|Drug: Muromonab,St. Jude Children's Research Hospital,All,"up to 21 Years Â  (Child, Adult)",Phase 2,73,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HIFLEX|NCI-2011-03670,29-Nov-07,11/1/07,1/1/17,3-May-16,Mar-16,27-Jan-16,null,Jan-15,"Event-free Survival (EFS)|Overall Survival (OS)|Disease-Free Survival (DFS)|Incidence of Non-hematologic Regimen-related Toxicities|Incidence of Regimen-related Mortality|To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.|To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.",https://ClinicalTrials.gov/show/NCT00566696
208,NCT02435901,HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity,Recruiting,No Results Available,Sickle Cell Disease|Beta Thalassemia-Major,Drug: alemtuzumab (Campath IH)|Drug: Fludarabine|Drug: Melphalan|Drug: Cyclosporine|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Biological: Hematopoietic Stem Cell Transplantation,Northwell Health,All,"1 Year to 21 Years Â  (Child, Adult)",Phase 1|Phase 2,29,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,8057,24-Apr-15,12/1/08,1/1/17,16-Aug-16,Aug-16,No Study Results Posted,null,Jan-17,Assessment of Stem Cell Engraftment|Assessment of treatment related mortality and morbidity|Event Free Survival|Immunological Reconstitution,https://ClinicalTrials.gov/show/NCT02435901
107,NCT01120028,"Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy","Active, not recruiting",No Results Available,Kidney Transplantation,Drug: Alemtuzumab|Drug: Basiliximab|Drug: Sirolimus|Drug: Tacrolimus,"University of Oxford|National Health Service, United Kingdom|Pfizer|Novartis",All,"18 Years and older Â  (Adult, Senior)",Phase 2|Phase 3,800,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,CTSU3C1|2008-008553-27|ISRCTN88894088,6-May-10,9/1/10,2/1/17,4-Jan-17,Jan-17,No Study Results Posted,3C,Feb-14,Biopsy-proven acute rejection|Graft function|Graft survival|Serious infection|Malignancy|Major vascular event,https://ClinicalTrials.gov/show/NCT01120028
53,NCT00217594,A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome,Completed,No Results Available,Myelodysplastic Syndromes,Drug: Alemtuzumab (Campath),"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 72 Years Â  (Adult, Senior)",Phase 2,40,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,050206|05-H-0206,20-Sep-05,7/20/05,2/6/17,10-Mar-17,9-Feb-17,No Study Results Posted,null,6-Feb-17,Hematologic response (complete or partial) at 3 months after the first dose of alemtuzumab and sustained on greater than or equal to 2 serial measurements performed 1 month apart.|Transfusion independence for red blood cells and/or platelets|Overall survival|Life-threatening toxicity|Overall survival and transformation-free survival,https://ClinicalTrials.gov/show/NCT00217594
271,NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,"Active, not recruiting",No Results Available,Myelodysplastic Syndrome|Hodgkin's Lymphoma|Non-Hodgkin's Disease|Acute Leukemia|Multiple Myeloma,Biological: Rituximab|Drug: Cyclosporine|Drug: Allogenic stem cell transplant (ASCT)|Drug: Conditioning Chemotherapy|Drug: TMS|Drug: FLAG|Drug: EPOCH-F|Biological: Alemtuzumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 74 Years Â  (Adult, Senior)",Phase 1|Phase 2,92,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,070195|07-C-0195,21-Aug-07,7/1/07,3/1/17,11-May-16,Mar-16,No Study Results Posted,null,Oct-15,"To assess the effects of two biologically distinct GVHD prophylaxis regimens|To determine and monitor incidence, organ severity and overall severity of chronic GVHD|To assess overall safety of these two regimens in this setting, and overall survival.|Study of engraftment kinetics|Toxicities",https://ClinicalTrials.gov/show/NCT00520130
267,NCT00943319,Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies,"Active, not recruiting",No Results Available,Leukemia|Lymphoma|Myeloma,Drug: Busulfan|Drug: Fludarabine|Drug: Campath|Procedure: Stem Cell Transplant,University of Chicago,All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,124,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12-0132,20-Jul-09,3/1/12,3/1/17,3-Aug-16,Aug-16,No Study Results Posted,null,Mar-17,Toxicity|Evaluate disease free and overall survival,https://ClinicalTrials.gov/show/NCT00943319
303,NCT01422603,Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML),"Active, not recruiting",No Results Available,Acute Myeloid Leukaemia|Myelodysplasia,Drug: Clofarabine|Drug: Clofarabine,"University Hospital Southampton NHS Foundation Trust|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,20,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,RHM CAN0638|2008-007043-14,22-Aug-11,2/1/11,5/1/17,12-Oct-16,Oct-16,No Study Results Posted,null,May-14,"Treatment related mortality (TRM)|Overall survival (OS)|Event free survival (EFS)|Efficacy of Clofarabine as a leukaemia bulk-reducing agent prior to transplant conditioning|Time to engraftment|Donor/recipient chimerism|Immune reconstitution parameters (T, B and NK cell subsets)|Duration of hospital stay|Incidence of acute and chronic graft versus host disease|Grade of acute and chronic graft versus host disease",https://ClinicalTrials.gov/show/NCT01422603
144,NCT00331162,Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation,"Active, not recruiting",No Results Available,Graft Rejection,Drug: Alemtuzumab|Drug: Anti-Thymocyte Globulin,Wake Forest University Health Sciences,All,18 Years to 65 Years Â  (Adult),Phase 4,275,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,BG04-498,26-May-06,2/1/05,6/1/17,10-Jan-17,Jan-17,No Study Results Posted,null,Jun-17,Patient survival|Graft survival|Acute Rejection|Hematologic adverse events|Infectious adverse events|Other adverse events|Cost|Health status and quality of life,https://ClinicalTrials.gov/show/NCT00331162
231,NCT01043640,Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders,"Active, not recruiting",No Results Available,Mucopolysaccharidosis|Hurler Syndrome|Hunter Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Adrenoleukodystrophy (ALD)|Krabbe Disease|Metachromatic Leukodystrophy (MLD)|Sphingolipidoses|Peroxisomal Disorders,Drug: Campath-1H|Drug: Cyclophosphamide|Drug: Busulfan|Procedure: Allogeneic stem cell transplantation|Drug: Cyclosporine A|Drug: Mycophenolate Mofetil,"Masonic Cancer Center, University of Minnesota",All,"up to 21 Years Â  (Child, Adult)",Phase 2,46,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2009LS088|MT2009-19,5-Jan-10,12/1/09,6/1/17,21-Jan-16,Jan-16,No Study Results Posted,null,Jun-15,Number of Patients with Donor Derived Engraftment|Number of Patients with Graft-Versus-Host Disease (GVHD) by Severity|Number of Patients Died Peri-Transplant|Donor Cell Chimerism Following Transplant,https://ClinicalTrials.gov/show/NCT01043640
39,NCT01395316,Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis,"Active, not recruiting",No Results Available,Multiple Sclerosis,Drug: Alemtuzumab,"University of Chicago|Genzyme, a Sanofi Company",All,18 Years to 50 Years Â  (Adult),Phase 4,8,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,10-490B,13-Jul-11,6/1/11,7/1/17,12-Jan-17,Jan-17,No Study Results Posted,null,Oct-15,Diffusion and myelin fraction water changes on MRI,https://ClinicalTrials.gov/show/NCT01395316
193,NCT00176865,Stem Cell Transplant for Immunologic or Histiocytic Disorders,"Active, not recruiting",No Results Available,Hemophagocytic Lymphohistiocytosis|X-Linked Lymphoproliferative Disorders|Chediak-Higashi Syndrome|Griscelli Syndrome|Immunologic Deficiency Syndromes|Langerhans-Cell Histiocytosis,"Procedure: Stem Cell Transplant|Drug: Fludarabine, melphalan, ATG or Campath","Masonic Cancer Center, University of Minnesota",All,"up to 35 Years Â  (Child, Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MT2002-12|0207M29448,12-Sep-05,8/1/02,8/1/17,26-Oct-12,Oct-12,No Study Results Posted,null,Aug-12,"To demonstrate the safety and the ability to establish stable mixed chimerism (>10% donor cells at day 100) using a nonmyeloablative preparative regimen in a phase 2 pilot trial|Determine the incidence of chimerism at 100 days, 6 months and 1 year|Determine the incidence of grade 2-4 and 3-4 acute graft versus host disease (aGVHD)|Determine the incidence of chronic graft versus host disease (cGVHD)|Compare quality of life (QOL)|Determine overall survival",https://ClinicalTrials.gov/show/NCT00176865
298,NCT00448357,Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases,"Active, not recruiting",No Results Available,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,Biological: rabbit anti-thymocyte globulin|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: methotrexate,UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),All,18 Years to 55 Years Â  (Adult),Phase 1|Phase 2,60,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LCCC 0510|P30CA016086|CDR0000550145,14-Mar-07,10/1/05,8/1/17,23-Nov-15,Nov-15,No Study Results Posted,LCCC 0510,Nov-16,One-year disease-free survival (DFS) rate at the maximum tolerated dose identified during phase I of the trial (target AUC 6912)|Overall and disease-free survival|Dose-limiting toxicities of busulfan|Capacity of test dosing of busulfan that would result in the desired area under the curve concentration exposure of patients receiving a full-dose busulfan regimen|To assess the incidence of graft vs host disease and DNA chimerism in patients between one month and two years post transplant,https://ClinicalTrials.gov/show/NCT00448357
235,NCT00977691,Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia,"Active, not recruiting",No Results Available,"Peripheral Blood Stem Cell Transplantation|Anemia, Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath )",Procedure: PBMC Transplant|Drug: Alemtuzumab (Campath )|Drug: Sirolimus (Rapamune )|Drug: Cyclophosphamide (Cytoxan )|Procedure: Low Dose Irradiation,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years and older Â  (Child, Adult, Senior)",Phase 1|Phase 2,56,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,090225|09-H-0225,15-Sep-09,9/1/09,8/1/17,10-Mar-17,23-Feb-17,No Study Results Posted,null,1-Aug-17,1 year post-transplant w/ sustained donor type hemoglobin for pts w/sickle cell dx or are transfusion-independent for pts w/thalassemia and not have severe graft-versus-host disease.|1) The level of chimerism required to maintain both graft survival as well as hematologic normalcy; 2) Incidence of acute and chronic GVHD; 3) Disease-free survival and overall survival; 4) Relapse rate and graft rejection rate.,https://ClinicalTrials.gov/show/NCT00977691
28,NCT01624714,Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects,"Active, not recruiting",No Results Available,Multiple Sclerosis,Drug: Alemtuzumab|Drug: Alemtuzumab immunotherapy,"Samuel Forrester Hunter, MD, PhD|Advanced Neurosciences Institute",All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 1,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NPI-004,18-Jun-12,9/1/12,9/1/17,8-Mar-14,Mar-14,No Study Results Posted,null,Apr-17,Change in Neurostatus Expanded Disability Status Scale|Change in MS Severity Scale|Change in annualized relapse rate|Number of treatment days with high dose corticosteroids|Rate of serious adverse events|MRI-based cerebral volumes and burden of disease (in selected subjects),https://ClinicalTrials.gov/show/NCT01624714
24,NCT01712945,Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis,Recruiting,No Results Available,Multiple Sclerosis,Drug: Palifermin|Drug: Alemtuzumab,Cambridge University Hospitals NHS Foundation Trust,All,"18 Months to 50 Years Â  (Child, Adult)",Phase 1|Phase 2,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",EudraCT 2011-005606-30,19-Oct-12,6/1/12,10/1/17,23-Oct-12,Oct-12,No Study Results Posted,CAM-THY,Aug-17,incidence of clinical autoimmunity|Absolute numbers of naive T cells|Safety events,https://ClinicalTrials.gov/show/NCT01712945
264,NCT02529839,Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS),Not yet recruiting,No Results Available,Multiple Sclerosis,Procedure: Autologous bone marrow transplantation|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab,Hadassah Medical Organization,All,18 Years to 65 Years Â  (Adult),,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,0105-15-HMO-CTIL,10-Jun-15,10/1/15,10/1/17,19-Aug-15,Apr-15,No Study Results Posted,null,Oct-17,"Engraftment parameters of Neutrophils and Platelets|Transplant related mortality by Day 100|Changes in the Expanded Disability Status Scale (EDSS score, as compared to baseline)|Overall survival (OS) at 1 year|Progression-free survival (PFS) at 1 year|Changes in MRI activity",https://ClinicalTrials.gov/show/NCT02529839
206,NCT00408447,Stem Cell Transplant in Sickle Cell Disease and Thalassemia,Recruiting,No Results Available,Sickle Cell Disease|Beta Thalassemia,Drug: Busulfan|Drug: Fludarabine|Drug: Alemtuzumab|Procedure: Allogeneic stem cell transplant,Columbia University|Yale University,All,"1 Month to 30 Years Â  (Child, Adult)",Phase 2,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAA7701|CHNY-01-503,6-Dec-06,9/1/04,11/1/17,5-Jan-16,Jan-16,No Study Results Posted,null,Nov-17,"Prevalence of toxicity associated with moderately ablative therapy (busulfan/fludarabine/alemtuzumab) and allogeneic stem cell transplantation in selected patients with sickle cell disease and Beta thalassemia|Time to donor hematological reconstitution (neutrophil, RBC and platelet recovery) following moderately ablative therapy and allogeneic stem cell transplantation in selected patients with SCD and BT|Incidence of acute and chronic graft versus host disease (GVHD) following moderately ablative therapy and allogeneic stem cell transplantation in selected patients with SCD and BT|Percent of patients who have either a complete, very good partial, partial or no response (clinical/laboratory) following moderately ablative therapy and allogeneic stem cell transplantation in selected patients with SCD and BT|Quality of life (QOL) score|Incidence of stroke and/or bleeding",https://ClinicalTrials.gov/show/NCT00408447
315,NCT00745420,Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601),"Active, not recruiting",No Results Available,Sickle Cell Disease,Biological: Hematopoietic Stem Cell Transplantation,"Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program|Sickle Cell Disease Clinical Research Network",All,"3 Years to 19 Years Â  (Child, Adult)",Phase 2,39,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BMTCTN0601|U01HL069294|5U24CA076518,29-Aug-08,8/1/08,12/1/17,17-May-16,May-16,No Study Results Posted,SCURT,Jul-15,"Event-free survival|Survival; neutrophil and platelet recovery; acute graft-versus-host disease (aGVHD); chronic GVHD (cGVHD); hepatic veno-occlusive disease; idiopathic pneumonia syndrome; and central nervous system toxicity|Neurocognitive dysfunction; cytomegalovirus, adenovirus, and fungal infections; Epstein Barr virus infection; chimerism; immune reconstitution; and quality of life",https://ClinicalTrials.gov/show/NCT00745420
237,NCT02867800,Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease,Recruiting,No Results Available,Sickle Cell Disease|Graft Versus Host Disease,Drug: Diphenhydramine|Drug: Acetaminophen|Drug: Methylprednisolone|Drug: Meperidine|Drug: Alemtuzumab|Drug: Thymoglobulin|Drug: Fludarabine|Drug: Melphalan|Drug: Thiotepa|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Methotrexate|Drug: Abatacept|Procedure: Marrow infusion,Monica Bhatia|Columbia University,All,"3 Years to 20 Years Â  (Child, Adult)",Phase 1,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAQ2350,11-Aug-16,7/1/16,12/1/17,16-Aug-16,Aug-16,No Study Results Posted,null,Dec-17,Number of patients who tolerated abatacept|Bearman Scale Score of Regimen-Related Toxicity (RRT)|Number of infections,https://ClinicalTrials.gov/show/NCT02867800
79,NCT00047060,Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome,"Active, not recruiting",No Results Available,Mycosis Fungoides|Sezary Syndrome,Drug: Campath-1H,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 70 Years Â  (Adult, Senior)",Phase 1,10,NIH,Interventional,Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Treatment,020250|02-H-0250,3-Oct-02,7/30/02,12/30/17,31-Mar-17,10-Mar-17,No Study Results Posted,null,30-Dec-17,"The primary goal is to find the minimal dose of conditioning regimen (of the two considered) which will establish engraftment in greater than 80% of patients.|Assess donor-host chimerism in various hematopoietic and lymphoid cells, dx response, incidence of acute/chronic GVHD, graft failure, assessment of lymphoid subset reconstitution, transplant related morbidity/mortality and dx-free and survival.",https://ClinicalTrials.gov/show/NCT00047060
226,NCT02038478,Allograft for Sickle Cell Disease and Thalassemia,Recruiting,No Results Available,Sickle Cell Disease and Thalassemia,Biological: Donor Stem Cell Transplantation,University of Texas Southwestern Medical Center,All,18 Years to 45 Years Â  (Adult),Phase 2,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STU 012013-015,10-Jan-14,1/1/14,1/1/18,7-Jun-16,Jun-16,No Study Results Posted,null,Jan-18,Treatment Success at One Year|Level of chierism required to maintain Graft Survival and hematologic normalcy,https://ClinicalTrials.gov/show/NCT02038478
227,NCT00061568,Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias,Recruiting,No Results Available,Congenital Hemolytic Anemia|Diamond-Blackfan Anemia,Procedure: Radiotherapy|Drug: Alemtuzumab (Campath )|Drug: Sirolimus (Rapamune ),"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years to 80 Years Â  (Child, Adult, Senior)",Phase 2,124,NIH,Interventional,Primary Purpose: Treatment,030170|03-H-0170,29-May-03,5/19/03,1/31/18,4-Apr-17,21-Mar-17,No Study Results Posted,null,31-Jan-18,Rate of engraftment,https://ClinicalTrials.gov/show/NCT00061568
322,NCT02694770,"A Study Evaluating the Efficacy and Safety of Neihulizumab vs ""Conventional Treatment"" to Treat Sr-aGvHD",Withdrawn,No Results Available,Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation,Biological: Neihulizumab Treatment|Biological: Conventional Treatment,AbGenomics B.V Taiwan Branch,All,"18 Years and older Â  (Adult, Senior)",Phase 2,0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2015.011.01,18-Feb-16,7/1/16,2/1/18,22-Apr-16,Apr-16,No Study Results Posted,null,Sep-17,Overall response rate (Complete Response+Partial Response)|Complete Response+Very Good Partial Response|Overall survival|Cumulative steroid dose|Cumulative incidence of chronic GvHD|Cumulative incidence of primary disease relapse,https://ClinicalTrials.gov/show/NCT02694770
37,NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,"Active, not recruiting",Has Results,"Lymphoma, T-Cell|Lymphoma, Extranodal NK-T-Cell",Biological: Alemtuzumab (Campath)|Drug: EPOCH,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"17 Years and older Â  (Child, Adult, Senior)",Phase 2,31,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,030304|03-C-0304,17-Sep-03,9/1/03,3/1/18,1-Aug-16,Aug-16,7-Oct-15,null,Jun-09,Maximum Tolerated Dose (MTD) of Alemtuzumab|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00069238
2,NCT01639573,Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis,Recruiting,No Results Available,Scleroderma,Drug: Campath,Children's Hospital Los Angeles,All,"8 Years to 18 Years Â  (Child, Adult)",,3,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CAMPATH-1H SSc,18-Jun-12,4/1/11,4/1/18,5-Aug-16,Aug-16,No Study Results Posted,CAMPATH-1H,Jan-18,Primary outcome|Campath,https://ClinicalTrials.gov/show/NCT01639573
201,NCT01499888,Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD),Recruiting,No Results Available,Sickle Cell Disease,Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation|Drug: Alemtuzumab|Drug: Sirolimus,University of Illinois at Chicago,All,18 Years to 60 Years Â  (Adult),Phase 1|Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2011-0096,23-Nov-11,5/1/11,5/1/18,24-Oct-16,Oct-16,No Study Results Posted,null,May-18,To determine the engraftment after non-myeloablative HSC transplant|To assess the frequency of acute and chronic complications of sickle cell disease|To evaluate the immune reconstitution after transplant.|To determine the transplant related morbidity and mortality.|To determine the long-term engraftment after non-myeloablative HSC transplant,https://ClinicalTrials.gov/show/NCT01499888
130,NCT01361711,Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia,"Active, not recruiting",No Results Available,Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia,Biological: alemtuzumab|Biological: ofatumumab|Procedure: biopsy,Northwestern University|GlaxoSmithKline|National Comprehensive Cancer Network,All,"18 Years and older Â  (Adult, Senior)",Phase 2,60,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NU 10H06|NCI-2011-00514|STU00044115,16-May-11,6/1/11,5/1/18,14-Sep-16,Sep-16,No Study Results Posted,null,May-18,Response rates|Survival rates|Treatment toxicity as measured by adverse events experienced while on treatment|Correlation of disease characteristics with disease outcomes|Compare efficacy between this study and historical control study of alemtuzumab-rituximab,https://ClinicalTrials.gov/show/NCT01361711
218,NCT01877837,Stem Cell Transplantation for Sickle Cell Anemia,Recruiting,No Results Available,Sickle Cell Disease,Drug: Alemtuzumab|Drug: Fludarabine|Drug: Melphalan|Procedure: Stem Cells,Hackensack University Medical Center,All,"2 Years to 30 Years Â  (Child, Adult)",Phase 3,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,Pro00001894,12-Jun-13,6/1/11,6/1/18,31-Jan-17,Jan-17,No Study Results Posted,null,Jun-18,Graft Failure|Overall survival,https://ClinicalTrials.gov/show/NCT01877837
54,NCT01982175,Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia,Recruiting,No Results Available,B-cell Chronic Lymphocytic Leukemia,Biological: Alemtuzumab,Shanghai Zhangjiang Biotechnology Limited Company,All,"18 Years to 75 Years Â  (Adult, Senior)",Phase 2,120,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CMAB004,5-Nov-13,7/1/11,6/1/18,21-Nov-16,Nov-16,No Study Results Posted,CLL004,Dec-17,Objective Response Rate(ORR)|Progression-Free Survival|Disease Control Rate(DCR)|Duration of Response(DOR)|Overall Survival|Summary of patients with Adverse Events(AEs),https://ClinicalTrials.gov/show/NCT01982175
108,NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,"Active, not recruiting",No Results Available,Progressive Multiple Sclerosis,Drug: Acyclovir|Drug: Methylprednisolone|Drug: alemtuzumab GZ402673|Drug: alemtuzumab GZ402673|Drug: Paracetamol|Drug: Loratadine|Drug: Ceterizine|Drug: Dexchlorpheniramine,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 1,24,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TDU14260|2015-002550-12|U1111-1171-7939,16-Oct-15,12/1/15,6/1/18,8-Apr-16,Apr-16,No Study Results Posted,SCALA,Mar-16,Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration|Change from baseline in lymphocyte subsets after alemtuzumab administration|Change from baseline in total lymphocyte count after alemtuzumab administration|Change from baseline in helper/suppressor ratio after alemtuzumab administration|Assessment of pharmacokinetic parameter after alemtuzumab administration: maximum plasma concentration observed (Cmax)|Assessment of pharmacokinetic parameter after alemtuzumab administration: time to reach Cmax (Tmax)|Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration versus time curve from time zero until the last measurable concentration (AUClast)|Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration (AUC)|Assessment of pharmacokinetic parameter after alemtuzumab administration: terminal half-life (t1/2z)|Number of patients with adverse events|Number of patients with adverse events of special interest|Number of patients with injection site reactions,https://ClinicalTrials.gov/show/NCT02583594
284,NCT00924170,"Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia","Active, not recruiting",No Results Available,Adult T-Cell Leukemia (ATL),Drug: LMB-2|Drug: Fludarabine|Drug: Cyclophosphamide,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 100 Years Â  (Adult, Senior)",Phase 1|Phase 2,18,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,090025|09-C-0025,17-Jun-09,10/31/08,6/30/18,17-Mar-17,13-Mar-17,No Study Results Posted,null,2-Jan-16,Response Rate,https://ClinicalTrials.gov/show/NCT00924170
253,NCT00578643,Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease,Recruiting,No Results Available,Chronic Granulomatous Disease,Drug: Busulfan|Biological: Alemtuzumab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Cyclosporine|Procedure: Stem Cell Infusion,Baylor College of Medicine|Texas Children's Hospital,All,"Child, Adult, Senior",Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,14771-MUNCHR,19-Dec-07,3/1/04,7/1/18,20-Jan-17,Jan-17,No Study Results Posted,MUNCHR,Nov-17,"Number of patients that have engraftment after transplant.|Estimating the risk for acute and chronic GVHD and regimen related morbidity/mortality for patients with CGD following SCT from 5/6 or 6/6 HLA-matched unrelated or 5/6 or 6/6 HLA phenotype-matched related donors.|Examining the potential for reversal of organ toxicity (e.g. lung, liver, intestine) following engraftment and stable normal neutrophil function.",https://ClinicalTrials.gov/show/NCT00578643
131,NCT01013961,Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia,Terminated,Has Results,Chronic Lymphocytic Leukemia,Biological: alemtuzumab|Biological: rituximab,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group,All,"65 Years and older Â  (Adult, Senior)",Phase 2,31,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,E1908|U10CA180794,13-Nov-09,10/1/10,7/1/18,1-Feb-16,Feb-16,22-Dec-15,null,Jul-15,Proportion of Patients With Complete Response (CR)|Proportion of Patients With Overall Response (OR)|Overall Survival (OS)|Progression-free Survival (PFS)|Time to Response|Duration of Response,https://ClinicalTrials.gov/show/NCT01013961
25,NCT00057967,Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or SÃ©zary Syndrome,"Active, not recruiting",No Results Available,Lymphoma,Biological: alemtuzumab,"Northwestern University|Millennium Pharmaceuticals, Inc.|Genzyme, a Sanofi Company",All,"18 Years and older Â  (Adult, Senior)",Phase 2,37,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NU 99H8|STU00012258,7-Apr-03,7/1/00,8/1/18,23-Feb-16,Feb-16,No Study Results Posted,null,Aug-17,Determine response rate associated with Campath-1H therapy in patients with relapsed Mycosis Fungoides/Sezary Syndrome|Collect data on toxicity associated with Campath-1H therapy,https://ClinicalTrials.gov/show/NCT00057967
318,NCT02411084,"Study of BEGEDINAÂ® vs ""Conventional Treatment"" for Treating Steroid-Resistant Acute GvHD",Recruiting,No Results Available,Graft vs Host Disease,Biological: Begelomab|Biological: Conventional Second-line Treatment,Adienne SA|ADIENNE S.r.l. S.U.,All,18 Years to 65 Years Â  (Adult),Phase 3,184,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ADN011|2015-001360-19,24-Mar-15,2/1/16,8/1/18,21-Oct-16,Oct-16,No Study Results Posted,null,Feb-18,Overall response rate|Transplant-related mortality (TRM)|Change from baseline in stages of GvHD by target organ|Cumulative Incidence of Chronic Graft-versus Host Disease|Cumulative Steroid Dose|Cumulative incidence of relapse and relapse-related mortality|Second malignancy|Karnofsky Performance Status|Adverse Events|Assessment of Clinical Laboratory Evaluations|Analysis of infection markers in blood|Immunogenicity assessment|Assessment of glucose metabolism|Vital Signs: number of patients with cardiovascular safety concerns|Vital Signs: number of patients with respiratory safety concerns|Number of patients with abnormal physical findings|Pharmacokinetic assessment of BEGEDINA serum levels|Health assessment: Quality of life (QoL)|Duration of response|Overall Survival,https://ClinicalTrials.gov/show/NCT02411084
66,NCT02385110,Alemtuzumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis,Recruiting,No Results Available,Leukemia,Drug: Alemtuzumab|Drug: Etoposide|Drug: Dexamethasone|Drug: Methotrexate|Behavioral: Phone Call,M.D. Anderson Cancer Center,All,"Child, Adult, Senior",Phase 2,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2014-0989|NCI-2015-00526,5-Mar-15,9/23/15,9/1/18,10-Feb-17,Feb-17,No Study Results Posted,null,Sep-18,Overall Response Rate (ORR) of Alemtuzumab in Combination with Etoposide and Dexamethasone in Participants with Hemophagocytic Lymphohistiocytosis (HLH).,https://ClinicalTrials.gov/show/NCT02385110
209,NCT02013375,SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD,"Active, not recruiting",No Results Available,Sickle Cell Disease,Procedure: Haploidentical Transplant|Drug: Alemtuzumab|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Sirolimus,"Damiano Rondelli, MD|University of Illinois at Chicago",All,"16 Years to 60 Years Â  (Child, Adult)",Phase 2,110,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2013-0849,11-Dec-13,11/1/13,10/1/18,24-Oct-16,Oct-16,No Study Results Posted,SCD-Haplo,Oct-18,Engraftment Rate|Acute & Chronic Complications|Overall & Disease-Free Survival|Morbidity & Mortality,https://ClinicalTrials.gov/show/NCT02013375
228,NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,Recruiting,No Results Available,Acute Lymphoblastic Leukemia|Non Hodgkins Lymphoma|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Hemophagocytic Lymphohistiocytosis (HLH)|Familial Hemophagocytic Lymphohistiocytosis (FLH)|Viral-associated Hemophagocytic Syndrome (VAHS)|X-linked Lymphoproliferative Disease (XLP),Drug: Ara-C|Drug: Cyclophosphamide|Biological: Campath-1H|Radiation: Total Body Irradiation|Procedure: Stem Cell Infusion,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System",All,"up to 55 Years Â  (Child, Adult)",Phase 2,87,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-8701-MOHEL|MOHEL,21-Sep-05,4/1/00,12/1/18,21-Dec-16,Dec-16,No Study Results Posted,MOHEL,Dec-17,Number of patients with severe acute GVHD|Number of patients with engraftment|Number of patients with severe Chronic GVHD|Assessment of immune reconstitution,https://ClinicalTrials.gov/show/NCT00368355
198,NCT01050855,Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders,Recruiting,No Results Available,Non Malignant Diseases|Immunodeficiencies|Hemoglobinopathies,Drug: RIC: Distal Campath|Drug: RIC:Intermediate Campath|Drug: RIC: Mini Busulfan,Children's Hospital of Philadelphia,All,"6 Months to 25 Years Â  (Child, Adult)",Phase 2,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,08-005658|CHP 894,15-Jan-10,1/1/08,12/1/18,21-Dec-16,Dec-16,No Study Results Posted,RIC,Dec-18,Engraftment and Survival,https://ClinicalTrials.gov/show/NCT01050855
41,NCT01307332,Advanced MRI Measures of Repair in Alemtuzumab Treated Patients,"Active, not recruiting",No Results Available,Relapsing Remitting Multiple Sclerosis,Drug: MabCampath-1h,"University of British Columbia|Genzyme, a Sanofi Company",All,18 Years to 50 Years Â  (Adult),Phase 3,25,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H10-02482|142402,26-Jan-11,3/1/11,12/1/18,18-May-16,May-16,No Study Results Posted,iCAMMS-IST,Sep-18,Changes in normal appearing white matter from baseline through month 24.|To identify specific changes in T cell subsets and functions in Relapsing Remitting Multiple Sclerosis from baseline through month 48.,https://ClinicalTrials.gov/show/NCT01307332
286,NCT01049854,CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant,Recruiting,No Results Available,Leukemia|Lymphoma|Bone Marrow Failure|Immunodeficiencies|Histiocytosis|Sickle Cell Disease|Beta Thalassemia|Inborn Errors of Metabolism,Drug: Full Intensity with TBI|Drug: Full Intensity|Drug: Reduced Intensity|Drug: Reduced Intensity (Fanconi),New York Medical College,All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 2,35,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,"L 10,321|NYMC 525",5-May-08,9/1/11,12/1/18,21-Mar-17,Mar-17,No Study Results Posted,null,Dec-17,"The safety CD34+ stem cell selection|Immune reconstitution (T, B, DC) following CD34+ selection",https://ClinicalTrials.gov/show/NCT01049854
241,NCT01897688,A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients,Recruiting,No Results Available,Type 1 Diabetes|Severe Hypoglycemic Unawareness,Biological: Islet Cell Transplant,Northwestern University,All,18 Years to 65 Years Â  (Adult),Phase 3,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STU00059469,9-Jul-13,6/1/12,12/1/18,1-Dec-16,Dec-16,No Study Results Posted,null,Dec-17,To demonstrate the safety and efficacy of islet transplantation under alemtuzumab induction for treatment of Type-1 Diabetes (T1D) in subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes.|To relate clinical transplant outcomes based upon islet quantity/quality to organ donor characteristics.,https://ClinicalTrials.gov/show/NCT01897688
268,NCT02061800,CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant,Recruiting,No Results Available,Chronic Myeloid Leukemia (CML)|Acute Myelogenous Leukemia (AML);|Myelodysplastic Syndrome (MDS);|Juvenile Myelomonocytic Leukemia (JMML);|Acute Lymphoblastic Leukemia (ALL);|Lymphoma (Hodgkin's and Non-Hodgkin's),Device: CliniMACS CD34+ Reagent System|Drug: Thiotepa|Drug: Cyclophosphamide|Drug: Alemtuzumab|Drug: Tacrolimus|Drug: Melphalan|Drug: Busulfan|Drug: Fludarabine|Drug: Methylprednisolone,"Diane George, MD|Columbia University",All,"up to 22 Years Â  (Child, Adult)",Phase 1|Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAK8060,11-Feb-14,11/1/13,12/1/18,26-Jul-16,Jul-16,No Study Results Posted,null,Dec-18,"Incidence of acute GVHD|Incidence of chronic GVHD|Severity of acute GVHD|Severity of chronic GVHD|Incidence of primary graft failure|Incidence of secondary graft failure|Time to neutrophil engraftment|Time to immune reconstitution|Incidence of infection complications including bacterial, viral, fungal and atypical mycobacterial and other infections|Time to platelet engraftment",https://ClinicalTrials.gov/show/NCT02061800
278,NCT01998633,Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204),"Active, not recruiting",No Results Available,Hemophagocytic Lymphohistiocytosis|Chronic Active Epstein-Barr Virus Infection|Chronic Granulomatous Disease|HIGM-1|Leukocyte Adhesion Deficiency|IPEX,Biological: Hematopoietic Stem Cell Transplant,"Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program",All,"4 Months to 45 Years Â  (Child, Adult)",Phase 2,46,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,BMTCTN1204|2U10HL069294-11|5U24CA076518,29-Oct-13,12/1/13,12/1/18,7-Feb-17,Feb-17,No Study Results Posted,RICHI,Dec-17,Overall survival (OS)|Sustained Engraftment|HLH Reactivation|Immune Reconstitution|Neutrophil Engraftment|Platelet Engraftment|Cumulative Incidence of Grade Acute GVHD|Cumulative Incidence of Chronic GVHD|Frequency of Transplant-Related Complications,https://ClinicalTrials.gov/show/NCT01998633
63,NCT02472054,Treatment of Familiar Lymphohistiocytosis,Recruiting,No Results Available,Hemophagocytic Lymphohistiocytosis (HLH),Drug: Alemtuzumab|Drug: Methyl Prednisolone (MP)|Drug: Cyclosporin A (CSA),Assistance Publique - HÃ´pitaux de Paris,All,up to 17 Years Â  (Child),Phase 1|Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P120109|2014-005585-30,8-Jun-15,6/1/15,4/1/19,2-Dec-16,Dec-16,No Study Results Posted,C-HLH,Oct-18,Number of surviving patients until HSCT|Number of complete remissions following treatment|Time of delay between the first administration of Alemtuzumab and complete remission|Dosage of Alemtuzumab|Number of side effects,https://ClinicalTrials.gov/show/NCT02472054
254,NCT01596699,Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation,Suspended,No Results Available,Myeloid Malignancy|Bone Marrow Failure Syndrome|Transfusion-dependent Red Blood Cell (RBC) Defect|Congenital Immunodeficiency|Metabolic Disease|Severe Immune Dysregulation,Drug: Alemtuzumab|Drug: Busulfan|Drug: Fludarabine|Drug: Clofarabine,"Christopher Dvorak|University of California, San Francisco",All,"3 Months to 30 Years Â  (Child, Adult)",,31,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UCSF Protocol No. 110819,7-May-12,7/1/12,6/1/19,14-Aug-14,Aug-14,No Study Results Posted,null,Jun-18,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Change in the engraftment rate of patients with non-malignant diseases (Stratum A) undergoing allogeneic HCT as compared to historic controls|Change in the full donor chimerism of patients with high-risk myeloid malignancies (Stratum B) undergoing allogeneic HCT as compared to historic controls|Serum concentrations and potential for drug-drug interaction of Fludarabine and Clofarabine,https://ClinicalTrials.gov/show/NCT01596699
246,NCT02059239,Lymphoma Bridge Transplant Study,Recruiting,No Results Available,Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma,Drug: Bendamustine|Drug: Carmustine|Drug: Etoposide|Drug: Melphalan|Drug: Cytarabine|Drug: Alemtuzumab|Biological: Autologous Stem Cell Transplantation|Biological: Allogeneic Stem Cell Transplantation|Drug: Rituximab,Weill Medical College of Cornell University,All,"18 Years and older Â  (Adult, Senior)",,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,1208012875,6-Feb-14,6/4/14,6/1/19,1-Mar-17,Mar-17,No Study Results Posted,null,Jun-17,"Number of patients who recover from bendamustine and proceed to transplant|Number of patients who exhibit a response after bendamustine and after transplant|Survival of subjects at 100 days, 1 year after treatment|Transplant-related mortality rate",https://ClinicalTrials.gov/show/NCT02059239
265,NCT02653196,A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,Recruiting,No Results Available,Neuroepithelial Tumor|Solid Tumor|Allogeneic Hematopoietic Stem Cell Transplantation,Procedure: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Drug: Keratinocyte Growth Factor|Drug: Alemtuzumab|Drug: Thiotepa|Drug: Etoposide|Drug: Fludarabine|Drug: Melphalan|Drug: Tacrolimus|Drug: Cyclosporine A|Drug: Mycophenolate mofetil,Montefiore Medical Center|Children's Hospital Los Angeles|Nationwide Children's Hospital,All,"up to 30 Years Â  (Child, Adult)",Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2014-3856,7-Jan-16,9/1/15,7/1/19,8-Jan-16,Jan-16,No Study Results Posted,null,Jul-18,Progression-Free Survival|Overall Survival|Transplant Related Mortality|Engraftment|Regimen Related Toxicity|Time to Immune Reconstitution,https://ClinicalTrials.gov/show/NCT02653196
197,NCT00565773,Belatacept Post Depletional Repopulation to Facilitate Tolerance,"Active, not recruiting",No Results Available,Organ Transplantation,Drug: Belatacept|Drug: Belatacept|Drug: Alemtuzumab|Other: donor bone marrow,Emory University|Bristol-Myers Squibb,All,"18 Years and older Â  (Adult, Senior)",Phase 2,40,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,IRB00005064|Grant # FD-R-003539|eIRB 00005064|BMS IM103-036,28-Nov-07,12/1/07,8/1/19,16-Feb-17,Feb-17,No Study Results Posted,null,Aug-19,"The primary endpoint will be the number of patients successfully withdrawn from oral immunosuppression for one year after their last dose of an immunosuppressive drug.|Assessment of proposed therapies to prevent acute and/or chronic rejection by 1,3, and 5 years compared to the standard reported in the UNOS database for patients with similar demographics.",https://ClinicalTrials.gov/show/NCT00565773
328,NCT02171104,MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis,Recruiting,No Results Available,Mucopolysaccharidosis Disorders|Hurler Syndrome|Hunter Syndrome|Maroteaux Lamy Syndrome|Sly Syndrome|Alpha-Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Glycoprotein Metabolic Disorders|Sphingolipidoses|Recessive Leukodystrophies|Globoid Cell Leukodystrophy|Metachromatic Leukodystrophy|Niemann-Pick B|Niemann-Pick C Subtype 2|Sphingomyelin Deficiency|Peroxisomal Disorders|Adrenoleukodystrophy With Cerebral Involvement|Zellweger Syndrome|Neonatal Adrenoleukodystrophy|Infantile Refsum Disease|Acyl-CoA Oxidase Deficiency|D-Bifunctional Enzyme Deficiency|Multifunctional Enzyme Deficiency|Alpha-methylacyl-CoA Racmase Deficiency|Mitochondrial Neurogastrointestingal Encephalopathy|Severe Osteopetrosis|Hereditary Leukoencephalopathy|Inherited Metabolic Disorders,"Biological: Stem Cell Transplantation|Drug: IMD Preparative Regimen|Drug: Osteopetrosis Only Preparative Regimen|Drug: Osteopetrosis Haploidentical Only Preparative Regimen|Drug: cALD SR-A (Standard-Risk, Regimen A)|Drug: cALD SR-B (Standard-Risk, Regimen B)|Drug: cALD HR-D (High-Risk, Regimen C)|Drug: cALD HR-D (High-Risk, Regimen D)","Masonic Cancer Center, University of Minnesota",All,"up to 55 Years Â  (Child, Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2013LS104,20-Jun-14,7/10/14,9/1/19,22-Mar-17,Mar-17,No Study Results Posted,null,Sep-19,"percentage of subjects who achieve high-level donor hematopoietic engraftment (defined as neutrophil recovery by Day +42 post-transplant and â‰¥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant)|percentage of subjects who develop graft-versus-host disease|number of subjects who die from transplant complications|incidence of regimen-related toxicity (such as infection, acute renal failure, respiratory failure, cardiac failure, and veno-occlusive disease)|incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical changes",https://ClinicalTrials.gov/show/NCT02171104
196,NCT02626715,Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS,Recruiting,No Results Available,Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Hematopoietic Stem Cell Transplant (HSCT),Drug: Reduced-Intensity Conditioning Regimen|Drug: Myeloablative Conditioning Regimen,University of Pittsburgh,All,"1 Month to 22 Years Â  (Child, Adult)",Phase 2,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment,PRO14100126,24-Sep-15,9/4/15,9/1/19,5-Apr-17,Apr-17,No Study Results Posted,null,Sep-18,"Safety (non-relapse mortality at Day 100) in pediatric patients receiving a myeloablative or reduced-intensity preparative regimen prior to HSCT for high-risk AML and MDS.|Preliminary efficacy (disease-free survival at 1 year) in pediatric patients receiving a myeloablative or reduced-intensity preparative regimen prior to HSCT for high-risk AML and MDS.|The pace of neutrophil and platelet recovery using absolute neutrophil count and platelet count, respectively.|The incidence of acute Graft versus Host Disease (GVHD) (II-IV, III-IV) and chronic GVHD.|The number of subjects with disease-free survival (DFS) by Day 100 and 180 post-transplant, using adverse events assessed by CTCAE version 4.0.|The number of subjects with treatment-related mortality (TRM) by Day 100 and 180 post-transplant, using adverse events assessed by CTCAE version 4.0.|The number of subjects with overall survival (OS) by Day 100 and 180 post-transplant, using adverse events assessed by CTCAE version 4.0.|The pace of immune reconstitution using lymphocyte subset panel and chimerism assay (recipient's percentage of donor and recipient stem cell populations)|Day 0 Campath (Alemtuzumab) level|Correlation of Day 0 Campath (alemtuzumab) levels with rate of relapse, rate of viral infections, and pace of immune reconstitution.|Incidence of primary graft failure.|Incidence of Grades 4 and 5 adverse events as assessed by CTCAE 4.0.",https://ClinicalTrials.gov/show/NCT02626715
297,NCT01240525,Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers,Recruiting,No Results Available,Graft Versus Host Disease|Leukemia|Lymphoma|Myeloma|Myelodysplastic Syndrome,Other: CD4 DLI|Other: No DLI,"University College, London",All,"18 Years to 69 Years Â  (Adult, Senior)",Phase 2,68,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UCL/10/0241|UCL-10/0241|LRF-09041|EU-21081|CRUK-UCL-PROT4,11-Nov-10,11/1/11,11/1/19,7-Nov-16,Nov-16,No Study Results Posted,ProT4,Nov-17,"Progression-free survival at 1 year post-transplant|Proportion of patients attaining multi-lineage full donor chimerism in peripheral blood|Incidence of infection requiring inpatient treatment|Rate of reconstitution of T-cell subsets and viral-specific immunity|Cumulative incidence of non-relapse mortality at 1 year|Overall survival and non-relapse mortality|Incidence, grade, or pattern of graft-versus-host disease",https://ClinicalTrials.gov/show/NCT01240525
240,NCT01962415,"Reduced Intensity Conditioning in Patients Aged â‰_35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT",Recruiting,No Results Available,Primary Immunodeficiency Syndromes|Congenital Bone Marrow Failure Syndromes|Inherited Metabolic Disorders (IMD)|Hereditary Anemias|Patients With Sickle Disease Presenting Specific Symptoms,Drug: Hydroxyurea|Drug: Alemtuzumab|Drug: Fludarabine|Drug: Melphalan|Drug: Thiotepa,University of Pittsburgh,All,"2 Months to 35 Years Â  (Child, Adult)",Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,RIC for HSCT in NMD|PRO13100018,10-Oct-13,12/1/13,11/1/19,16-Mar-17,Mar-17,No Study Results Posted,RIC HSCT NMD,Nov-18,Post-transplant treatment-related mortality (TRM)|Neurodevelopmental milestones|Immune Reconstitution|Severe opportunistic infections|GVHD occurrence|Donor cell engraftment|Normal enzyme level|Neutrophil recovery|Platelet recovery|Grade 3-4 organ toxicity|Long-term complications|Late graft failure,https://ClinicalTrials.gov/show/NCT01962415
17,NCT00858117,A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL,"Active, not recruiting",No Results Available,Leukemia,Biological: Alemtuzumab|Biological: Rituximab,Northwestern University|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NU 04H6|STU00004494,6-Mar-09,3/1/05,12/1/19,10-Jan-17,Jan-17,No Study Results Posted,null,Dec-18,"To determine the response rate to the study medications, Alemtuzumab and Rituximab|Collect data on the toxicity of the study medications, Alemtuzumab and Rituximab",https://ClinicalTrials.gov/show/NCT00858117
327,NCT00889798,Tumor Registry of Lymphatic Neoplasia,"Active, not recruiting",No Results Available,Non-Hodgkin's Lymphoma (NHL)|Chronic Lymphocytic Leukemia (CLL)|Multiple Myeloma (MM),,iOMEDICO AG,All,"18 Years and older Â  (Adult, Senior)",,3750,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,IOM-TLN,28-Apr-09,4/1/09,12/1/19,27-Jun-16,Jun-16,No Study Results Posted,TLN-Registry,Aug-19,"Documentation of anamnestic data and therapy sequences|Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions",https://ClinicalTrials.gov/show/NCT00889798
187,NCT01729494,Belatacept Early Steroid Withdrawal Trial,"Active, not recruiting",No Results Available,Renal Transplantation,Drug: Alemtuzumab|Drug: rabbit antithymocyte globulin|Drug: Belatacept|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: early cessation of steroids,University of Cincinnati,All,"18 Years and older Â  (Adult, Senior)",Phase 4,316,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BEST,10-Oct-12,9/1/12,12/1/19,15-Dec-16,Dec-16,No Study Results Posted,null,Dec-18,Composite endpoint|Secondary endpoint,https://ClinicalTrials.gov/show/NCT01729494
311,NCT01966367,CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease,Recruiting,No Results Available,Bone Marrow Failure Syndrome|Severe Aplastic Anemia|Severe Congenital Neutropenia|Amegakaryocytic Thrombocytopenia|Diamond-Blackfan Anemia|Schwachman Diamond Syndrome|Primary Immunodeficiency Syndromes|Acquired Immunodeficiency Syndromes|Histiocytic Syndrome|Familial Hemophagocytic Lymphocytosis|Lymphohistiocytosis|Macrophage Activation Syndrome|Langerhans Cell Histiocytosis (LCH)|Hemoglobinopathies|Sickle Cell Disease|Sickle Cell-beta-thalassemia,Biological: CD34 Stem Cell Selection Therapy,"Diane George, MD|Columbia University",All,"up to 30 Years Â  (Child, Adult)",,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAL0156,17-Oct-13,3/1/13,12/1/19,10-Mar-16,Mar-16,No Study Results Posted,null,Dec-19,Incidence of acute graft versus host disease (GVHD)|Incidence of primary graft failure|Survival Rate|Time to neutrophil and platelet engraftment|Time to immune reconstitution|Incidence of infectious complications|Incidence of secondary graft failure,https://ClinicalTrials.gov/show/NCT01966367
189,NCT01935128,Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following CampathÂ® Induction,Recruiting,No Results Available,Renal Transplant,Drug: Arm 1 Everolimus/Reduced dose tacrolimus,University of Toledo Health Science Campus|Novartis Pharmaceuticals,All,"18 Years and older Â  (Adult, Senior)",Phase 4,50,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,Everolimus,21-Aug-13,7/1/13,12/1/19,10-Mar-17,Mar-17,No Study Results Posted,null,Dec-19,Renal function|Graft survival|Biopsy proven acute rejection|Patient survival|Impaired glucose tolerance|Proteinuria|Lipid levels|Mouth ulcers|Gastrointestinal complaints|Leukopenia|Thrombocytopenia|Neurotoxicity|Pneumonitis|Cytomegalovirus|Infection requiring hospitalization|BK infection|BK nephropathy|Malignancies|Cardiovascular complications|Development of donor specific antibody,https://ClinicalTrials.gov/show/NCT01935128
232,NCT01875237,Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene,Terminated,No Results Available,Leukemia|Myeloma|Myeloproliferative Diseases,Drug: Fludarabine|Drug: Melphalan|Drug: Alemtuzumab|Procedure: Stem Cell infusion|Drug: Tacrolimus|Drug: Mini Methotrexate|Drug: G-CSF|Procedure: Donor Lymphocyte Infusion (DLI)|Drug: AP1903|Drug: Methylprednisolone|Behavioral: Questionnaire,M.D. Anderson Cancer Center|Bellicum Pharmaceuticals,All,18 Years to 65 Years Â  (Adult),Phase 1|Phase 2,3,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2012-0501|NCI-2013-01666,7-Jun-13,12/27/13,12/1/19,9-Mar-17,Mar-17,No Study Results Posted,null,1-Dec-19,Graft Versus Host Disease (GVHD) Free Survival|Disease-Free Survival (DFS),https://ClinicalTrials.gov/show/NCT01875237
77,NCT00345345,Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia,Recruiting,No Results Available,Lymphoproliferative Disorders,Drug: Alemtuzumab (Campath),"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"18 Years to 85 Years Â  (Adult, Senior)",Phase 2,39,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,060190|06-H-0190,27-Jun-06,6/20/06,12/31/19,24-Jan-17,7-Nov-16,No Study Results Posted,null,31-Dec-19,"The primary end point of the study is the response rate at three months, defined as improvement in cytopenia(s)|Secondary endpoints will include relapse-free survival, response at 6 months, life threatening toxicity, reduction in the number of abnormal T-LGL clone, and overall survival.",https://ClinicalTrials.gov/show/NCT00345345
164,NCT02255656,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,"Active, not recruiting",No Results Available,Relapsing Remitting Multiple Sclerosis,Drug: alemtuzumab GZ402673,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 4,812,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LPS13649|2013-003884-71|U1111-1148-2987,30-Sep-14,1/1/15,3/1/20,19-Aug-16,Aug-16,No Study Results Posted,TOPAZ,Mar-20,"Incidence, duration, grade/intensity, relationship to study drug, and outcome of the following: Serious Adverse Events; Adverse Events|Incidence, nature, seriousness, grade/intensity, relationship to study drug, and outcome of the following adverse events of special interest: Specific autoimmune mediated conditions, Infusion-associated reactions, Malignancy, Infections|Changes in laboratory parameters|Annualized relapse rate (AR)|Proportion of participants relapse free|Change over time in Expanded Disability Status Scale (EDSS) scores|Change over time in brain imaging findings|Change over time in self-reported quality of life (QoL) as assessed by the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36) Version 2|Change over time in the Functional Assessment of Multiple Sclerosis (FAMS)|Change over time in the EuroQoL in 5 Dimensions (EQ-5D)|Pharmaco-economic evaluation (Modify Health Resources Utilization Questionnaire [HRUQ] / Health Related Productivity Questionnaire [HRPQ])",https://ClinicalTrials.gov/show/NCT02255656
80,NCT02419378,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,Recruiting,No Results Available,"Multiple Sclerosis, Relapsing-Remitting",Drug: Alemtuzumab,"University Hospital Muenster|Genzyme, a Sanofi Company",All,18 Years to 55 Years Â  (Adult),Phase 4,15,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science,UKM12_0026|U1111-1156-6489,31-Mar-15,5/1/15,5/1/20,17-Jun-16,Jun-16,No Study Results Posted,ALAIN01,May-20,"Absolute change from baseline in naÃ¯ve CD4 positive T cell counts in peripheral blood|Relative change from baseline in naÃ¯ve CD4 positive T cell counts in peripheral blood|Relative change from baseline in naÃ¯ve CD8 positive T cell counts in peripheral blood|Absolute change from baseline in naÃ¯ve CD8 positive T cell counts in peripheral blood|Absolute change from baseline in CD4 positive T effector cell counts in peripheral blood|Relative change from baseline in CD4 positive T effector cell counts in peripheral blood|Absolute change from baseline in CD8 positive T effector cell counts in peripheral blood|Absolute change from baseline in CD4 positive T memory cell counts in peripheral blood|Relative change from baseline in CD4 positive T memory cell counts in peripheral blood|Absolute change from baseline in CD8 positive T memory cell counts peripheral blood|Relative change from baseline in CD8 positive T memory cell counts in peripheral blood|Absolute change from baseline in CD4 positive regulatory T cell counts in peripheral blood|Relative change from baseline in CD4 positive regulatory T cell counts in peripheral blood|Absolute change from baseline in CD8 positive regulatory T cell counts in peripheral blood|Relative change from baseline in CD8 positive regulatory T cell counts in peripheral blood|Absolute change from baseline in Th1 T-helper cell counts in peripheral blood|Relative change from baseline in Th1 T-helper cell counts in peripheral blood|Absolute change from baseline in Th2 T-helper cell counts in peripheral blood|Relative change from baseline in Th2 T-helper cell counts in peripheral blood|Absolute change from baseline in Th17 T-helper cell counts in peripheral blood|Relative change from baseline in Th17 T-helper cell counts in peripheral blood|Absolute change from baseline in recent bone marrow emigrant B cell counts peripheral blood|Relative change from baseline in recent bone marrow emigrant B cell counts in peripheral blood|Absolute change from baseline in mature naÃ¯ve B cell counts in peripheral blood|Relative change from baseline in mature naÃ¯ve B cell counts in peripheral blood|Absolute change from baseline in memory B cell counts in peripheral blood|Relative change from baseline in memory B cell counts in peripheral blood|Absolute change from baseline in plasma cell counts in peripheral blood|Relative change from baseline in plasma cell counts in peripheral blood|Absolute change from baseline in CD56bright natural killer cell counts in peripheral blood|Relative change from baseline in CD56bright natural killer cell counts in peripheral blood|Absolute change from baseline in CD56dim natural killer cell counts in peripheral blood|Relative change from baseline in CD56dim natural killer cell counts in peripheral blood|Absolute change from baseline in natural killer T cell counts in peripheral blood|Relative change from baseline in natural killer T cell counts in peripheral blood|Absolute change from baseline in CD303+ plasmacytoid dendritic cell counts in peripheral blood|Relative change from baseline in CD303+ plasmacytoid dendritic cell counts in peripheral blood|Absolute change from baseline in CD11c+ myeloid dendritic cell counts in peripheral blood|Relative change from baseline in CD11c+ myeloid dendritic cell counts in peripheral blood|Absolute change from baseline in CD141+ myeloid dendritic cell counts in peripheral blood|Relative change from baseline in CD141+ myeloid dendritic cell counts in peripheral blood|Absolute change from baseline in monocyte counts in peripheral blood|Relative change from baseline in monocyte counts in peripheral blood|Absolute change from baseline in macrophage counts in peripheral blood|Relative change from baseline in macrophage counts in peripheral blood|Absolute change from baseline in myeloid-derived suppressor cell counts in peripheral blood|Relative change from baseline in myeloid-derived suppressor cell counts in peripheral blood|Absolute change from baseline in naÃ¯ve CD4 positive T cell counts in cerebrospinal fluid|Relative change from baseline in naÃ¯ve CD4 positive T cell counts in cerebrospinal fluid|Absolute change from baseline in naÃ¯ve CD8 positive T cell counts in cerebrospinal fluid|Relative change from baseline in naÃ¯ve CD8 positive T cell counts in cerebrospinal fluid|Absolute change from baseline in CD4 positive T effector cell counts in cerebrospinal fluid|Relative change from baseline in CD4 positive T effector cell counts in cerebrospinal fluid|Absolute change from baseline in CD8 positive T effector cell counts in cerebrospinal fluid|Relative change from baseline in CD8 positive T effector cell counts in cerebrospinal fluid|Absolute change from baseline in CD4 positive T memory cell counts in cerebrospinal fluid|Relative change from baseline in CD4 positive T memory cell counts in cerebrospinal fluid|Absolute change from baseline in CD8 positive T memory cell counts in cerebrospinal fluid|Relative change from baseline in CD8 positive T memory cell counts in cerebrospinal fluid|Absolute change from baseline in CD4 positive regulatory T cell counts in cerebrospinal fluid|Relative change from baseline in CD4 positive regulatory T cell counts in cerebrospinal fluid|Absolute change from baseline in CD8 positive regulatory T cell counts in cerebrospinal fluid|Relative change from baseline in CD8 positive regulatory T cell counts in cerebrospinal fluid|Absolute change from baseline in Th1 T-helper cell counts in cerebrospinal fluid|Relative change from baseline in Th1 T-helper cell counts in cerebrospinal fluid|Absolute change from baseline in Th2 T-helper cell counts in cerebrospinal fluid|Relative change from baseline in Th2 T-helper cell counts in cerebrospinal fluid|Absolute change from baseline in Th17 T-helper cell counts in cerebrospinal fluid|Relative change from baseline in Th17 T-helper cell counts in cerebrospinal fluid|Absolute change from baseline in recent bone marrow emigrant B cell counts in cerebrospinal fluid|Relative change from baseline in recent bone marrow emigrant B cell counts in cerebrospinal fluid|Absolute change from baseline in mature naÃ¯ve B cell counts in cerebrospinal fluid|Relative change from baseline in mature naÃ¯ve B cell counts in cerebrospinal fluid|Absolute change from baseline in memory B cell counts in cerebrospinal fluid|Relative change from baseline in memory B cell counts in cerebrospinal fluid|Absolute change from baseline in plasma cell counts in cerebrospinal fluid|Relative change from baseline in plasma cell counts in cerebrospinal fluid|Absolute change from baseline in CD56bright natural killer cell counts in cerebrospinal fluid|Relative change from baseline in CD56bright natural killer cell counts in cerebrospinal fluid|Absolute change from baseline in CD56dim natural killer cell counts in cerebrospinal fluid|Relative change from baseline in CD56dim natural killer cell counts in cerebrospinal fluid|Absolute change from baseline in natural killer T cell counts in cerebrospinal fluid|Relative change from baseline in natural killer T cell counts in cerebrospinal fluid|Absolute change from baseline in CD303+ plasmacytoid dendritic cell counts in cerebrospinal fluid|Relative change from baseline in CD303+ plasmacytoid dendritic cell counts in cerebrospinal fluid|Absolute change from baseline in CD11c+ myeloid dendritic cell counts in cerebrospinal fluid|Relative change from baseline in CD11c+ myeloid dendritic cell counts in cerebrospinal fluid|Absolute change from baseline in CD141+ myeloid dendritic cell counts in cerebrospinal fluid|Relative change from baseline in CD141+ myeloid dendritic cell counts in cerebrospinal fluid|Absolute change from baseline in monocyte counts in cerebrospinal fluid|Relative change from baseline in monocyte counts in cerebrospinal fluid|Absolute change from baseline in macrophage counts in cerebrospinal fluid|Relative change from baseline in macrophage counts in cerebrospinal fluid|Absolute change from baseline in myeloid-derived suppressor cell counts in cerebrospinal fluid|Relative change from baseline in myeloid-derived suppressor cell counts in cerebrospinal fluid|Activation status of cell surface receptors on T cells fom peripheral blood as assessed by flow cytometry|Activation status of cell surface receptors on T cells from cerebrospinal fluid as assessed by flow cytometry|Expression of co-inhibitory molecules by T cells from peripheral blood as assessed by flow cytometry|Expression of co-inhibitory molecules by T cells from cerebrospinal fluid as assessed by flow cytometry|Effector functions of CD4 and CD8 positive T cells from peripheral blood|Effector functions of CD4 and CD8 positive T cells from cerebrospinal fluid|Migrational capacity of T cells from peripheral blood|Migrational capacity of T cells from cerebrospinal fluid|Spectratyping of the T cell repertoire of T cells from peripheral blood concerning the expansion of distinct clones|Spectratyping of the T cell repertoire of T cells from cerebrospinal fluid concerning the expansion of distinct clones|Regulatory T-cell function in peripheral blood|Regulatory T-cell function in cerebrospinal fluid|Relative and absolute change from baseline in the concentration of markers in the cerebrospinal fluid|Relative and absolute change from baseline in neuronal activity, action potential generation and cellular integrity by obtained human CSF supernatant samples using multi-electrode arrays|Relative and absolute change from baseline in the concentration of neurotrophic factors in the peripheral blood|Relative and absolute change from baseline in the concentration of neurotrophic factors in cerebrospinal fluid|Percent change from Baseline in the following MRI findings which are defined as markers for neurodegeneration: MRI-T1-measured cerebral volume, MRI-T1-measured number of black holes|Relative and absolute change from baseline in retinal nerve fiber layer thickness (assessment by optical coherence tomography)|Data on Adverse Events",https://ClinicalTrials.gov/show/NCT02419378
238,NCT02678143,Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease,Recruiting,No Results Available,Sickle Cell Disease,Drug: Alemtuzumab|Drug: Cyclophosphamide|Drug: Mycophenolate mofetil|Drug: Sirolimus|Drug: Fludarabine|Radiation: Total body irradiation|Procedure: Hematopoietic stem cell transplant,Washington University School of Medicine,All,"19 Years and older Â  (Adult, Senior)",Phase 1,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,201602019,4-Feb-16,4/26/16,5/31/20,23-Feb-17,Feb-17,No Study Results Posted,null,31-May-20,"Safety and tolerability of treatment regimen as measured by grade 3, 4, and 5 toxicities|Feasibility of treatment regimen as measured by accrual|Feasibility of treatment regimen as measured by patient compliance to treatment and follow-up|Rate of engraftment|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease|Incidence of infectious complications|Incidence of transplant related mortality|Incidence of engraftment failure|Overall survival rate|Event-free survival rate",https://ClinicalTrials.gov/show/NCT02678143
61,NCT01030900,Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas,"Active, not recruiting",No Results Available,Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma,Biological: campath|Biological: Rituximab|Drug: EPOCH,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 100 Years Â  (Adult, Senior)",Phase 2,50,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,100011|10-C-0011,11-Dec-09,10/21/09,9/1/20,24-Jan-17,12-Dec-16,No Study Results Posted,null,1-Sep-20,PFS and OS,https://ClinicalTrials.gov/show/NCT01030900
145,NCT01465334,Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL,Recruiting,No Results Available,CLL|SLL,Drug: Ofatumumab|Drug: High-Dose Methylprednisolone|Drug: Alemtuzumab,Dana-Farber Cancer Institute|National Comprehensive Cancer Network|GlaxoSmithKline,All,"18 Years and older Â  (Adult, Senior)",Phase 2,54,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,11-304|NCCN Protocol Number: NCCN-001|GSK Protocol Number: OFT115580,18-Oct-11,11/1/11,12/1/20,25-Oct-16,Oct-16,No Study Results Posted,null,Dec-18,"Overall Response Rate (ORR)|Complete response (CR) Rate|ORR, CR Rate|Improvement in ORR, CR rate|Improvement in ORR, CR Rate during maintenance|Rate of subjects proceeding to transplant|Safety",https://ClinicalTrials.gov/show/NCT01465334
274,NCT01652092,Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies,Recruiting,No Results Available,SCID|Omenn's Syndrome|Reticular Dysgenesis|Wiskott-Aldrich Syndrome|Bare Lymphocyte Syndrome|Common Variable Immunodeficiency|Chronic Granulomatous Disease|CD40 Ligand Deficiency|Hyper IgM Syndrome|X-linked Lymphoproliferative Disease|Hemophagocytic Lymphohistiocytosis|Griscelli Syndrome|Chediak-Higashi Syndrome|Langerhan's Cell Histiocytosis,Drug: Alemtuzumab 0.3 mg|Drug: Cyclophosphamide|Drug: Busulfan|Biological: Stem Cell Transplantation|Drug: Fludarabine phosphate 40 mg|Drug: Melphalan|Drug: Alemtuzumab 0.2 mg|Drug: Busulfan|Drug: Fludarabine phosphate 30 mg|Drug: MESNA,"Masonic Cancer Center, University of Minnesota",All,"up to 50 Years Â  (Child, Adult)",,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2012OC055|MT2012-10C,25-Jul-12,9/4/12,12/1/20,17-Feb-17,Feb-17,No Study Results Posted,null,Dec-18,Neutrophil Engraftment|Incidence of Graft Failure|Incidence of Chimerism|Incidence of Acute Graft-Versus-Host Disease|Incidence of Chronic Graft-Versus-Host Disease|Incidence of Transplant-Related Mortality|Disease-Free Survival|Overall Survival,https://ClinicalTrials.gov/show/NCT01652092
84,NCT00195624,Alemtuzumab to Treat Severe Aplastic Anemia,"Active, not recruiting",No Results Available,Relapsed or Refractory Severe Aplastic Anemia|Severe Aplastic Anemia,Drug: Alemtuzumab (Campath ),"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years and older Â  (Child, Adult, Senior)",Phase 2,47,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,050242|05-H-0242,16-Sep-05,9/14/05,12/31/20,24-Jan-17,15-Nov-16,No Study Results Posted,null,31-Dec-18,"Response rate at six months, defined as no longer satisfying blood count criteria for SAA.|Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia.",https://ClinicalTrials.gov/show/NCT00195624
167,NCT00619528,HLA-Identical Sibling Renal Transplant Tolerance,"Active, not recruiting",No Results Available,Immunosuppression|Kidney Transplantation|Graft Rejection,Biological: Infusion of Donor Hematopoietic Stem Cells and Campath-1H,Northwestern University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 65 Years Â  (Adult),,230,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,2R01DK025243-25A2|R01DK025243,8-Feb-08,7/1/07,2/1/21,7-Oct-16,Oct-16,No Study Results Posted,null,Feb-18,"The ability to withdraw immunosuppression as above 24 months post-transplant with follow-up to 10 years.|Patient and graft survival measured at the one-year timepoint post-transplant.|Patient and graft survival measured at the three year timepoint post-transplant..|Incidence rate of biopsy-proven acute rejection, defined as a renal biopsy demonstrating acute cellular or humoral rejection of Banff Grade IA or greater.|Incidence of chronic allograft nephropathy, determined using renal biopsies and laboratory values, including 24 hour urine protein excretion.|Incidence of graft versus host disease (GVHD).|Incidence of adverse events associated w/ renal transplantation and immunosuppression, including infections, malignancies, post transplant lymphoproliferative disease (PTLD), thromboembolic events, hyperlipidemia, leukopenia, thrombocytopenia, GI toxic",https://ClinicalTrials.gov/show/NCT00619528
182,NCT02623946,Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients,Recruiting,No Results Available,Multiple Sclerosis,,Clinique Neuro-Outaouais|CogState Ltd.,All,"18 Years and older Â  (Adult, Senior)",,10,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CNO-004,30-Nov-15,11/1/15,2/1/21,26-Jul-16,Jul-16,No Study Results Posted,null,Dec-20,"intrapatient correlation coefficient of MEP's|Correlation coefficient between the mean group changes from baseline of MEP results and clinical measures (EDSS, 6MW, T25FWT, 9HPT)",https://ClinicalTrials.gov/show/NCT02623946
248,NCT02497404,Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR,Recruiting,No Results Available,"Leukemia, Erythroblastic, Acute|Myelodysplastic Syndromes",Drug: 5-Azacytidine|Drug: Fludarabine|Drug: Melphalan|Drug: Alemtuzumab,Weill Medical College of Cornell University,All,"18 Years and older Â  (Adult, Senior)",Phase 2,55,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,1306014009,19-Feb-15,2/13/15,7/1/21,1-Mar-17,Mar-17,No Study Results Posted,null,Jun-18,disease free survival|Incidence and severity of acute and chronic GVHD|Engraftment and chimerism patterns|evaluate changes in global methylation,https://ClinicalTrials.gov/show/NCT02497404
316,NCT02179359,Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies,Recruiting,No Results Available,Sickle Cell Disease|Transfusion Dependent Alpha- or Beta- Thalassemia|Diamond Blackfan Anemia|Paroxysmal Nocturnal Hemoglobinuria|Glanzmann Thrombasthenia|Severe Congenital Neutropenia|Shwachman-Diamond Syndrome|Non-Malignant Hematologic Disorders,Drug: Reduced Toxicity Ablative Regimen|Drug: Reduced Intensity Preparative Regimen|Drug: Myeloablative Preparative Regimen,"Masonic Cancer Center, University of Minnesota",All,"up to 55 Years Â  (Child, Adult)",,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,2014OC034|MT2014-10C,27-Jun-14,9/2/14,8/1/21,17-Feb-17,Feb-17,No Study Results Posted,null,Aug-19,incidence of graft failure|overall survival|disease free survival,https://ClinicalTrials.gov/show/NCT02179359
245,NCT02105766,Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure,Recruiting,No Results Available,Sickle Cell Disease|Thalassemia|Stem Cell Transplantation|Graft vs Host Disease,Drug: Alemtuzumab|Drug: Sirolimus|Drug: Cyclophosphamide|Drug: Pentostatin|Drug: Radiotherapy,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)",All,"16 Years to 80 Years Â  (Child, Adult, Senior)",Phase 1|Phase 2,162,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,140077|14-H-0077,1-Apr-14,3/13/14,8/31/21,24-Jan-17,25-Nov-16,No Study Results Posted,null,31-Aug-21,"Determine regimen failure rate, defined as graft rejection, severe GVHD (acute GVHD grade 3 or higher or extensive chronic GVHD), or prolonged donor red cell aplasia ( greater than 2 years post -HSCT)|Examine the level of chimerism required to maintain both graft survival as well as hematologic normalcy using a regimen containing pentostatin, cyclophosphamide, alemtuzumab, and low total body irradiation.",https://ClinicalTrials.gov/show/NCT02105766
89,NCT02689453,Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL),Recruiting,No Results Available,"Leukemia, Adult T-Cell|HTLV I Associated T Cell Leukemia|Adult T-Cell Leukemia (ATL)",Biological: IL-15 plus alemtuzumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),All,"18 Years to 100 Years Â  (Adult, Senior)",Phase 1,30,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,160062|16-C-0062,20-Feb-16,1/28/16,1/31/22,24-Jan-17,14-Dec-16,No Study Results Posted,null,15-Feb-20,Determine MTD and DLTs of s.c. rhIL-15 administered with 3 times per week IV Alemtuzumab|Clinical response rate and progression free survival,https://ClinicalTrials.gov/show/NCT02689453
266,NCT01625351,A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,Recruiting,No Results Available,Ewing Sarcoma|Gastrointestinal Tumor|Germ Cell Tumor|Hepatic Tumor|Lymphoma|Wilms Tumor|Rhabdoid Tumor|Clear Cell Carcinoma|Renal Cell Carcinoma|Melanoma|Neuroblastoma|Rhabdomyosarcoma|Non-rhabdomyosarcoma,Drug: alemtuzumab|Drug: fludarabine|Drug: sirolimus|Drug: Busulfan|Drug: melphalan|Biological: stem cells|Device: CliniMACS,"St. Jude Children's Research Hospital|CURE Childhood Cancer, Inc.",All,"2 Years to 21 Years Â  (Child, Adult)",Phase 1,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,RADIANT|NCI-2012-00588,19-Jun-12,8/20/12,7/31/22,30-Mar-17,Oct-16,No Study Results Posted,null,31-Jul-17,Feasibility of haploidentical HSCT|hematopoietic cell recovery and engraftment rates|infection rates and complications|overall survival (OS)|event-free survival,https://ClinicalTrials.gov/show/NCT01625351
324,NCT01949129,Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia,Recruiting,No Results Available,Acute Lymphoblastic Leukaemia,Drug: VP16|Radiation: TBI|Drug: Thiotepa|Drug: Treosulfan|Drug: Fludarabine|Drug: Busulfan,St. Anna Kinderkrebsforschung|ALL SCTped Forum,All,"6 Months to 18 Years Â  (Child, Adult)",Phase 2|Phase 3,1000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ALL SCTped FORUM 2012,9-Sep-13,4/1/13,4/1/23,15-Feb-16,Feb-16,No Study Results Posted,null,Apr-18,Overall Survival (OS) Stratum 1 (randomisation TBI+ chemo-conditioning vs. chemo-conditioning only)|Event free survival (EFS) Stratum 2 (mismatched donor transplantation)|EFS (Stratum 1)|Cumulative Incidence of Treatment-related mortality (TRM) for Stratum 1 and 2|Cumulative Incidence of Relapse for Stratum 1 and 2|acute and late toxicity for Stratum 1 and 2|OS (Stratum 2),https://ClinicalTrials.gov/show/NCT01949129
175,NCT00426517,Donor Stem Cell Transplantation for Congenital Immunodeficiencies,Recruiting,No Results Available,Inherited Immune Deficiencies,"Drug: Fludarabine|Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine|Drug: Sirolimus or equivalent based on response|Drug: Granulocyte Colony Stimulating Factor (G-CSF)|Other: hematopoietic progenitor cells",National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"2 Years to 65 Years Â  (Child, Adult)",Early Phase 1,100,NIH,Interventional,Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment,070075|07-I-0075,23-Jan-07,1/19/07,12/1/23,24-Jan-17,1-Dec-16,No Study Results Posted,null,1-Dec-20,"The primary objective for this study is to evaluate the use of immunosuppressive drugs such as Campath -1H or h-ATG, fludarabine, and sirolimus in conjunction with a novel busulfan-based conditioning regimen with or without the addition of radia...|To measure the engraftment rate and the engraftment kinetics using such a regimen|To further elucidate the required dose levels of busulfan as compared to historical controls in conditioning regimens for transplantation in general|To assess the level and kinetics of immune reconstitution when using these conditioning regimens. To further elucidate the factors involved in the development of graft versus host disease.",https://ClinicalTrials.gov/show/NCT00426517
285,NCT02162420,Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia,Recruiting,No Results Available,Dyskeratosis Congenita|Aplastic Anemia,Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Biological: Stem Cell Transplant|Drug: Anti-thymocyte globulin,"Masonic Cancer Center, University of Minnesota",All,"up to 70 Years Â  (Child, Adult, Senior)",,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2013OC127|MT2013-34C,10-Jun-14,1/1/15,7/1/24,15-Aug-16,Aug-16,No Study Results Posted,null,Jul-24,Incidence of neutrophil engraftment|Incidence of regimen related mortality|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease,https://ClinicalTrials.gov/show/NCT02162420
321,NCT01459107,Human Upper Extremity Allotransplantation,Recruiting,No Results Available,"Amputation, Traumatic|Wounds and Injuries|Hand Injuries",Procedure: Deceased donor hand transplantation|Drug: Bone marrow cell-based therapy & single-drug immunosuppression.,Johns Hopkins University|Armed Forces Institute of Regenerative Medicine|U.S. Army Medical Research Acquisition Activity,All,"18 Years to 69 Years Â  (Adult, Senior)",Phase 2,30,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NA_00046418,29-Sep-11,7/1/11,6/1/26,8-Mar-16,Mar-16,No Study Results Posted,null,Jun-21,Graft Survival|Documentation of immunosuppression required by transplanted participants to maintain graft.,https://ClinicalTrials.gov/show/NCT01459107
313,NCT01889381,Human Craniomaxillofacial Allotransplantation,Recruiting,No Results Available,Facial Injuries|Traumatic Wounds and Injuries|Craniofacial Injuries|Craniofacial Defects,Drug: Bone marrow cell-based therapy & 1-drug immunosuppression.,Johns Hopkins University,All,18 Years to 60 Years Â  (Adult),Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NA_00067257,26-Jun-13,8/1/12,8/1/26,8-Mar-16,Mar-16,No Study Results Posted,null,Aug-21,Graft Survival|Documentation of immunosuppression required by transplanted participants to maintain graft.,https://ClinicalTrials.gov/show/NCT01889381
308,NCT03077542,Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease,Recruiting,No Results Available,Sickle Cell Disease,Procedure: haploidentical stem cell transplant|Drug: sirolimus|Drug: campath|Drug: pentostatin|Drug: cyclophosphamide,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"2 Years to 80 Years Â  (Child, Adult, Senior)",Phase 1|Phase 2,84,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,170069|17-H-0069,10-Mar-17,3/8/17,8/31/26,15-Mar-17,14-Mar-17,No Study Results Posted,null,30-Sep-25,"The percentage of patients at 100 days (+/- 1 week) post-transplantwith sustained donor type hemoglobin on hemoglobin electrophoresis (HbS less than 50% when donors have sickle cell trait and <10% when donors have normal hemoglobin), who d...|The level of chimerism required to maintain both graft survival as wellas hematologic normalcy.",https://ClinicalTrials.gov/show/NCT03077542
279,NCT01247701,Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies,Recruiting,No Results Available,Myeloid Hematological Malignancies,Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Cord Blood Stem Cell Infusion,"Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",All,up to 17 Years Â  (Child),,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,26558-UCAML,22-Nov-10,11/1/10,11/1/27,27-Feb-17,Feb-17,No Study Results Posted,UCAML,Nov-24,Overall survival at 1 year after UCB transplant in pediatric patients.|Number of participants with severe acute GVHD Grade III-IV as an assessment of safety.|Number of participants with chronic GvHD as an assessment of safety.|Assess relapse rate after transplant.|To evaluate donor engraftment after transplant.|Assessment of platelet count recovery.|Assessment of neutrophil count recovery.,https://ClinicalTrials.gov/show/NCT01247701
291,NCT02629120,High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease,Recruiting,No Results Available,X-Linked Chronic Granulomatious Disease,Drug: Campath|Drug: Busulfan|Other: allogeneic peripheral blood allograft infusion|Drug: cyclophosphamide,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"4 Years to 65 Years Â  (Child, Adult)",Early Phase 1,50,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,160032|16-I-0032,10-Dec-15,12/3/15,12/1/30,24-Jan-17,2-Nov-16,No Study Results Posted,null,1-Dec-25,Reduced incidence of graft failure or rejection (Engraftment as defined by >20% engraftment by oxidase positive neutrophils in at least 95% of participants by Day 100)|Same or reduced rate of Graft versus Host Disease of <10%|Establish stable mixed chimerism.|Improve rapidity of immune reconstitution.,https://ClinicalTrials.gov/show/NCT02629120
199,NCT01659606,Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita,Recruiting,No Results Available,Dyskeratosis Congenita|Hoyeraal Hreidarsson Syndrome|Revesz Syndrome|Aplastic Anemia,Biological: alemtuzumab|Drug: Fludarabine|Drug: Cyclosporins|Drug: Mycophenolate mofetil,"Boston Childrenâ€™s Hospital|Dana-Farber Cancer Institute|Children's Hospital Medical Center, Cincinnati|Children's Hospital Los Angeles",All,"up to 65 Years Â  (Child, Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,12-950|IRB-P00003466,6-Aug-12,7/1/12,12/1/34,27-Jan-17,Jan-17,No Study Results Posted,null,Dec-19,Primary engraftment|Survival to day+100 post-BMT|Viral reactivation and infection|Treatment related adverse events as assessed by CTCAE version 4.0|Secondary graft failure|Acute and chronic graft-versus-host disease (GVHD)|Engraftment monitoring (chimerism)|Immune reconstitution as assessed by quantitation of lymphocyte subsets|Changes in pulmonary function as assessed by pulmonary function testing|Secondary malignancies|Long-term survival,https://ClinicalTrials.gov/show/NCT01659606
125,NCT00048412,Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H,Completed,No Results Available,Myelodysplastic Disorders|Leukemia|Multiple Myeloma|Plasma Cell Dyscrasia|Lymphoproliferative Disorders,Drug: FLUDARABINE|Drug: CAMPATH 1H|Drug: FK50|Procedure: Stem Cell Collection and Infusion,"Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"up to 70 Years Â  (Child, Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,H8714|DIMSUM,30-Oct-02,6/1/00,null,9-Apr-07,Apr-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00048412
293,NCT00040469,Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies,Terminated,No Results Available,Sickle Cell Anemia|Hemoglobinopathy|Thalassemia,Drug: Campath -1H|Drug: Dilantin|Drug: Busulfan|Drug: Cyclophosphamide,"Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"up to 64 Years Â  (Child, Adult)",Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H6847|Scallo2,26-Jun-02,8/1/00,null,9-Apr-07,Apr-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00040469
309,NCT00040417,Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies,Terminated,No Results Available,Sickle Cell Anemia|Hemoglobinopathy|Thalassemia,Drug: FLUDARABINE|Drug: CAMPATH-IH|Procedure: Total Body Irradiation|Drug: FK506|Drug: G-SCF (Granulocyte-colony stimulating factor),Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System,All,"up to 65 Years Â  (Child, Adult)",Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H8750|Smallo,26-Jun-02,8/1/00,null,9-Apr-07,Apr-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00040417
127,NCT00048399,"Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H",Terminated,No Results Available,Graft Failure,Drug: Fludarabine|Drug: CAMPATH 1H|Drug: FK506|Procedure: Stem Cell Transplantation,Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital,All,"up to 64 Years Â  (Child, Adult)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,H9446|CAMGRAFT,30-Oct-02,12/1/00,null,9-Apr-07,Apr-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00048399
166,NCT00006390,Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia,Completed,No Results Available,Leukemia,Biological: alemtuzumab|Biological: filgrastim|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),All,18 Years to 65 Years Â  (Adult),Phase 2,null,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000068272|ECOG-8998,4-Oct-00,2/1/01,null,26-Jan-10,Jan-10,No Study Results Posted,null,Dec-04,,https://ClinicalTrials.gov/show/NCT00006390
137,NCT00040846,"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","Active, not recruiting",Has Results,"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|WaldenstrÃ¶m Macroglobulinemia",Biological: alemtuzumab|Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: mycophenolate mofetil|Drug: cyclosporine,"Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",All,"up to 74 Years Â  (Child, Adult, Senior)",Phase 2,60,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,1591.00|NCI-2011-00471|P30CA015704|P01CA018029,8-Jul-02,11/1/01,null,26-Jan-17,Jan-17,26-Jan-17,null,Dec-09,"Evaluate the Risk of Transplant Related Mortality.|Evaluate the Risk of Occurrence of Acute and Chronic GVHD|Determine Whether Engraftment Can be Maintained With a Single Dose Fludarabine, DLI and Continued MMF/CSP, Defined as Rejection Rate < 20%.|Evaluate the Risk/Incidence of Infections|Evaluate the Risk for Disease Progression and Relapse",https://ClinicalTrials.gov/show/NCT00040846
169,NCT00920972,Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases,Recruiting,No Results Available,"Metabolic Disorders|Hematologic, Immune, or Bone Marrow Disorders|Hemoglobinopathies|Non-malignant Disorders","Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan",Washington University School of Medicine|St. Louis Children's Hospital,All,"up to 20 Years Â  (Child, Adult)",Phase 1|Phase 2,220,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,01-0923,15-Jun-09,12/1/01,null,1-Nov-16,Nov-16,No Study Results Posted,null,Dec-18,Donor engraftment as measured by chimerism|Major toxicities as graded by the CTC v4|Time to neutrophil and platelet engraftment as measured by complete blood counts|Incidence of acute graft-versus-host disease as measured by protocol grading scale|Incidence of chronic graft-versus-host disease as measured by protocol grading scale|Long-term donor engraftment by donor chimerism|Immune reconstitution by laboratory evaluations|Overall and disease free survival,https://ClinicalTrials.gov/show/NCT00920972
20,NCT02701517,Cyclosporine Plus Methotrexate or Alemtuzumab,Suspended,No Results Available,Unrecognized Condition: Mature B or T-cell Neoplasm,Drug: Cyclosporine + METHOTREXATE|Drug: Cyclosporine + CAMPATH-1H,Grupo EspaÃ±ol de Linfomas y Transplante AutÃ_logo de MÃ©dula Ã“sea,All,45 Years to 65 Years Â  (Adult),Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TIRCAMPATH-alo 2002,12-Mar-15,9/1/03,null,2-Mar-16,Mar-16,No Study Results Posted,null,Nov-09,Efficacy of transplantation in terms of event-free survival|Incidence of infections and transplant-related mortality,https://ClinicalTrials.gov/show/NCT02701517
62,NCT00077961,"Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL",Terminated,No Results Available,Non-Hodgkin's Lymphoma,Drug: CAMPATH (alemtuzumab),"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,49,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAM.NHL233,13-Feb-04,12/1/03,null,25-Mar-15,Mar-15,No Study Results Posted,null,Feb-06,,https://ClinicalTrials.gov/show/NCT00077961
116,NCT00081068,Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia,Withdrawn,No Results Available,Lymphoma,Biological: alemtuzumab,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,0,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000358811|UCLA-0309058,7-Apr-04,1/1/04,null,7-Jan-13,Jan-13,No Study Results Posted,null,null,Objective response|Time to treatment failure|Toxicity,https://ClinicalTrials.gov/show/NCT00081068
58,NCT00226512,To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning,Withdrawn,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: Campath-1H /ATG,Hadassah Medical Organization|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 3,203,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,230704-HMO-CTIL,9-Sep-05,7/1/04,null,7-Apr-11,Sep-05,No Study Results Posted,null,null,"To determine the efficacy of s.c. Campath-1H or ATG in decreasing the incidence and severity of acute and chronic GVHD in patients with AML and MDS treated with non-myeloablative stem cell transplantation.|Investigate the role of different conditioning regimens on:|Infection, engraftment relapse rate and disease free survival.",https://ClinicalTrials.gov/show/NCT00226512
85,NCT00089349,Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia,Completed,No Results Available,Recurrent Childhood Acute Lymphoblastic Leukemia,Biological: alemtuzumab|Drug: methotrexate|Drug: mercaptopurine,National Cancer Institute (NCI),All,"up to 30 Years Â  (Child, Adult)",Phase 2,25,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-01814|ADVL0222|CDR0000378240|NCI-05-C-0248|COG-ADVL0222|U01CA097452,4-Aug-04,7/1/04,null,4-Jun-13,Jun-13,No Study Results Posted,null,Sep-06,Response rate to Campath-1H alone|Response to combined treatment with Campath-1H and chemotherapy|Tolerability of the combination therapy evaluated by dose-limiting toxicity,https://ClinicalTrials.gov/show/NCT00089349
92,NCT00161590,"Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma",Completed,No Results Available,"T-Cell Lymphoma|Lymphoma, Non-Hodgkin's",Drug: CHOP and alemtuzumab,Weill Medical College of Cornell University|Bayer,All,"18 Years and older Â  (Adult, Senior)",Phase 1,null,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,0204-157,7-Sep-05,7/1/04,null,21-Oct-08,Oct-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00161590
319,NCT00074282,"Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Unknown status,No Results Available,Leukemia,Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: lenalidomide|Drug: pentostatin,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,110,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000343796|ECOG-2903,10-Dec-03,12/1/04,null,9-Nov-12,Nov-12,No Study Results Posted,null,Oct-14,"Response (CR, nPR, PR) rate in all patients treated with PCR|Minimal-residual disease (MRD) as assessed by both flow cytometry and real-time allele-specific oligonucleotide polymerase chain reaction (RT-PCR)|Toxicity as measured by CTCAE criteria every month|Overall survival and progression-free survival as measured by Kaplan-Meier method during study treatment|Rate of molecular complete remission (MCR) after the treatment of PCR and alemtuzumab (before May 2011) or lenalidomide after May 2011) in patients who achieve a CR or nPR",https://ClinicalTrials.gov/show/NCT00074282
129,NCT00118352,"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","Active, not recruiting",No Results Available,"Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|WaldenstrÃ¶m Macroglobulinemia",Biological: alemtuzumab|Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Biological: graft versus host disease prophylaxis/therapy|Other: laboratory biomarker analysis,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),All,"up to 74 Years Â  (Child, Adult, Senior)",Phase 2,11,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1959.00|NCI-2009-01496|P01CA018029|P30CA015704,8-Jul-05,3/1/05,null,13-Jun-16,Jun-16,No Study Results Posted,null,Jul-10,Dose of alemtuzumab that allows an incidence of grade III-IV acute GVHD less than 40%|Graft rejection|Number of days of steroids greater than 1 mg/kg required in each patient|Non-relapse mortality|Infection|Immune reconstitution|Disease progression/relapse,https://ClinicalTrials.gov/show/NCT00118352
29,NCT00214214,A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus,Withdrawn,No Results Available,New Onset Type 1 Diabetes Mellitus,Drug: Campath 1HÂ® (Alemtuzumab),"University of Wisconsin, Madison",All,18 Years to 35 Years Â  (Adult),Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,H-2003-0405,13-Sep-05,10/1/05,null,6-Oct-15,Oct-15,No Study Results Posted,null,null,to determine if Campath-1H can be used in patients recently diagnosed with type I DM|to determine if Campath-1H can eliminate or lower insulin requirements,https://ClinicalTrials.gov/show/NCT00214214
157,NCT00895739,Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure,Unknown status,No Results Available,Nonmalignant Neoplasm,Biological: alemtuzumab|Drug: cyclosporine,Federico II University|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,50,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,UNMS-ALESAA|CDR0000639649|EU-20927|EUDRACT-2008-001151-22,7-May-09,6/1/06,null,9-Aug-13,May-09,No Study Results Posted,null,null,"Safety, as defined by occurrence of adverse effects|Overall survival|Hematologic response (partial and complete response, including time to response)|Failure-free survival (failure is defined as no response, chronic treatment-maintained response, or relapse)|Incidence of adverse effects after treatment|Long-term safety of alemtuzumab treatment|Time to achieve a complete hematological response|Proportion of patients maintaining hematological response free of any treatment|Incidence of relapse in responding patients|Incidence of severe infections|Requirement for IV antibiotics and antifungal therapy|Requirement for red cell and platelet transfusion|Incidence of CMV reactivation|Kinetics of immune reconstitution|Incidence of paroxysmal nocturnal hemoglobinuria (PNH) clone (lymphoid or myeloid) development|Incidence of clonal evolution (i.e., karyotypic abnormalities or secondary myelodysplasia/leukemia)",https://ClinicalTrials.gov/show/NCT00895739
163,NCT00553098,"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders","Active, not recruiting",No Results Available,Immunodeficiency Syndrome|Non-Cancer Diagnosis,Biological: Alemtuzumab|Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation,"Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)",All,"up to 54 Years Â  (Child, Adult)",Phase 2,29,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2007.00|NCI-2009-01550|2007|P30CA015704,2-Nov-07,6/1/06,null,26-Feb-16,Feb-16,No Study Results Posted,null,Mar-15,Proportion of patients who achieve greater than 50% donor T-cell chimerism,https://ClinicalTrials.gov/show/NCT00553098
186,NCT00410657,Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant,Completed,No Results Available,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,Biological: alemtuzumab|Drug: methylprednisolone|Drug: prednisone|Other: flow cytometry|Other: immunologic technique|Other: pharmacological study,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),All,"Child, Adult, Senior",Phase 2,53,Other|NIH,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Supportive Care,2096.00|FHCRC-2096.00|CDR0000523371,11-Dec-06,7/1/06,null,12-May-10,May-10,No Study Results Posted,null,Nov-06,"Proportion of patients with methylprednisolone (MP)-equivalent glucocorticoid doses â‰_ 0.75 mg/kg on day 28 after starting therapy for graft-versus-host disease (GVHD)|Total cumulative dose of MP-equivalent treatment during the first 8 weeks after study entry|Proportion of patients with complete response, measured weekly through day 56|Incidence of secondary systemic therapy for acute GVHD|Cumulative acute GVHD activity index score at day 56|Incidence of chronic GVHD at 1 year|Nonrelapsing mortality at 1 year|Survival at 1 year|Cumulative incidence of opportunistic infections at 1 year|Cumulative incidence of recurrent or progressive malignancy at 1 year|Peripheral blood CD4, CD8, CD19, and CD16/56 counts at baseline and then periodically for 1 year",https://ClinicalTrials.gov/show/NCT00410657
323,NCT00454480,Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes,Completed,No Results Available,Leukemia|Myelodysplastic Syndromes,Biological: alemtuzumab|Drug: arsenic trioxide|Drug: azacitidine|Drug: busulfan|Drug: clofarabine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: fludarabine phosphate|Drug: gemtuzumab ozogamicin|Drug: melphalan|Drug: tipifarnib|Genetic: DNA methylation analysis|Genetic: cytogenetic analysis|Genetic: gene expression analysis|Genetic: mutation analysis|Other: diagnostic laboratory biomarker analysis|Other: immunologic technique|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation,The University of New South Wales|National Cancer Institute (NCI),All,"Child, Adult, Senior",Phase 2|Phase 3,2000,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000526121|UHW-AML16|EU-20677|ISRCTN11036523|EUDRACT-2005-002846-14|MREC-CU106,27-Mar-07,8/1/06,null,23-Aug-13,Aug-08,No Study Results Posted,null,Aug-12,"Overall survival|Achievement of complete remission and reasons for failure|Duration of remission, relapse rates, and deaths|Hematological and nonhematological toxicity|Supportive care requirements (and other aspects of health economics)",https://ClinicalTrials.gov/show/NCT00454480
174,NCT00363090,"Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma",Unknown status,No Results Available,Lymphoma,Biological: alemtuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: flow cytometry|Other: pharmacological study,Toronto Sunnybrook Regional Cancer Centre|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,84,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000491451|TSRCC-164-2006,10-Aug-06,9/1/06,null,19-Sep-13,Jun-09,No Study Results Posted,null,Dec-10,"Toxicity as assessed by NCI Common Toxicity Criteria Version 3.0|Safety|Dose-limiting toxicities|Pharmacokinetics of alemtuzumab|Efficacy as assessed by clinical, radiologic, pathologic, and laboratory measurements|Overall response rate|Progression-free survival|Overall survival|Effects of treatment on T- and B-cell reconstitution by flow cytometry at baseline and at 3, 6, and 12 months",https://ClinicalTrials.gov/show/NCT00363090
165,NCT00562068,"Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma",Unknown status,No Results Available,Lymphoma|Small Intestine Cancer,Biological: alemtuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisolone|Drug: vincristine sulfate|Genetic: polymerase chain reaction|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacological study,Cancer Research UK|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 1,30,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000576439|UCL-BRD/05/170|EU-20785|EUDRACT-2006-000365-11|CTA 21786/0201/001-0001|CRUK-UCL-BRD/05/170-CHOP-CAMPA|UCL-CHOP-CAMPATH,20-Nov-07,5/1/07,null,23-Aug-13,Nov-08,No Study Results Posted,null,May-09,"Immediate toxicity (incidence of infusion-related reactions)|Hematopoietic toxicity (number of cycles of therapy associated with neutrophils < 0.5e9/L or platelets < 50e9/L)|Incidence of infection (number of days with fever â‰¥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)|Disease response (remission rate [complete response and partial response])|Disease outcome (time to progression and overall survival at 2 years from completion of therapy)|Immune reconstitution (time to recover peripheral blood CD4 count to 0.2 e9/L)|Relative dose intensity|Pharmacokinetics assessment of alemtuzumab trough levels before each cycle of treatment|Epstein-Barr virus copy number (measured retrospectively)",https://ClinicalTrials.gov/show/NCT00562068
156,NCT00555048,"Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",Terminated,No Results Available,Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,Biological: alemtuzumab|Drug: busulfan|Drug: cyclophosphamide|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),All,"up to 50 Years Â  (Child, Adult)",Phase 1|Phase 2,1,Other|NIH,Interventional,Primary Purpose: Treatment,1981.00|P30CA015704|FHCRC-1981.00|CDR0000574145,6-Nov-07,9/1/07,null,4-Jan-11,Jan-11,No Study Results Posted,null,Oct-10,Lowest dose of alemtuzumab associated with transplant-related mortality at day 180|Life-threatening infection|Grades III-IV acute graft-vs-host disease (GVHD)|Survival at 1 year|Disease relapse at 1 year|Extensive chronic GVHD at 1 year|Graft failure at day 100,https://ClinicalTrials.gov/show/NCT00555048
118,NCT00562328,"Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia","Active, not recruiting",Has Results,Leukemia,Biological: Alemtuzumab|Biological: Rituximab|Biological: Sargramostim,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years to 120 Years Â  (Adult, Senior)",Phase 2,33,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000574754|P30CA015083|MC0785|U4449s|001.0888|07-002087,21-Nov-07,1/1/08,null,19-Apr-16,Jun-15,11-Apr-12,null,Aug-10,Proportion of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months|Time to Disease Progression|Time to Response|Duration of Response|Overall Survival|Time to Subsequent Therapy,https://ClinicalTrials.gov/show/NCT00562328
320,NCT00720447,Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma,Unknown status,No Results Available,Lymphoma,Biological: alemtuzumab|Biological: donor lymphocytes|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,Cancer Research UK|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Primary Purpose: Treatment,UCL-BRD-07-137|CDR0000597903|EUDRACT 2007-003081-18,19-Jul-08,11/1/08,null,1-Aug-13,Jul-11,No Study Results Posted,null,Nov-10,Progression-free survival|Overall survival|Toxicity,https://ClinicalTrials.gov/show/NCT00720447
220,NCT00907036,"Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma",Unknown status,No Results Available,Lymphoma,Biological: alemtuzumab|Biological: donor lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: allogeneic hematopoietic stem cell transplantation,Cancer Research UK|National Cancer Institute (NCI),All,"16 Years to 65 Years Â  (Child, Adult)",Phase 2,49,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CRUK-ReACH|CDR0000640500|EUDRACT-2008-004956-60|EU-20928|UCL/08/0122,21-May-09,7/1/09,null,1-Aug-13,Jun-09,No Study Results Posted,null,Jul-15,"3-year progression-free survival|Donor engraftment rates, including chimerism at 3 and 6 months|Non-relapse mortality at 100 days and at 1 and 2 years post-transplant|Incidence of grade II-IV toxicity as assessed by NCI CTCAE v3.0|Incidence, severity, and timing of graft-vs-host disease|Response rates|Relapse rates|Response to donor lymphocyte infusions|Overall survival",https://ClinicalTrials.gov/show/NCT00907036
223,NCT00908180,"Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",Unknown status,No Results Available,Lymphoma,Biological: alemtuzumab|Biological: donor lymphocytes|Drug: carmustine|Drug: cyclosporine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: allogeneic hematopoietic stem cell transplantation,Cancer Research UK|National Cancer Institute (NCI),All,"16 Years to 65 Years Â  (Child, Adult)",Phase 2,47,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CRUK-PAIReD|CDR0000640493|EUDRACT-2008-004956-60|EU-20930|UCL/08/0121,22-May-09,7/1/09,null,1-Aug-13,Jun-09,No Study Results Posted,null,Jul-14,"Progression-free survival at 3 years|Donor engraftment rates, including chimerism at 3 and 6 months|Non-relapse mortality at 100 days, 1 year, and 2 years post-transplant|Incidence of grade II-IV toxicity as assessed by NCI CTCAE v3.0|Incidence, severity, and timing of acute and chronic graft-versus-host disease|Response rates|Relapse rates|Response to donor lymphocyte infusions|Overall survival",https://ClinicalTrials.gov/show/NCT00908180
317,NCT00986557,T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant,Unknown status,No Results Available,Graft Versus Host Disease|Nonneoplastic Condition,Biological: adoptive immunotherapy|Biological: alemtuzumab|Biological: in vitro-treated peripheral blood lymphocyte therapy|Drug: foscarnet sodium|Drug: ganciclovir|Genetic: polymerase chain reaction|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: infection prophylaxis and management|Procedure: peripheral blood stem cell transplantation|Procedure: standard follow-up care|Radiation: radiation therapy,University Hospital Birmingham|National Cancer Institute (NCI),All,"16 Years and older Â  (Child, Adult, Senior)",Phase 2,78,Other,Interventional,Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive Care,CDR0000650654|CRC-TU-ACE-CMV|53325562|EU-20974,29-Sep-09,9/1/09,null,23-Aug-13,Apr-10,No Study Results Posted,null,Aug-13,CMV reactivation in the first year after ASCT measured by quantitative PCR|CMV-specific T-cell reconstitution by detection of circulating T-cell responses to CMV in the first year after ASCT|Time to CMV reactivation|Use of antiviral therapy|Incidence of secondary CMV reactivation and CMV disease|Incidence of acute and chronic graft-versus-host disease,https://ClinicalTrials.gov/show/NCT00986557
191,NCT01005576,Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia,Unknown status,No Results Available,Severe Thalassemia,"Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan",Washington University School of Medicine|New England Research Institutes|Pediatric Blood and Marrow Transplant Consortium,All,1 Year to 16 Years Â  (Child),Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TCRN-NMD 0901,29-Oct-09,1/1/10,null,15-Apr-14,Apr-14,No Study Results Posted,URTH,Apr-14,Primary objective: To determine event-free survival at 1 year.|Secondary objectives: To determine the effect of hematopoietic cell transplant on clinical and laboratory manifestations of thalassemia and determining the incidence of transplant-related outcomes for 2 years.,https://ClinicalTrials.gov/show/NCT01005576
34,NCT01191749,"Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)",Terminated,No Results Available,Leukemia,Drug: Alemtuzumab,M.D. Anderson Cancer Center,All,"Child, Adult, Senior",Phase 2,7,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2010-0187,27-Aug-10,8/1/10,null,18-Dec-13,Dec-13,No Study Results Posted,null,Nov-13,Overall Response,https://ClinicalTrials.gov/show/NCT01191749
283,NCT01256398,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,"Active, not recruiting",No Results Available,Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Untreated Adult Acute Lymphoblastic Leukemia,Biological: Alemtuzumab|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dasatinib|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Etoposide Phosphate|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Melphalan|Drug: Mercaptopurine|Drug: Methotrexate|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: Tacrolimus|Drug: Vincristine Sulfate,National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 2,66,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment,NCI-2011-02621|CDR0000690286|CALGB 10701/CTSU C10701|CALGB-10701|U10CA180821|U10CA031946,7-Dec-10,12/1/10,null,4-Apr-17,Nov-16,No Study Results Posted,null,Feb-18,DFS defined from the date of first induction complete response (CR) to relapse or death due to any cause|DFS|Feasibility of maintenance therapy in this patient population (restricted to those patients achieving a CR)|OS|Probability of being BCR-ABL negative in the bone marrow and peripheral blood at the completion of the CNS prophylaxis course (restricted to those patients achieving a CR)|Response,https://ClinicalTrials.gov/show/NCT01256398
151,NCT01269385,"Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia","Active, not recruiting",No Results Available,B-cell Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia,Biological: alemtuzumab|Biological: rituximab|Drug: PGG beta-glucan|Other: flow cytometry|Other: laboratory biomarker analysis|Genetic: DNA analysis|Genetic: fluorescence in situ hybridization|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Genetic: mutation analysis,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older Â  (Adult, Senior)",Phase 1|Phase 2,55,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LS1084|NCI-2010-02329|10-003025,23-Dec-10,1/1/11,null,19-Apr-16,Jun-15,No Study Results Posted,null,Jun-14,"To determine the maximum tolerated dose (MTD) of PGG beta glucan in combination with alemtuzumab and rituximab (Phase I)|Proportion of complete responses (Phase II)|Overall response rate as estimated by the total number of complete responses or partial responses (CR or PR) divided by the total number of evaluable patients (Phase II)|Time to disease progression (Phase II)|Duration of response for all evaluable patients who have achieved an objective response (Phase II)|Time to subsequent therapy (Phase II)|The number and severity of all adverse events (Phase I)|Toxicity profile, including non-hematologic toxicities; hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia; and overall toxicity incidence as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 (Phase I)|The number and severity of grade 3+ adverse events (Phase I)",https://ClinicalTrials.gov/show/NCT01269385
229,NCT01821781,Immune Disorder HSCT Protocol,Recruiting,No Results Available,Immune Deficiency Disorders|Severe Combined Immunodeficiency|Chronic Granulomatous Disease|X-linked Agammaglobulinemia|Wiskott-Aldrich Syndrome|Hyper-IgM|DiGeorge Syndrome|Chediak-Higashi Syndrome|Common Variable Immune Deficiency|Immune Dysregulatory Disorders|Hemophagocytic Lymphohistiocytosis|IPEX|Autoimmune Lymphoproliferative Syndrome|X-linked Lymphoproliferative Syndrome,"Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan",Washington University School of Medicine,All,"up to 21 Years Â  (Child, Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,201301135,19-Mar-13,3/1/13,null,1-Nov-16,Nov-16,No Study Results Posted,null,Mar-17,Number of participants with donor engraftment|Major Transplant Related Toxicities|Time to neutrophil recovery|Number of patient with acute GVHD|Number of participants with infectious complications|Time to immune reconstitution|Overall survival|Time to platelet recovery|Number of patients with chronic GVHD|Disease free survival,https://ClinicalTrials.gov/show/NCT01821781
123,NCT01020370,Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies,Completed,No Results Available,Multiple Sclerosis,,Wayne State University,All,18 Years to 65 Years Â  (Adult),,null,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CAMMS030081ST,24-Nov-09,null,null,24-Nov-09,Nov-09,No Study Results Posted,null,null,Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies|Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes,https://ClinicalTrials.gov/show/NCT01020370
128,NCT00175266,Islet Transplantation Using Campath-1H and Infliximab Induction,Completed,No Results Available,Type 1 Diabetes,Drug: alemtuzumab|Procedure: islet transplant|Drug: infliximab,University of Alberta|Juvenile Diabetes Research Foundation,All,18 Years to 65 Years Â  (Adult),Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3516,12-Sep-05,null,null,1-Oct-09,Oct-09,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00175266
170,NCT00292760,A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion,Completed,No Results Available,Chronic Lymphocytic Leukaemia,Drug: Alemtuzumab|Drug: Methyprednisolone,Royal Marsden NHS Foundation Trust,All,"18 Years and older Â  (Adult, Senior)",Phase 2,null,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CCR2729|UKCLL 06 (CAM-PRED),15-Feb-06,null,null,15-Dec-09,Dec-09,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00292760
210,NCT00849238,Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation,Withdrawn,No Results Available,Primary Liver Transplant,Drug: mycophenolate mofetil,"University of Wisconsin, Madison",All,"45 Years and older Â  (Adult, Senior)",,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,H-2005-0291|CEL,14-Dec-07,null,null,6-Oct-15,Oct-15,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00849238